CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL ii CONFIDENTIALDOCUMENT REVISION HISTORY
Document Version Date
Original protocol 18 October 2016
Original protocol (Rev.1) 18 October 2016
Amendment 1 23 February 2017 (Local â€“ USA)
Amendment 2 16 June 2017
Amendment 3 16 February 2018
Amendment 4 4 December 2018
Amendment 5 31 July 2019
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL iii CONFIDENTIALABBREVIATIONS & DEFINITIONS
ADLs Activities of Daily Living
ADR Adverse Drug Reaction
AE Adverse Event
ALT Alanine Aminotransferase
ANC Absolute Neutrophil CountAST Aspartate Aminotransferase
BMI Body Mass Index
BP Blood pressure
CHF Congestive Heart Failure
CR Complete ResponseCRC Colorectal cancer
CRO Contract Research Organization 
CSC Cancer Stem Cell 
DCR Disease Control Rate
DSMB Data Safety and Monitoring BoardEDC Electronic Data Capture
EORTC-QLQ-C30
European Organization for Research and Treatment of Cancer Qual ity of Life Questionnaire
FFPE Formalin Fixed Paraffin Embedded
FOLFIRINOX 5-FU, leucovorin, irinotecan and oxaliplatin
FSH Follicle Stimulating Hormone
GCP Good Clinical Practice
GLP Good Laboratory PracticeHCG Human Chorionic Gonadotropin 
HED Human Equivalent Dose 
Hgb Hemoglobin
HIV Human Immunodeficiency Virus
HRT Hormone Replacement TherapyICH International Conference on Harmonization
IHC Immunohistochemical
IND Investigational New Drug
IRB Institutional Review Board
ITT Intention to TreatIUD Intrauterine Device
IUS Intrauterine Hormone-Releasing System 
MMP7 Matrix Metalloproteinase-7
mOS Median Overall Survival
mPFS Median Progression-Free SurvivalMTD Maximum Tolerated Dose
NCI CTCAE National Cancer Institute Common Toxicity Criteria for  Adverse Events 
NOAEL No Observed Adverse Effect Level
ORR Overall Response Rate
OS Overall SurvivalPD Progressive Disease
PDAC Pancreatic ductal adenocarcinoma 
PFS Progression-Free Survival
PK Pharmacokinetics  
PR Partial Response
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL iv CONFIDENTIALPS Performance Status
PT Prothrombin Time
PTT Partial Thromboplastin TimeQoL Quality of Life
RECIST Response Evaluation Criteria In Solid Tumors 
RP2D Recommended Phase 2 Dose
RTSM Randomized Trial Supply Management
SAE Serious Adverse EventSAP Statistical Analysis Plan
SD Study Day
SD Stable Disease
SU Safety Updates
TCPS Tri-Council Policy StatementULN Upper Limit of Normal
WOCBP Women of Child Bearing Potential
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL v CONFIDENTIALSTUDY SYNPOSIS
Study Title: A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabin e in Adult 
Patients with Metastatic Pancreatic Adenocarcinoma.
Study Number: CanStem111P 
Study Phase: III
Study Drug: BBI-608 (also called napabucasin, BBI608, BB608) is a small mol ecule that is 
hypothesized to affect multiple oncogenic cellular pathways, in cluding inhibition of 
the STAT3 pathway, which has been implicated in cancer stem cel l viability.
Primary 
Objective: T o  c o m p a r e  o v e r a l l  s u r v i v a l  ( O S )  o f  p a t i e n t s  w i t h  m e t a s t a t i c  p a ncreatic 
adenocarcinoma (PDAC) treated with BBI-608 plus weekly nab-pacl itaxel with 
gemcitabine (Arm 1) versus weekly nab-paclitaxel with gemcitabine  (Arm 2).  
Secondary 
Objectives: Key Secondary Objectives
xTo compare Progression-Free Survival (PFS) in patients with met astatic 
PDAC treated with BBI-608 plus weekly nab-paclitaxel with gemci tabine 
versus weekly nab-paclitaxel with gemcitabine. 
xTo compare Disease Control Rate (DCR) in patients with metastatic  PDAC
treated with BBI-608 plus weekly nab-paclitaxel with gemcitabin e versus 
weekly nab-paclitaxel with gemcitabine.  
xTo compare Overall Response Rate (ORR) in patients with metasta tic PDAC 
treated with BBI-608 plus weekly nab- paclitaxel with gemcitabine versus 
weekly nab-paclitaxel with gemcitabine.
Other Secondary Objectives
xTo evaluate the safety profile of BBI-608 administered daily pl us weekly nab-
paclitaxel and gemcitabine in patients with metastatic PDAC with safety 
assessed according to the National Cancer Institute Common Toxi city Criteria 
for Adverse Events (NCI CTCAE) version 4.0. 
xTo compare the Quality of Life (QoL), as measured using the Eur opean 
Organization for Research and Treatment of Cancer Quality of Li fe 
questionnaire (EORTC-QLQ-C30), in patients with metastatic PDAC  treated 
with BBI-608 plus weekly nab-paclitaxel with gemcitabine versus weekly 
nab-paclitaxel with gemcitabine.  
Exploratory Objectives
xTo compare OS in patients treated with BBI 608 plus weekly nab paclitaxel 
with gemcitabine (Arm 1) versus weekly nab paclitaxel with gemc itabine 
(Arm 2) in biomarker pos itive PDAC patients.
xTo compare PFS in patients with metastatic PDAC treated with BB I 608 plus 
weekly nab paclitaxel with gemcitabine versus weekly nab paclit axel with 
gemcitabine in biomarker positive patients.
xTo compare DCR in patients with metastatic PDAC treated with BB I 608 plus 
weekly nab paclitaxel with gemcitabine versus weekly nab paclit axel with 
gemcitabine in biomarker positive patients.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL vi CONFIDENTIALxTo compare ORR in patients with metastatic PDAC treated with BB I 608 plus 
weekly nab paclitaxel with gemcitabine versus weekly nab paclit axel with 
gemcitabine in biomarker positive patients.
Study Design: This is a randomized, open-label, multi-center, phase III study o f BBI-608 plus weekly 
nab-paclitaxel with gemcitabine (Arm 1) vs. weekly nab-paclitaxel  with gemcitabine
(Arm 2) for adult patients with metastatic PDAC.
1132 patients will be randomized in a 1:1 ratio, stratified acco rding to geographical 
region (North America/Western Europe/Australia vs. Japan/Korea vs. Rest o f the 
World), Eastern Cooperative Oncology Group (ECOG) performance st atus (0 vs. 1), 
and presence of liver metastases (yes vs. no). Enrollment was c ompleted prior to this 
amendment.  
Until the time of this amendment, the study proceeded in 28-day (4-week) cycles. BBI-
608 was administered orally, twice daily, with doses separated by appro ximately 12 
hours. BBI-608 administration began 2-5 days prior to the first nab-paclitaxel with 
gemcitabine infusion. Nab-paclitaxel 125 mg/m2immediately followed by 
gemcitabine 1000 mg/m2were administered on Days 1, 8 and 15 of every 28-day cycle
via intravenous infusion.  
From the time of this amendment, and since the outcome of the i nterim analysis which 
was futile, patients may continue protocol therapy if it is bel ieved to be in their best 
interest by the investigator and patient, and with the patientâ€™ s informed consent.
Patients will receive BBI-608, nab-paclitaxel and/or gemcitabin e at the same dose and 
schedule that they were receiving prior to the amendment. Patien ts on Arm 1 may 
continue BBI-608 with the Sponsorâ€™s approval. Patients on Arm 1  m a y  a l s o  
discontinue BBI-608 but choose to continue with nab-paclitaxel and gemcitabine
alone.  
Tumor assessments will be performed every 8 weeks after randomi zation until 
objective disease progression or  treatment discontinuation due to toxicity.
The protocol will continue to be followed for all endpoints unt il study completion. The 
study is planned for completion on February 28th, 2020. 
Study Population: This study will enroll patients with histologically or cytologi cally confirmed 
adenocarcinoma of the pancreas that is metastatic (Stage IV). Patients with local 
recurrence following surgical resection will be excluded. At ra ndomization, patients 
will not have received systemic chemotherapy for metastatic pan creatic 
adenocarcinoma previously (with a fluoropyrimidine or gemcitabi ne administered as
a radiation sensitizer in the adjuvant setting allowed). Other i nclusion criteria for all 
patients include: age Â•\ ears(&2*SHUIRUPDQFHVWDWXVÂ”DQGDGHTXDWHKHSDWLF
renal, and bone-marrow function.  
Test Product, 
Dose, and Mode of 
Administration:Until the time of this amendment, patients randomized to Arm 1 o n this study received
BBI-608 orally, daily, at 240 mg bid (480 mg total daily dose).  BBI-608 was taken 
daily continuously throughout each 4 week (28 day) study cycle i n combination with 
nab-paclitaxel and gemcitabine. BBI-608 was administered twice dai ly, one hour prior 
or two hours after meals, with the  first dose taken in the morn ing and doses separated 
by approximately 12 hours. 
Patients randomized to Arm 1 received BBI-608 in combination wit h nab-paclitaxel
and gemcitabine. Patients randomized to Arm 2 received nab-pacli taxel and 
gemcitabine alone. Nab-paclitaxel 125 mg/m2was administered intravenously starting 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL vii CONFIDENTIALon Day 1 of Cycle 1. Gemcitabine 1000 mg/m2was administered intravenously
following nab-paclitaxel infusion. This regimen was repeated on Days 1, 8 and 15 of 
every 28-day cycle.
Dose modification of BBI-608 and/ or nab-paclitaxel and/or gemci tabine was allowed.
There were no dose reductions or adjustments for lymphopenia or  alopecia.  
From the time of this amendment, and since the outcome of the i nterim analysis was 
communicated to investigators, patients may continue protocol t herapy if it is believed
to be in their best interest by the investigator and patient, and  with the patientâ€™s 
informed consent. Patients will receive BBI-608, nab-paclitaxel  and/or gemcitabine at 
the same dose and schedule that they were receiving prior to th e amendment. Patients 
on Arm 1 may continue BBI-608 with the Sponsorâ€™s approval. Pati ents on Arm 1 may 
discontinue BBI-608 but choose t o continue with nab-paclitaxel and gemcitabine.. 
Duration of 
Treatment: Patients may continue to receive assigned protocol therapy as l ong as they have not 
experienced any adverse events requiring permanent discontinuation of study 
medication, have not demonstrated disease progression based on R esponse Evaluation 
Criteria In Solid Tumors (RECIST) 1.1 criteria, it is believed to  be in the patientâ€™s best 
interest by the investigator and patient, or until February 28th, 2020, whichever occurs 
first. If nab-paclitaxel and/or gemcitabine is/are discontinued du e to toxicity, BBI-608 
may be continued until another discontinuation criterion is met with the Sponsorâ€™s 
approval, if it is believed to be in the patientâ€™s best interest  by the investigator and 
patient, and with the patientâ€™s informed consent. If BBI-608 is  discontinued due to 
toxicity, nab-paclitaxel and gemcitabine may be continue d until another 
discontinuation criterion is met. 
The study is planned for completion on February 28th, 2020. 
Statistical 
Methods: The primary study endpoint is Overall Survival (OS), defined as  t h e  t i m e  f r o m  
randomization until death from any cause.  
A multiplicity adjustment strategy will be applied to control t he overall Type I error 
rate with respect to several sources of multiplicity in the tri al. This multiplicity 
adjustment will account for the analysis of the treatment effec t on the primary (OS) 
and key secondary (PFS, DCR, ORR) endpoints.
The study is designed to have a power of 90% and a one-sided al pha of 2.5% to detect 
a 20% reduction in the continuous risk of death (HR 0.80, which  corresponds to an 
increase of median survival from 8.5 to 10.63 months) in the In tention to Treat (ITT) 
general study population. It is estimated that 864 events will b e required to detect this 
reduction which would be observed by randomizing 1132 patients e nrolled over 24 
months with patient follow up for  an additional 12 months, for total study duration of 
36 months. It is anticipated that up to 5% dropout rate will oc cur for the entire study.  
The primary hypothesis is: 
H0: BBI-608 + nab-paclitaxel with gemcitabine Â”QDE -paclitaxel with gemcitabine 
versus
H1: BBI-608+ nab-paclitaxel with gemcitabine > nab-paclitaxel with g emcitabine. 
This hypothesis will be evaluated for the superiority of BBI-60 8 by performing a 
stratified log-rank test adjusting for the stratification varia bles at randomization. The 
final analysis will be perfor med when 864 OS events have been o bserved.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL viii CONFIDENTIALThe overall power of the study will be approximately 90% after the multiplicity control 
procedure is considered.
Prior to this amendment, there was one interim analysis presente d to the independent 
Data Safety and Monitoring Board (DSMB). Additionally, the DSMB reviewed safety 
during conduct of the study. The role and responsibility of the  DSMB are defined in a 
separate Charter.
The interim analysis involved a stratified log-rank test. Nominal  p-values were based 
on the Lan-DeMets error spending function using an Oâ€™Brien- Fleming stopping 
boundary in order to preserve the overall one-sided alpha level  at 0.025.  
The interim analysis was performed when approximately 432 deaths  (50% of the 
required events) were observed. The interim analysis was for futilit y only, with the
futility boundary set at HR > 1. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL ix CONFIDENTIALTABLE OF CONTENTS
DOCUMENT REVISION HISTORY ..................................... ............................................................... ...... ii  
ABBREVIATIONS & DEFINITIONS ................................... ............................................................... ..... iii  
STUDY SYNP OSIS................................................. ............................................................... ...................... v  
TABLE OF CONTENTS ............................................. ............................................................... ................ ix  
STUDY ACKNOWLEDGMEN T/DISCLO SURE ................................ ....................................................... 1  
TREATMENT SCHEMA ............................................... ............................................................... ............... 2  
1.0 OBJECTIVES..................................................... ............................................................... ............... 4  
1.1 Primary Objective .............................................................................................................. ............................. 4  
1.2 Secondary Objectives ........................................................................................................... ........................... 4  
2.0 BACKGROUND INFORMATI ON AND RATI ONALE........................... ..................................... 5  
2.1 Pancreatic Ductal Adenocarcinoma ............................................................................................... ................ 5  
2.2 Cancer Stem Cells (CSC) and PDAC............................................................................................... ............... 5  
2.3 BBI-608  ...................................................................................................................... ................................. 6  
2.4 Summary  ...................................................................................................................... ................................. 8  
3.0 TRIAL DESIGN .................................................. ............................................................... ............ 10  
3.1 Stratifica tion................................................................................................................. .................................10  
3.2 Randomization .................................................................................................................. ............................10  
3.3 Inclusion of Wome n and Minorities .............................................................................................. ................11  
3.4 Pharmaceutical Data ............................................................................................................ ........................11  
4.0 STUDY POPULA TION .............................................. ............................................................... .... 13  
4.1 Inclusion Criteria............................................................................................................. .............................13  
4.2 Exclusion Criteria ............................................................................................................. ............................16  
5.0 PRE-RANDOMIZATION (BASELINE) SCHEDULE OF EVENTS (SEE APPENDICES  I and II)
   ............................................................ ............................................................... ............. 20  
6.0 ENTRY/RANDOMIZATI ON PROCE DURES ................................ ............................................. 22  
6.1 Entry Procedures ............................................................................................................... ...........................22  
6.2 Stratifica tion................................................................................................................. .................................22  
6.3 Randomization .................................................................................................................. ............................22  
7.0 PROTOCOL TRE ATMENT ............................................ .............................................................. 24 
7.1 Treatment Plan................................................................................................................. .............................24  
7.2 Drug Administration ............................................................................................................ .........................24  
7.3 Adverse Event Prophylaxis...................................................................................................... ......................25  
7.4 BBI-608 Dose Modification ...................................................................................................... ....................27  
7.5 Nab-paclitaxel and Gemcitabi ne Dose Modification ............................................................................... .....29  
7.6 Blinding/Unblinding............................................................................................................ ..........................32  
7.7 Patient Monitoring............................................................................................................. ...........................32  
7.8 Concomitant Medica tions/Procedures............................................................................................. .............32  
7.9 Duration of Therapy............................................................................................................ ..........................33  
7.10 Patient Compliance............................................................................................................. ..........................33  
8.0 EVALUATION DURING AND AFTER PROTOCOL TRE ATMENT ................ ....................... 35  
8.1 Evaluation During Prot ocol Treatment ........................................................................................... .............35  
8.2 Evaluation after permane nt Protocol Treatmen t Discontinuation................................................................37  
9.0 CRITERIA FOR MEASUREME NT OF STUDY E NDPOINTS ................... ............................... 39  
9.1 Definitions  .................................................................................................................. ...................................39  
9.2 Response and Evaluat ion Endpoints .............................................................................................. ...............40  
9.3 Response Duration.............................................................................................................. ..........................42  
9.4 Stable Disease Duration........................................................................................................ ........................42  
9.5 Methods of Me asurement ......................................................................................................... .....................42  
10.0  SERIOUS ADVERSE EVE NT REPOR TING ............................... ................................................ 44  
10.1 Definition of a Protocol Report able Serious Adverse Event ...................................................................... ...44 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL x CONFIDENTIAL10.2 Serious Adverse Event Reporting Instructions................................................................................... ...........44  
10.3 Procedures In Case Of an Overdose.............................................................................................. ...............45  
10.4 Other Protocol Reportable Events  â€“ Pregnancy/Expos ure Reporting ..........................................................45  
10.5 Responsibility for Reporting Se rious Adverse Events to Regulatory Agencies .............................................46  
10.6 Reporting Safety Reports to Investigators...................................................................................... ...............47  
11.0  PROTOCOL TREATMENT DISCONTINUATION AND THERAPY AFTER STOPPING A LL 
STUDY TREA TMENT ............................................... ............................................................... ................. 48  
11.1 Criteria for Discontinuing Protocol Treatment .................................................................................. ..........48  
11.2 Duration of Protocol Treatment................................................................................................. ...................48  
11.3 Therapy After Protocol Treatment is permanently discontinued ..................................................................4 8 
11.4 Follow-up Off Protocol Treatment............................................................................................... .................48  
12.0  CENTRAL REVIEW PROCEDURES, TISSUE COLLECTION, AND CORRELATIVE S TUDIES
   ............................................................ ............................................................... ............. 50  
12.1 Central Radiology Review....................................................................................................... ......................50  
12.2 Central Pathology Review....................................................................................................... ......................50  
12.3 Tissue Collection.............................................................................................................. .............................50  
12.4 Sparse Pharmacokinetic Plasma Sample Collection â€“ Na b-paclitaxel with gemcitabine and BBI-608 (Arm 1 
only)   ....................................................................................................................... ..............................50  
13.0  STATISTICAL CONSIDERATIONS .................................... ....................................................... 52  
13.1 Objectives and Design.......................................................................................................... .........................52  
13.2 Study Endpoints and Analysis ................................................................................................... ....................52  
13.3 Sample Size and Duration of Study .............................................................................................. .................54  
13.4 Safety Monitoring.............................................................................................................. ............................55  
13.5 Interim Analysis ............................................................................................................... .............................55  
13.6 Correlative Studies............................................................................................................ ............................55  
13.7 Sparse Pharmacoki netic Analysis ................................................................................................ .................57  
14.0  PUBLICATION ................................................... ............................................................... ........... 58  
15.0  RESEARCH OUTSIDE THE TERMS OF THIS PROTOCOL .................... ................................ 59  
16.0  ETHICAL, REGULATORY AND ADM INISTRATIVE ISSUES ................. .............................. 60  
16.1 Regulatory Considerations...................................................................................................... ......................60  
16.2 Inclusivity in Research ........................................................................................................ ..........................60  
16.3 Obtaining Informed Consent..................................................................................................... ....................61  
16.4 Discontinuation of the Trial ................................................................................................... .......................62  
16.5 Retention of Patient Records and Study Files ................................................................................... ............62  
16.6 On-Site Monito ring/Auditing.................................................................................................... .....................62  
16.7 Case Report Forms .............................................................................................................. .........................63  
REFERENC ES  ................................................... ............................................................... ...................... 64  
APPENDIX I - PATIENT EVALUATION FLOW SHEET: Arm 1 (treatment wi th nab-paclitaxel and 
gemcitabine with BBI-608) ..................................... ............................................................... ..................... 68  
APPENDIX II - PATIENT EVALUATION FLOW SHEET: Arm 2 (treatment w ith nab paclitaxel and 
gemcitabine)  ................................................. ............................................................... ........................ 70  
APPENDIX III - PERFORMANC E STATUS SCA LES/SCORES ............... ............................................ 72  
APPENDIX IV - NCI COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENT S ................. 73  
APPENDIX V - QUALITY OF LIFE ASSESSMENT ....................... ....................................................... 74  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 1 CONFIDENTIALSTUDY ACKNOWLEDGMENT/DISCLOSURE
I understand that this protocol contains information that is co nfidential and proprietary to Boston Biomedical, 
Inc.
I have read the protocol and agree that it contains all necessa ry details for carrying out the study as described. 
I will conduct this protocol as outlined herein, and according to Good Clinical Practice and any applicable 
local regulations. I will make a reasonable effort to complete the study within the time designated. I confirm 
that I and study personnel participating under my supervision h ave adequate resource to fulfill their 
responsibilities as outlined in this protocol. I will maintain d ocumentation of any Investigator responsibilities 
assigned to participating study personnel. I confirm that all d ata will be submitted in a timely manner and will 
be accurate, complete and supported by source documents. I will  complete any protocol specific training 
required by the sponsor and that I understand the requirement t o inform additional site personnel with delegated 
duties of this information.  
I will provide copies of the protocol and access to all informa tion furnished by Boston Biomedical, Inc. and/or 
the designated Contract Research Organization (CRO) to the stud y personnel under my supervision. I will 
discuss this material with them to ensure that they are fully i nformed about the investigational product and the 
study.  
I understand that this trial will be registered on a public tri al registry and that my contact information and site 
name will be included in the registry listing. 
The contents of this protocol may not be used in any other clin ical trial and may not be disclosed to any other 
person or entity without the prior written permission of Boston  Biomedical, Inc. The foregoing shall not apply 
to disclosure required by governmental regulations or laws; how ever, I will give prompt notice to Boston 
Biomedical, Inc. of any such disclosure. 
I understand that I may terminate or suspend enrolment of the s tudy at any time if it becomes necessary to 
protect the best interests of the study subjects, however I wil l give prompt notice to Boston Biomedical Inc., 
and/or the designated CRO. The study may be terminated at any t ime by Boston Biomedical, Inc. with or 
without cause. 
Any supplemental information that may be added to this document  is also confidential and proprietary to 
Boston Biomedical, Inc. and must be  kept in confidence in the s ame manner as the contents of this protocol.
___________________________________________________ ___________ ______________ 
Principal Investigator Date
(Printed Name and Signature)
Site Name: ___________________________________________ 
Protocol Number: CanStem111P  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 2 CONFIDENTIALTREATMENT SCHEMA
This is an international multi-center, prospective, open-label,  randomized phase III trial of the cancer stem cell 
inhibitor BBI-608 plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 
2) in patients with metastatic PDAC.
Stratification:
xGeographical region (North America/Western Europe/Australia vs.  Japan/Korea vs. Rest of the World)  
xECOG performance status (0 versus  1)
xPresence of liver metastases (yes versus  no)
Metastatic
PDAC
RANDOMIZEÕ¡A
r
m
1BBI-608 orally, 
twice daily
plus 
Nab-Paclitaxel + 
Gemcitabine IV, 
weeklyDisease 
progression based 
on RECIST 
criteria1,2
or 
Unacceptable 
toxicity occurs OS ÄºÄº
Õ¢A
r
m
2Nab-Paclitaxel + 
Gemcitabine IV, 
weekly
1If no other standard therapies are available at the time of dis ease progression, and the patient has not 
experienced any adverse events requiring permanent discontinuat ion, BBI-608 may be continued in 
monotherapy. 
2From the time of this amendment, and since the outcome of the i nterim analysis was communicated to 
investigators, patients may continue protocol therapy if it is b elieved to be in their best interest by the 
investigator and patient, and with the patientâ€™s informed conse nt. Patients on Arm 1 may continue BBI-608 
with the Sponsorâ€™s approval. Patients on Arm 1 may discontinue BBI-608 but choose to continue with nab-
paclitaxel and gemcitabine.
Primary Objective: 
xOverall Survival in the general study population 
Key Secondary Objectives: 
xProgression-Free Survival (PFS) in the general study population.  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 3 CONFIDENTIALxDisease Control Rate (DCR) in the general study population.  
xObjective Response Rate (ORR) i n the general study population. 
Other Secondary Objectives:
xSafety profile  
xQoL in the general study population
Exploratory Objectives:
xOS in the predefined biomarker sub populationÂ¥
xPFS in the predefined biomarker positive sub populationÂ¥
xDCR and ORR in the predefined biomarker positive sub populationÂ¥
Â¥This biomarker-positive sub-population is defined as those pati ents with phospho-STAT3 positivity on 
immunohistochemical (IHC) staining of Formalin Fixed Paraffin E mbedded (FFPE) tumor tissue.
Sample Size:
Planned sample size is 1132 patients (566 on Arm 1 and 566 on Arm  2).  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 4 CONFIDENTIAL1.0 OBJECTIVES
1.1 PRIMARY OBJECTIVE
To compare overall survival (OS) of patients with metastatic (S tage IV) PDAC treated with BBI-608 
plus weekly nab-paclitaxel with gemcitabine versus weekly nab-pa clitaxel with gemcitabine.  
1.2 SECONDARY OBJECTIVES
Key Secondary Objectives
xTo compare Progression Free Survival (PFS), in patients treated with BBI-608 plus weekly nab-
paclitaxel with gemcitabine vers us weekly nab-paclitaxel with ge mcitabine.  
xTo compare DCR in patients treated with BBI-608 plus weekly nab -paclitaxel with gemcitabine
versus weekly nab-paclitaxel with gemcitabine. 
xTo compare ORR in patients treated with BBI-608 plus weekly nab -paclitaxel with gemcitabine 
versus weekly nab-paclitaxel with gemcitabine. 
Other Secondary Objectives
xTo evaluate the safety profile of BBI-608 administered daily pl us weekly nab-paclitaxel with 
gemcitabine, with safety assessed according to the National Canc er Institute Common Toxicity 
Criteria for Adverse Event s (NCI CTCAE) version 4.0. 
xTo compare the Quality of Life (QoL), as measured using the EOR TC-QLQ-C30, in patients with 
treatment-naive metastatic PDAC treated with BBI-608 plus weekl y nab-paclitaxel with 
gemcitabine versus weekly nab-paclitaxel with gemcitabine. 
Exploratory Objectives:
xTo compare the OS in patient s treated with BBI 608 plus weekly nab paclitaxel with gemcitabine 
(Arm 1) versus weekly nab-paclitaxel with gemcitabine (Arm 2) i n biomarker positive PDAC 
patients.
xTo compare the PFS in patients treated with BBI 608 plus weekly  nab paclitaxel with gemcitabine 
versus weekly nab-paclitaxel with gemcitabine in biomarker posi tive PDAC patients.
xTo compare the ORR and DCR in patients treated with BBI 608 plu s weekly nab paclitaxel with 
gemcitabine versus weekly nab-paclitaxel with gemcitabine in bi omarker positive PDAC patients.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 5 CONFIDENTIAL2.0 BACKGROUND INFORMATION AND RATIONALE
2.1 PANCREATIC DUCTAL ADENOCARCINOMA
Pancreatic ductal adenocarcinoma (PDAC) is the most common form  of pancreatic cancer with the 
worst prognosis of all solid tumors (Corbo, 2012; Klimstra, 2007) . PDAC is the fourth leading cause 
of cancer death in the United States with an estimate of 38,460  deaths closely following the number
of 45,220 diagnoses in 2013 (Siegel, 2013) . Surgery is considered the only potentially curative 
treatment, however, more than 80% of patients present with loca lly advanced or metastatic disease 
(Davis, 2012) . Out of the minority of presenting patients who qualify for cu rative surgery, most will 
develop disseminated advanced disease with a 5-year survival ra te of less than 5% (Hidalgo, 2010) .
Standard treatment for unresectable and metastatic disease curr ently includes first-line combination 
regimen with FOLFIRINOX (5-FU, leucovorin, irinotecan and oxali platin), a regimen that provides a 
median overall survival (OS) of 11.1 months in patients with tr eatment-naÃ¯ve disease (Conroy, 2011) .
Moreover, a number of uncontrolled studies have shown that modi fied FOLFIRINOX 
(mFOLFIRINOX) regimen results in decreased toxicity while maint aining efficacy in patients with 
pancreatic adenocarcinoma (Blazer, 2015; Mahaseth, 2013) . Most recently, a liposomal irinotecan 
formulation was shown to improve overall survival by 1.9 months (6.1 months vs 4.2 months) in 
combination with 5-FU and leucovorin in patients with metastatic  PDAC progressing on gemcitabine-
based first-line treatment as compared to patients treated with  5-FU and leucovorin alone  (Chen, 2015). 
An alternative regimen for this patient population is a combina tion of nab-paclitaxel with gemcitabine.
A recent updated survival analysis of the phase II/III study, MP ACT (Von Hoff, 2013) , randomizing 
861 patients with metastatic PDAC to gemcitabine versus gemcita bine in combination with nab-
paclitaxel, revealed a sustained difference in OS between the 2  arms with median survival of 8.7 
months in the combination group compared to 6.6 months in the g emcitabine monotherapy group and 
more importantly a first ever 3-year survival rate of 4% in the  combination treatment group (Goldstein,
2014) . These results encourage continued efforts to build upon these  backbones to further extend 
s u r v i v a l .  C u r r e n t l y ,  a  p a t i e n t  w i t h  a d v a n c e d  d i s e a s e  p r o g r e s s i n g in first-line therapy has limited 
treatment options. Given the morbidity associated with this dis ease, there is an urgent need to identify 
novel therapies to improve the outcome of patients with advance d unresectable PDAC. 
2.2 CANCER STEM CELLS (CSC) AND PDAC
CSCs or cancer cells with stemness phenotypes are a sub-populat ion of cancer cells that have self-
renewal capability, are highly malignant and are considered to be fundamentally responsible for 
malignant growth, recurrence, drug-resistance and metastasis. M oreover, CSCs are highly resistant to 
chemotherapies and current targeted agents. CSCs have been isol ated from almost all major tumor 
types, including PDAC (Lee, 2008; Boman, 2008; Clevers, 2011; Gupta, 2009; Hanahan, 2011; 
Gupta, 2011) .
Accumulating evidence indicates that CSCs may play a key role in the pathogenesis of PDAC ( Lee, 
2008) . Cancer stem cells have been isolated from human pancreatic ade nocarcinomas using a
combination of three cell surface markers including CD44, CD24, and ESA (Li, 2007). These CSCs 
isolated from pancreatic adenocarcinoma patients display tumour- initiating properties ( Shah, 2007; Li, 
2007) . Additionally, the CD133 cell surface marker also discriminate s for pancreatic cancer cells with 
potent proliferative capacity (Hermann, 2007) and pancreatic cancer cells positive for both CD133 and 
CXCR4 cell surface markers have the ability to migrate and meta stasize in addition to having a potent 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 6 CONFIDENTIALproliferative capacity ( Hermann, 2007) . Moreover, CSCs in PDAC display resistance to therapeutics 
as it has been observed that treatment with ionizing radiation a nd chemotherapy results in enrichment 
of cancer stem cells in pancreatic adenocarcinoma. Exposure of pancreatic cancer cell line to 
gemcitabine results in enrichment of the CSC population ( Hermann, 2007; Hong, 2009) . Finally, as is 
the case with other cancers including colorectal, breast, prost ate, and ovarian carcinoma, expression 
of CSC markers in pancreatic tumors correlates with diminished survival (Rasheed, 2012; Maeda, 
2008; Ohara, 2013) . These findings suggest that the development of cancer stem cel l inhibitors may 
represent a novel strategy for potential use in the treatment of PDAC.
2.3 BBI-608 
BBI-608 (also called napabucasi n, BBI608, BB608) is a small mol ecule that is hypothesized to affect 
multiple oncogenic cellular pathways, including inhibition of t he STAT3 pathway, which has been 
implicated in cancer stem cell viability. For further pre-clini cal information, please refer to the 
Investigator Brochure.
BBI-608 has been evaluated in multiple clinical trials as both a monotherapy and as a component of 
combination therapy with standard anti-cancer therapeutics. Ava ilable data from many of these trials, 
including detailed adverse event (AE) tables and pharmacokineti c information, can be found in the IB.  
Highlighted below are general information on the BBI-608 safety  p r o f i l e  a n d  a  s u m m a r y  o f  t h e  
BBI608-118 (aka BBI608-201PANC) phase I/II clinical trial of BB I-608 in combination with standard 
chemotherapy for advanced PDAC.
2.3.1 Pre-Clinical Rationale
The pre-clinical rationale for the development of BBI-608 can b e found in the Investigator Brochure. 
2.3.2 Safety Profile
The predominant adverse drug reactions (ADRs) associated with B BI-608 are gastrointestinal in 
nature. BBI-608 appears to irritate the gastrointestinal epithe lium, which can result in diarrhea, 
abdominal pain, nausea, vomiting, and decreased appetite (anore xia). Fatigue is also reported.  
These ADRs are predominantly mild (grade 1 or grade 2), but can  be severe (grade 3). Gastrointestinal 
or other ADRs that are grade 4 in severity are rare (<1%). Howe ver, even mild or moderate events, if 
persistent, can result in dehydration; which, if severe, can le ad to other events such as hypovolemia, 
hypotension, electrolyte abnormalities, and increased serum cre atinine/acute kidney injury. Other 
sequelae such as dizziness or falls could also occur.  
The common ADRs for BBI-608 are shown in Table 1 below. The table shows two sets of frequencies 
or rates. The first set (3rdcolumn) is the range of rates reported for each event as a non- serious 
occurrence across the clinical trials. Different rates are obse rved in each trial because of different study 
populations and the different combination therapeutics involved . The second set of rates (4th column) 
is the overall frequency in which the event is reported as a se rious adverse drug reaction.  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 7 CONFIDENTIALTable 1: Frequency of Common Adverse Drug Reactions
System Organ Class (SOC) Preferred Term (PT)Event Rates (Range)Â¥
Non-seriousSerious Event RateÂ¥
Gastrointestinal disorders Diarrhoea 60 â€“ 80% 3.2%
Vomitin g 20 â€“ 30% 1.4%
Nausea 30 â€“ 50% 1.1%
Abdominal pain 20 â€“ 40% 0.7%
General disorders Fati gue 25 â€“ 40% 0.5%
Asthenia 5 â€“ 10% 0.3%
Metabolism and nutrition disorders Decreased a ppetite 30 â€“ 50% 0.1%
Dehydration 10 â€“ 15% 1.6%
Electrol yte disorders* 5 â€“ 10% 0.2%
Renal and urinar y disorders Acute kidne y injury* 1 â€“ 2% 0.5%
Vascular disorders H ypotension* 1 â€“ 2% 0.1%
*Event can occur secondary to dehydration or fluid loss as the r esult of nausea, vomiting, diarrhea, abdominal pain, 
decreased appetite, or a combination of these events.
Â¥The ranges presented are the event rates observed across differ ent trials that involve different populations and different 
combination therapeutics, out of ~2500 exposed patients.
Refer to the current version of the Investigatorâ€™s Brochure for  more comprehensive safety data.
2.3.3 BBI-608 for Pancreatic Cancer 
The BBI608-118 (aka BBI608-201PANC) study was initiated to eval uate BBI-608 in combination 
with standard chemotherapy for advanced PDAC. The primary objec tives of the study included 
determination of the safety, tolerability, pharmacokinetic char acteristics, and recommended phase II 
dose (RP2D) of BBI-608 in combination with each of the backbone  regimens. Secondary objectives 
included evaluation of preliminary anti-tumor activity. The stu dy has completed accrual and analysis 
is ongoing. 
Patients with PDAC were eligible if they were appropriate to re ceive treatment with one of several 
standard regimens for advanced pancreatic cancer: albumin-bound  paclitaxel (nab-paclitaxel) plus 
gemcitabine, FOLFIRINOX, liposomal irinotecan (Onivyde [MM-398] ) plus 5FU/Leucovorin, or 
FOLFIRI. The trial was not randomized and a treatment arm was se lected by investigators based on 
the specific clinical context for each patient. 
Once enrolled, patients received twice daily administration of BBI-608 in combination with a standard 
chemotherapeutic backbone as set forth above. RP2D was determined  to be 240 mg BID (480 mg total 
daily) for all combination arms. 
In the BBI-608 in combination with gemcitabine plus nab-paclitax el study arm, patients received 
gemcitabine 1000 mg/m2intravenously plus nab-paclitaxel 125 mg/m2intravenously on days 1, 8, and
15 of a 28-day study cycle. Dose adjustment of either BBI-608 o r gemcitabine/nab-paclitaxel (either 
agent) was permitted in the event of toxicity.
Out of 71 patients enrolled, a total of 66 patients had not pre viously received BBI-608. A majority of 
these patients had not received any systemic therapy, with appr oximately 25% having received 
adjuvant therapy with recurrence at less than 6 months of the l ast adjuvant dose.  
As of September 1, 2017, 64 out of the 66 patients enrolled had  protocol treatment dose-administration 
confirmed in the study database. These 64 patients were include d in an analysis of safety and efficacy. 
Objective response per RECIST 1.1 was observed in 31 (48%) of p atients, including 2 (3%) with 
complete response (CR) and 29 (45%) with partial response (PR).  An additional 19 (30%) patients had 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 8 CONFIDENTIALstable disease (SD), and the disease control rate (DCR, proport ion with CR, PR, or SD per RECIST 
1.1) was 78%. There were 39 (61%) patients with a progression e vent and 43 (67%) patients who died, 
with a median progression-free survival (mPFS) of 7.4 months an d a median overall survival (mOS) 
of 10.9 months.  
Adverse events (AEs) in the clinical database as of September 1 st, 2017 and observed in at least 10% 
of study patients are presented in Table 2 below. Updated clini cal data from this trial, if available, can 
be found in the IB. 
Table 2: BBI608-118 Adverse Events  - BBI-608 + Gemcitabine/nab- Paclitaxel 
(n = 64*) 
7UHDWPHQWHPHUJHQWDGYHUVHHYHQWVLQÂ•RI patients
Worst grade reported, data extract: 01SEP2017
System Organ Class Preferred TermGrade 1 Grade 2 Grade 3 Grade 4 Grade 5 Total
n%N %n%n%N%n%
Gastrointestinal Diarrhoea 31 48.4 11 17.2 4 6.3 1 1.6 0 0 47 73.4
N a u s e a 1 9 2 9 . 7 1 0 1 5 . 6 1 1 . 6 0000 3 0 4 6 . 9
Abdominal pain 12 18.8 10 15.6 3 4.7 0 0 1 1.6 26 40.6
Vomiting 10 15.6 9 14.1 1 1.6 1 1.6 0 0 21 32.8
C o n s t i p a t i o n 4 6 . 3 5 7 . 8 1 1 . 6 0000 1 0 1 5 . 6
D y s p e p s i a 5 7 . 8 2 3 . 1 0000007 1 0 . 9
General, administration site F a t i g u e 1 8 2 8 . 1 1 4 2 1 . 9 1 2 1 8 . 8 0000 4 4 6 8 . 8
O e d e m a  p e r i p h e r a l 1 9 2 9 . 7 5 7 . 8 3 4 . 7 0000 2 7 4 2 . 2
Pyrexia 17 26.6 2 3.1 2 3.1 1 1.6 0 0 22 34.4
M u c o s a l  i n f l a m m a t i o n 5 7 . 8 2 3 . 1 0000007 1 0 . 9
Metabolism and nutrition D e c r e a s e d  a p p e t i t e 1 1 1 7 . 2 1 0 1 5 . 6 000000 2 1 3 2 . 8
H y p o k a l a e m i a 4 6 . 3 4 6 . 3 4 6 . 3 0000 1 2 1 8 . 8
D e h y d r a t i o n 1 1 . 6 8 1 2 . 5 2 3 . 1 0000 1 1 1 7 . 2
H y p o n a t r a e m i a 4 6 . 3 1 1 . 6 3 4 . 7 00008 1 2 . 5
Nervous system N e u r o p a t h y  p e r i p h e r a l 1 5 2 3 . 4 6 9 . 4 4 6 . 3 0000 2 5 3 9 . 1
D y s g e u s i a 8 1 2 . 5 000000008 1 2 . 5
H e a d a c h e 7 1 0 . 9 000000007 1 0 . 9
Respiratory D y s p n o e a 6 9 . 4 4 6 . 3 3 4 . 7 0000 1 3 2 0 . 3
C o u g h 7 1 0 . 9 1 1 . 6 0000008 1 2 . 5
Skin and subcutaneous tissue A l o p e c i a 6 9 . 4 1 5 2 3 . 4 000000 2 1 3 2 . 8
R a s h 1 1 1 7 . 2 2  3 . 1 0  0  0  0  0  0  1 3 2 0 . 3
Blood and lymphatic system Neutropenia 1 1.6 0 0 13 20.3 4 6.3 0 0 18 28.1
A n a e m i a 1 1 . 6 6 9 . 4 8 1 2 . 5 0000 1 5 2 3 . 4
T h r o m b o c y t o p e n i a 4 6 . 3 1 1 . 6 6 9 . 4 0000 1 1 1 7 . 2
Investigations W e i g h t  d e c r e a s e d 6 9 . 4 5 7 . 8 000000 1 1 1 7 . 2
1HXWURSKLOFRXQWÄ» 3 4 . 7 1 1 . 6 003 4 . 7 007 1 0 . 9
Musculoskeletal P a i n  i n  e x t r e m i t y 5 7 . 8 2 3 . 1 1 1 . 6 00008 1 2 . 5
Psychiatric D e p r e s s i o n 4 6 . 3 3 4 . 7 0000007 1 0 . 9
Renal and urinary C h r o m a t u r i a 8 1 2 . 5 000000008 1 2 . 5
*Protocol therapy administration records were not available as of data extract for 2 of the 66 cohort patients.
Refer to the current version of the Investigatorâ€™s Brochure for  more comprehensive safety data.
2.4 SUMMARY
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 9 CONFIDENTIALBBI-608 at a dose of 240 mg BID (480 mg total daily) combined w ith a standard regimen of 
gemcitabine and nab-paclitaxel was tolerated in patients with a dvanced pancreatic cancer.  The clinical 
activity observed in the BBI608-118 (BBI608-201PANC) study, pai red with the unmet medical need 
for additional effective therapies in pancreatic cancer, provid es a rationale for further clinical 
investigation. CanStem111P is designed to evaluate the role of BBI-608 in combination with nab-
paclitaxel and gemcitabine as frontline therapy for metastatic PDAC.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 10 CONFIDENTIAL3.0 TRIAL DESIGN
This is an international multi-center, prospective, open label,  randomized phase III trial of BBI-608 
plus nab-paclitaxel with gemcitabine (Arm 1) versus nab-paclitaxel with gemcitabine (Arm 2) in adult 
patients with metastatic pancreatic adenocarcinoma.
Following the interim analysis, the trial will continue with pat ients who have not yet achieved the 
primary study endpoint (death), and with patients currently on protocol therapy and who may receive 
BBI-608 and/or gemcitabine and/or nab-paclitaxel on study based  on the clinical judgement of the 
investigator that this is in the patientâ€™s best interest, provi ded the patient is fully informed, in agreement
and has provided consent. Patients will receive protocol treatm ent until any of the discontinuation 
criteria are met or until February 28th, 2020, whichever occurs  first. The protocol will continue to be 
followed for all endpoints until study completion.  
3.1 STRATIFICATION
At randomization, patients will be stratified by:
1. Geographical region (North America/Western Europe/Australia v s. Japan/Korea vs. Rest of the 
World)  
2. ECOG performance status (ECOG 0 vsECOG 1) 
3. Presence of liver metastases (yes vs no) 
3.2 RANDOMIZATION
Patients will be randomized to the study according to a 1:1 rati o using a permuted block randomization 
procedure to receive one of the following 2 treatments:
1. Arm 1: BBI-608 plus nab-paclitaxel with gemcitabine  
2. Arm 2: nab-paclitaxel with gemcitabine  
Total planned sample size for this study is 1132 patients.
Patients will be randomized to one of the following two arms: 
Arm Study Treatment
Agent(s) Dose and Route Duration
1 BBI-608 240 mg orally two times daily1,2Patients may continue to receive protocol 
therapy as long as they have not 
experienced any adverse events requiring 
permanent discontinuation of study medication and have not demonstrated 
disease progression based on RECIST 1.1 criteria.
4,5Nab-paclitaxel 
with gemcitabineNab-Paclitaxel 125 mg/m2IV 
and
Gemcitabine 1000 mg/m2IV, 
on Days 1, 8 and 153
2
Nab-paclitaxel 
with gemcitabineNab-Paclitaxel 125 mg/m2IV 
and
Gemcitabine 1000 mg/m2IV, 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 11 CONFIDENTIALon Days 1, 8 and 153
1BBI-608 should be taken one hour before or two hours after a mea l, two times daily, with approximately 12 
hours between doses. BBI-608 administration will begin 2 days pri or to the backbone chemotherapy infusion 
on Day 1 of Cycle 1. These two days are referred to as Run-in Day 1 and Run-in Day 2 . The Run-in period 
may be extended by up to 3 additional calendar days. Run-in Day  1 should occur within 2 calendar days of 
patient randomization.
2Patients should be encouraged to maintain sufficient fluid inta ke while on protocol treatment, such as taking 
BBI-608 with approximately 250 mL of fluid over the course of 30  minutes after the dose.
3Nab-paclitaxel 125 mg/m2will be administered intravenously over approximately 30 minute s starting on Day 
1 of Cycle 1, at least 2 hours after the first daily dose of BB I-608. Gemcitabine 1000 mg/m2will be 
administered intravenously over approximately 30-60 minutes immed iately following nab-paclitaxel 
infusion. The infusions will repe at on Days 1, 8 and 15 of ever y 28-day cycle. 
4If nab-paclitaxel and/or gemcitabine is/are discontinued due to to xicity, BBI-608 may be continued as 
monotherapy until another criterion for stopping treatment is m et with the Sponsorâ€™s approval, if it is believed
to be in the patientâ€™s interest by the investigator and patient, and with the patientâ€™s informed consent. If BBI-
608 is discontinued due to toxicity, nab-paclitaxel and gemcitab ine may be continued until another criterion 
for stopping treatment is met.
5If at the time of disease progression based on RECIST 1.1 crite ria on nab-paclitaxel and gemcitabine with 
BBI-608, the patient has not experienced any adverse events req uiring permanent discontinuation of BBI-
608, the patient is not a candidate for second-line chemotherapy , it is believed to be in the patientâ€™s best
interest by the investigator and patient, and with the patientâ€™ s informed consent, BBI-608 may be continued 
in monotherapy following discontinuation of nab-paclitaxel and gemcitabine with the Sponsorâ€™s approval.
3.3 INCLUSION OF WOMEN AND MINORITIES
Patients enrolled in this study will be representative of the m ix of genders, races and ethnicities seen 
in the general population of patients with PDAC. The effect of the intervention under investigation 
will be analyzed in gender, racial and ethnic subgroups, with r ecognition of the potentially limited 
statistical power of this analysis.
3.4 PHARMACEUTICAL DATA
3.4.1 BBI-608  
Supplied: BBI-608 is supplied in 80 mg strength capsules. 
Stability: Initial product use dating is 24 months from the date of manufac ture and can be extended to 
a maximum of 5 years from date of manufacture assuming acceptab le results at re-assay time-point 
testing.
Storage: BBI-608 capsules should be stored in a tightly closed container  at a temperature between 15 
to 25ÂºC (59 Â°F to 77 Â°F).  
Route of Administration: Oral: Patients should take BBI-608 twice daily, approximately o ne hour prior 
to or two hours after meals, with the first dose given in the m orning and the second dose given 
approximately 12 hours later (ideally between 10 and 14 hours f rom the previous dose). 
3.4.2 Nab-Paclitaxel and Gemcitabine 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 12 CONFIDENTIALPlease refer to the nab-paclitaxel and gemcitabine Product Label s for product description, stability 
information, storage instructions, and route of administration.  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 13 CONFIDENTIAL4.0 STUDY POPULATION
The trial population will consist of subjects with metastatic hi stologically or cytologically confirmed 
PDAC. Subjects will not have received systemic chemotherapy for their  metastatic PDAC.
4.1 INCLUSION CRITERIA
Questions about eligibility criteria should be addressed prior torandomization. 
The eligibility criteria for this study have been carefully con sidered. Eligibility criteria are standards 
used to ensure that patients who enter this study are medically  appropriate candidates for this therapy, 
as well as to ensure that the results of this study can be usef ul for making treatment decisions regarding 
other patients with similar diseases. 
Eligibility criteria will be verified by the sponsor and/or spo nsor designee prior to patient 
randomization. 
Patients must fulfill all of the following criteria to be eligi ble for admission to the study:
4.1.1 Written, signed consent for trial participation must be obt ained from the patient appropriately 
in accordance with applicable ICH guidelines and local and regu latory requirements prior to 
the performance of any study specific procedure.
4.1.2 Must have histologically or cytologically confirmed advanc ed PDAC that is metastatic. The 
definitive diagnosis of metastatic PDAC will be made by integra ting the histopathological data 
within the context of the clinical and radiographic data. Patie nts with islet cell neoplasms are 
excluded. 
4.1.3 Must not have previously received chemotherapy or any inve stigational agent for the treatment 
of PDAC.
xA fluoropyrimidine or gemcitabine administered as a radiation s ensitizer in the adjuvant 
s e t t i n g  i s  a l l o w e d  f o r  a s  l o n g  a s  l a s t  d o s e  w a s  a d m i n i s t e r e d  >  6 months prior to 
randomization and no lingering toxicities are present. 
4.1.4 Nab-paclitaxel with gemcitabine therapy is appropriate for the patient and recommended by 
the Investigator.
4.1.5 Patient has one or more metastatic tumors evaluable by CT scan with contrast (or MRI, if 
patient is allergic to CT contrast media) per RECIST 1.1. Imaging  investigations including 
CT/MRI of chest/abdomen/pelvis or other scans as necessary to d ocument all sites of disease
must be performed within 14 days prior to randomization. Qualifyi ng scans performed as part 
of standard of care prior to pati ent signature of the study inf ormed consent will be acceptable 
as baseline scanning as long as scanning is performed < 14 days  prior to randomization. 
4.1.6 Must have ECOG Performance Status of 0 or 1, assessed with in 14 days prior to 
randomization. Two observers qualified to perform assessment of  the performance status will 
be required to perform this assessment. If discrepant, the one with the most deteriorated 
performance status will be considered true.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 14 CONFIDENTIALxPatients must not require any help with activities of daily liv ing (ADLs), including eating, 
dressing, washing or using the toilet.  
xPatients must not need to stay in bed or chair for 50% or more of waking hours. 
xPatients with factors that limit accurate assessment of perform a n c e  s t a t u s  w i l l  n o t  b e  
eligible for the study. This includes but is not limited to pat ients with pre-existing 
conditions preventing them from full mobility (including but no t limited to spinal or 
orthopedic conditions, amputees, morbid obesity defined by BMI > 40).
4.1.7 Must have life-expectancy of > 12 weeks.
4.1.8 Must be Â•\HDUVRIDJH .  
xDue to increased risk of sepsis in patients >80 years old, cand idate patients in this age 
group should be thoroughly evaluated prior to study randomizati on to ensure they are fit 
to receive chemotherapy. In addition to all of the inclusion/ex clusion criteria listed, 
clinical judgment should be used regarding patientsâ€™ susceptibi lity to infection (including 
but not limited to presence of ascites or diabetes mellitus inc reasing risk of infection). 
Furthermore, the expected stability of their performance status  while receiving repeat 
weekly chemotherapy cycles should be given special attention. P atients in this age group 
should not be randomized on the study should there be any hesita tion on any of these 
considerations. 
4.1.9 For male or female patients of child producing potential: Must agree to use contraception or 
take measures to avoid pregnancy during the study and for 180 d ays after the final dose of 
nab-paclitaxel and gemcitabine or for 30 days for female patients  and for 90 days for male 
patients, after the final BBI-608 dose if nab-paclitaxel and ge mcitabine were not administered. 
Adequate contraception is defined as follows:
1. Complete true abstinence: when this is in line with the prefe rred and usual lifestyle of the 
subject. 
2. Consistent and correct use of one of the following methods of  birth control: 
a. male partner who is sterile prior to the female subjects entr y into the study and is the 
sole sexual partner for that female subject; or 
b. implants of levonorgesterol; or 
c. injectable progestagen; or
d. any intrauterine device (IUD) with a documented failure rate of less than 1% per year; 
or 
e. any intrauterine hormone-releasing system (IUS) with a docume nted failure rate of 
less than 1% per year; or
f. oral contraceptive pill (either combined or progesterone only ); or 
g. one barrier method, for example diaphragm with spermicide or con dom with 
spermicide in combination with either implants of levonorgestero l or injectable 
progestagen, any intrauterine device (IUD) or intrauterine horm one-releasing system 
(IUS) with a documented failure rate of less than 1% per year, or oral contraceptive 
pill (either combined or progesterone only). 
4.1.10 Women of child bearing potential (WOCBP) must have a nega tive serum or urine pregnancy 
test within 3 days prior to randomization. The minimum sensitivit y of the pregnancy test must 
be 25 IU/L or equivalent units o f human chorionic gonadotropin (HCG). 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 15 CONFIDENTIALWOCBP include any female who has experienced menarche and who h as not undergone 
successful surgical sterilization (hysterectomy, bilateral tuba l ligation or bilateral 
oophorectomy) or is not postmenopausal (defined as amenorrhoea >  12 consecutive months; 
or women on hormone replacement therapy (HRT) with documented s erum follicle 
stimulating hormone (FSH) level > 35 mIU/mL). Even women who ar e using oral, implanted 
or injectable contraceptive hormones or mechanical products suc h as an intrauterine device or 
barrier methods (diaphragm, condoms, spermicides) to prevent pr egnancy or practicing 
abstinence or where partner is sterile (e.g. vasectomy), should  be considered to be of child 
bearing potential. 
4.1.11 Patient has adequate biological parameters as demonstrate d by the following blood counts at 
baseline (obtained < 14 days prior to randomization; laboratory  testing performed as part of 
standard of care prior to patient signature of informed consent  for the study will be acceptable 
as baseline laboratory work as long as testing is performed < 1 4 days prior to randomization):
xAbsolute neutrophil count (ANC) > 1.5 x 109/L  
xPlatelet count > 100,000/mm3(100 x 109/L). Must not have required transfusion of 
platelets within 1 week of baseline platelet count assessment.
xHemoglobin (Hgb) > 9 g/dL. Must not have required transfusion of  red blood cells within 
1 week of baseline Hgb assessment.
4.1.12 Patient has the following blood chemistry levels at basel ine (obtained < 14 days prior to 
randomization; laboratory testing performed as part of standard  of care prior to patient 
signature of informed consent for the study will be acceptable as baseline laboratory work as 
long as testing is performed < 14 days prior to randomization):
xAST (SGOT) and ALT (SG 37Â”Ã®LQVWLWXWLRQDOXSSHUOLPLWRIQRUPDO8/1>Â”Ã®
ULN in presence of liver metastases] 
x7RWDOELOLUXELQÂ” 1.5 x institutional ULN. If total bilirubin is > ULN and < 1.5 x ULN, it 
must be non-rising for at least 7 days.
xSerum creatinine within normal limits or calculated clearance >  60 mL/min/1.73 m2for 
patients with serum creatinine levels above or below the instit utional normal value. If 
using creatinine clearance, actual body weight should be used f or calculating creatinine 
clearance (eg. Using the Cockroft-Gault formula). For patients with a Body Mass Index 
(BMI) > 30 kg/m2, lean body weight should be used instead. 
4.1.13 Patient not on anticoagulation has acceptable coagulation  studies (obtained < 14 days prior to 
randomization; laboratory testing performed as part of standard  of care prior to patient 
signature of informed consent for the study will be acceptable as baseline laboratory work as 
long as testing is performed < 14 days prior to randomization) a s demonstrated by prothrombin 
time (PT) and partial thromboplastin time (PTT) below or within  normal limits (+15%). 
xPatients on anticoagulation must have coagulation values within  the therapeutic range 
appropriate for the anti-coagulation indication. 
4.1.14 Patient has no clinically significant abnormalities on ur inalysis results (obtained < 14 days 
prior to randomization; laboratory testing performed as part of  standard of care prior to patient 
signature of informed consent for the study will be acceptable as baseline laboratory work as 
long as testing is performed < 14 days prior to randomization).  
4.1.15 Patient must have adequate nutritional status with Body M ass Index (BMI) > 18 kg/m2and 
body weight of > 40 kg wit h serum albumin > 3 g/dL. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 16 CONFIDENTIAL4.1.16 Baseline laboratory evaluations must be done within 14 day s prior to randomization and some 
must be repeated < 72 hours prior to randomization, as listed i n Section 5.0.  
4.1.17 Patients requiring biliary stent placement must have bili ary stent placed > 7 days prior to 
screening.  
4.1.18 Pain symptoms should be stabl e (of tolerable Grade 2 or l ess). 
4.1.19 Only patients with available archival tumor tissue must co nsent to provision of, and 
Investigator(s) must confirm access to and agree to submit a re presentative formalin fixed 
paraffin block of tumor tissue in  order that the specific corre lative marker assays proscribed 
in Section 13.6 (Correlative Studies) of this protocol may be c onducted. Submission of the 
tissue does not have to occur prior to randomization. Where loc al center regulations prohibit 
submission of blocks of tumor tissue, two 2 mm cores of tumor f rom the block and 5-20 
unstained slides of whole sections of representative tumor tissu e are preferred. Where it is not 
possible to obtain two 2 mm cores of tumor from the block, 5-20  unstained slides of 
representative tumor tissue are also acceptable. 
xWhere no previously resected or biopsied tumor tissue exists or is available, on the
approval of the Sponsor/designated CRO, the patient may still b e considered eligible for 
the study.  
4.1.20 Patient must consent to provision of a sample of blood in  order that the specific correlative 
marker assays proscribed in Section 13.6 (Correlative Studies) may be conducted. 
4.1.21 Patients must be accessible for treatment and follow-up. Patients registered on this trial must 
receive protocol treatment and be followed at the participating center. This implies there must 
be reasonable geographical limits placed on patients being cons idered for this trial. 
Investigators must ensure that the patients randomized on this t r i a l  w i l l  b e  a v a i l a b l e  f o r  
complete documentation of the treatment, response assessment, a dverse events, and follow-
up.
4.1.22 Protocol treatment is to begin within 2 calendar days of p atient randomization for patients 
randomized to Arm 1. Patients randomized to Arm 2 must begin pr otocol treatment within 7
calendar days of randomization. 
4.1.23 The patient is not receiving therapy in a concurrent clin ical study and the patient agrees not to 
participate in other interventional clinical studies during the ir participation in this trial while 
on study treatment. Patients participating in surveys or observa tional studies are eligible to 
participate in this study.
4.2 EXCLUSION CRITERIA
Patients who fulfill any of the following criteria are not elig ible for admission to the study:
4.2.1 Patients with no evidence of metastatic disease as well as pa tients with a local recurrence 
following surgical resection of primary lesion.
4.2.2 Patient has experienced a decline in ECOG performance status between Baseline visit and 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 17 CONFIDENTIALwithin 72 hours prior to randomization.
4.2.3 Patient has a > 20% decrease in serum albumin level betwee n Baseline visit and within 72 
hours prior to randomization.
4.2.4 Patient has a > 10% decrease in weight between Baseline vi sit and within 72 hours prior to 
randomization. 
4.2.5 Any prior anti-cancer chemotherapy, biologic or investigati onal therapy for PDAC.
a. Patients receiving immunotherapy for non-cancer related treat ment within < 4 weeks of 
first planned dose of study t reatment will be excluded. 
b. A fluoropyrimidine or gemcitabine administered as a radiation  sensitizer in the adjuvant 
s e t t i n g  i s  a l l o w e d f o r  a s l o n g  a s  l a s t  d o s e  w a s  a d m i n i s t e r e d  >  6  months prior to 
randomization. 
4.2.6 Major surgery within 4 weeks prior to randomization. 4.2.7 Any known brain or leptomeningeal metastases are excluded,  even if treated.
4.2.8 Patients with clinically significant ascites or pleural eff usions. 
4.2.9 Women who are pregnant or breastfeeding. Women should not b reastfeed while taking study 
treatment and for 4 weeks after the last dose of BBI-608 or whi le undergoing treatment with 
nab-paclitaxel and gemcitabine and for 180 days after the last d ose of nab-paclitaxel and 
gemcitabine.
4.2.10 Gastrointestinal disorder(s) which, in the opinion of the  Principal Investigator, would 
significantly impede the absorption of an oral agent (e.g. acti ve Crohnâ€™s disease, ulcerative 
colitis, extensive gastric and small intestine resection).
4.2.11 Unable or unwilling to swallow BBI-608 capsules daily.
4.2.12 Uncontrolled inter-current illness including, but not lim ited to, ongoing or active infection, 
clinically significant non-healing or healing wounds, symptomat ic congestive heart failure, 
unstable angina pectoris, clinically significant cardiac arrhyt hmia, significant pulmonary 
disease (shortness of breath at rest or mild exertion), uncontr olled infection or psychiatric 
illness/social situations that would limit compliance with stud y requirements. 
a. History of cardiac disease: congestive heart failure (CHF) > NYHA Class II; active 
coronary artery disease, myocardial infarction or coronary sten ting within 6 months prior 
to randomization; unevaluated new onset angina within 3 months or unstable angina 
(angina symptoms at rest) or cardiac arrhythmias requiring anti -arrhythmic therapy (beta 
blockers or digoxin are permitted). 
b. Current uncontrolled hypertension (systolic blood pressure [B P] > 150 mmHg or diastolic 
pressure > 90 mmHg despite optimal medical management) as well as prior history of 
hypertensive crisis or hypertensive encephalopathy. 
c. Significant vascular disease (e.g., aortic aneurysm, aortic d issection, symptomatic 
peripheral vascular disease including claudication, Leo Buergerâ€™ s disease). Treated 
peripheral vascular disease that is stable for at least 6 month s is allowed. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 18 CONFIDENTIALd. Evidence of bleeding diathesis or clinically significant coag ulopathy.  
e. Major surgical procedure (including open biopsy, significant traumatic injury, etc.) within 
28 days, or anticipation of the need for major surgical procedu re during the course of the 
study as well as minor surgical procedure (excluding placement of a vascular access 
device or bone marrow biopsy) within 7 days prior to randomizat ion.  
f. Patients with clinically significant abnormalities on urinaly sis at < 14 days prior to 
randomization. 
g. History of abdominal fistula, gastrointestinal perforation, o r intra-abdominal abscess 
within 6 months prior to randomization.  
h. Ongoing serious, non-healing wound, ulcer, or bone fracture.  
i. Known infection with Human Immunodeficiency Virus (HIV), and/ or active infection 
with hepatitis B, or hepatitis C.
j. History of interstitial lung disease, history of slowly progres sive dyspnea and 
unproductive cough, sarcoidosis, silicosis, idiopathic pulmonar y fibrosis, pulmonary 
hypersensitivity pneumonitis or multiple allergies. 
k. History of hemolytic-uremic syndrome. 
l. History of connective tissue  disorders (eg, lupus, scleroderm a, arteritis nodosa). 
m. Serious medical risk factors involving any of the major organ  systems, or serious 
psychiatric disorders that could compromise the patientâ€™s safet y or the study data integrity.
4.2.13 Known hypersensitivity to gemcitabine, taxanes or any of their excipients, or the patient 
exhibits any of the events outlined in the Contraindications or  Special Warnings and 
Precautions sections of the product or comparator SmPC or Presc ribing Information. Possible 
hypersensitivity to BBI-608 or one of the excipients which incl ude the azo dyes sunset yellow 
and allura red.
4.2.14 Neurosensory neuropathy > grade 2 at baseline. 
4.2.15 Uncontrolled chronic diarrhea > grade 2 at baseline. 
4.2.16 Patients being treated with Warfarin. 
4.2.17 Patients with active, uncontrolled bacterial, viral or fu ngal infection(s) requiring systemic 
therapy 
4.2.18 Patients with a history of other malignancies except: ade quately treated non-melanoma skin 
cancer, curatively treated in-situ cancer of the cervix, or oth er solid tumors curatively treated 
by surgery alone or surgery plus radiotherapy with no evidence of disease continuously for > 
5 years.
4.2.19 Any active disease condition which would render the proto col treatment dangerous or impair 
the ability of the patient to receive protocol therapy.
4.2.20 Any condition (e.g. psychological, geographical, etc.) th at does not permit compliance with 
the protocol, including patients with history of poor complianc e or history of drug/alcohol 
abuse, or excessive alcohol beverage consumption that would inte rfere with the ability to 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 19 CONFIDENTIALcomply with the study protocol. Patients planning to take a vaca tion for 14 or more consecutive 
days during the course of the study are ineligible. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 20 CONFIDENTIAL5.0 PRE-RANDOMIZATION (BASELINE) SCHEDULE OF EVENTS (SEE APPENDI CES I AND
II) 
Baseline evaluations will be performed for all patients to dete rmine study eligibility. These evaluations 
must be obtained < 14 days prior to randomization.  
Repeat of screening laboratory tests will be allowed only in th e event of a laboratory error or for 
patients who halted screening previously without having failed any of the screening tests/evaluations 
or inclusion criteria for this study. Otherwise, re-screening w ill not be allowed. 
Any questions regarding patient eligibility should be directed to Sponsor or other Sponsor-nominated 
designee for written approval.  
Additional testing will be repeated < 72 hours prior to randomi zation: ECOG performance status (PS),
vital signs, weight, concurrent  medication list and serum album in will be repeated at < 72 hours prior 
to randomization after first being performed as part of Baseline  testing. Total bilirubin will be repeated 
< 72 hours prior to randomization for patients with total bilir ubin > 1 and < 1.5 x ULN at Baseline 
testing with at least 7 days between Baseline and repeat assess ments.
All appropriate eCRF pages must be completed for patients prior  to obtaining pre-randomization 
approval and following completion of additional testing at < 72  hours prior to randomization, in 
accordance with the eCRF completion guidelines and the Eligibil ity Verification Procedure Flow 
Chart. 
Investigations Timing of Baseline 
Evaluation prior to 
randomizationAdditional Testing at <
72 hrs prior to 
randomization3
Informed Consent1â€¢Signature < 14 days
Patient History and 
Evaluation including:â€¢All known prior medical and therapeutic history2
â€¢Physical examination11, 14
â€¢Vital signs5,11
â€¢Height, weight12, ECOG performance status11
â€¢Concurrent medication list11< 14 days x ECOG performance 
status
x Vital signs5
x Weight
x Concurrent 
medication list4
Hematology â€¢CBC + 5-part differential
â€¢Platelet count<1 4d a y s11-
Biochemistry â€¢Creatinine6, Total Bilirubin, AST, ALT, Alkaline 
Phosphatase, LDH, Albumin, Sodium, Potassium, Ma
gnesium, Phos phate, BUN (blood urea nitro gen)<1 4d a y s11x Serum Albumin
x Total Bilirubin12,13
Urinalysis â€¢Dipstick (including protein, specific gravity, 
glucose and blood )<1 4d a y s11-
Coagulation â€¢PT
â€¢PTT< 14 days11-
Tumor Marker â€¢CA 19-9 <1 4d a y s11-
Cardiac Assessment â€¢ECG (12 lead ) < 14 days11-
Radiology & Imaging7â€¢CT/MRI scan of chest/abdomen/pelvis with tumor 
measurement and evaluation b y RECIST 1.1 criteria< 14 days -
Correlative Studies â€¢Submission of representative diagnostic tumor 
tissue8On request -
â€¢Blood sam ple collection8 < 14 days -
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 21 CONFIDENTIALOther Investigations â€¢Serum or urine pregnanc y test9 <3d a y s -
Adverse Events10â€¢Baseline adverse event evaluation (to document 
residual adverse event from previous therapy and baseline s
ymptoms )< 14 days -
Quality of Life â€¢EORTC QLQ-C30 < 14 days -
1Study participants will undergo signature of informed consent p rior to randomization.
2Medical history must include date of diagnosis including histol ogical or cytological documentation of malignancy. 
3Patient will be excluded from participation if any of the follo wing occurs at < 72 hours prior to randomization: increase in EC OG PS
(two observers will be required to assess KPS on each occasion and if discrepant, the one with the most deteriorated performan ce status
will be considered true), weight loss of >10% from baseline tes ting, > 20% decrease in serum alb umin from baseline testing, or  in the 
event of a clinically-significant change in vital signs. 
4Any anesthesia procedures, such as spinal block or other inject ions administered for pain control following Baseline Evaluatio n will be 
reported at < 72 hours prior to randomization.
5Vital signs include temperature, heart rate, blood pressure, re spiratory rate and O 2saturation on room air.
6Baseline creatinine or creatinine clearance may be used to demo nstrate eligibility as per section 4.1.
7Standard tumor measurement procedures will be followed to asses s response to therapy. The same method of assessment and the sa me 
technique should be used to identify and report each lesion at baseline and at reassessment. Qualifying scans performed as par t of 
standard of care prior to patient  signature of the study inform ed consent will be acceptable as baseline scanning as long as sc anning is 
performed < 14 days prior to randomization. Should clinical or r adiologic progression occur from the time of baseline imaging p rior to 
randomization, a new baseline scan will need to be obtained pri or to randomization. 
8Details for collection, processing, storing and shipping these samples will be provided in a sep arate laboratory procedure man ual.
9In women of childbearing potential only. The minimum sensitivit y of the pregnancy test must be 25 IU/L or equivalent units of H CG.
10Adverse events will be graded according to the NCI Common Termi nology Criteria for Adverse Events version 4.0 (see Appendix IV ). 
11Laboratory testing performed as part of standard of care prior to patient signature of the study consent will be acceptable as  baseline 
labwork as long as testing is performed < 14 days prior to rand omization. If required laboratory tests cannot be performed wit hin 
indicated timelines due to technical reasons, lab retest and pr olongation of the screening period for 3 working days is allowe d.
12Total bilirubin assessment at < 72 hours prior to randomization  will be performed only for patients who had total bilirubin of  > 1 and < 
1.5 x ULN at baseline measurement. Patients with total bilirubin  < 1 ULN at baseline measurement will not require repeat total bilirubin 
measurement at < 72 hours prior to randomization.
13At least 7 days must pass between Baseline and < 72 hour measur ements of total bilirubin for pa tients with baseline total bili rubin 
measurement of > 1 and < 1.5 x ULN.
14A physical exam should include general appearance, HEENT (head,  eyes, ears, nose), dermatological, respiratory, 
cardiovascular/circulatory, abdomen, lymphatic, genitourinary, musculoskeletal, and neurological assessments.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 22 CONFIDENTIAL6.0 ENTRY/RANDOMIZATION PROCEDURES
6.1 ENTRY PROCEDURES
Repeat of screening laboratory testing will be allowed only in case of laboratory error. Otherwise, re-
screening will not be allowed for patients who screen fail duri ng initial screening procedures. 
Following Sponsor approval of patient eligibility pre-randomiza tion, patients will be randomized. All 
randomizations will be done through the randomization and trial  supply management (RTSM) system.
Complete details regarding obtaining a password, accessing the system and registering/randomizing 
patients will be provided at the time of study activation.  
All patients screened for the study by the participating treatm ent center will be assigned a subject 
screening number and all eligible patients enrolled on the stud y will be assigned an additional subject 
randomization number; these must be used on all documentation a nd correspondence. 
The following information will be required:
xpatientâ€™s date of birth (as allowed by local regulations) and a ge 
xpatient's initials (as allowed by local regulations)  
xconfirmation of the requirements listed in sections 4.1 and 4.2  
xstratification factors 
6.2 STRATIFICATION
The permuted block randomization procedure will balance between  treatment arms within each of the 
following stratification factors:
xGeographical region (North America/Western Europe/Australia vs.  Japan/Korea vs. Rest of the 
World)  
xECOG performance status (0 vs. 1)
xPresence of liver metastases (yes vs. no)
6.3 RANDOMIZATION
Patients will be randomized 1:1 between the two treatment arms and the randomization will be 
provided electronically (via RTSM). 
Note: The validity of results of the trial depends on the authe nticity of, and the follow-up of, all 
patients entered into the trial. Under no circumstances, theref ore, may an allocated patientâ€™s data be 
withdrawn prior to final analysis, unless the participant withd raws from the trial and requests that data 
collection/submission cease from the point in time of withdrawa l.
All eligible patients randomized to the trial will be followed by the coordinating center. It is the 
responsibility of the physician investigator to have full satis faction in that the patient is indeed eligible 
before requesting randomization. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 23 CONFIDENTIALAll randomized patients are to be followed until death or until  the study sponsor or sponsorâ€™s designee
inform sites that further follow-up is no longer required. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 24 CONFIDENTIAL7.0 PROTOCOL TREATMENT
7.1 TREATMENT PLAN
Protocol treatment is to begin within 2 calendar days of patient  randomization for patients randomized 
to Arm 1. Patients randomized to Arm 2 must begin protocol trea tment within 7 calendar days of 
randomization. 
Palliative and supportive care for other disease-related sympto ms and for toxicity associated with 
treatment will be permitted for all patients on this trial. Deta ils of interventions (e.g. medications such 
as antibiotics, analgesics, antihistamines, steroids, G-CSF, er ythropoietin), procedures (e.g. 
paracentesis, thoracentesis), or blood products (e.g. blood cel ls, platelets, or fresh frozen plasma 
transfusions) should be recorded on the case report forms.
Patients may continue to receive assigned protocol therapy unti l any of the discontinuation criteria are 
met or until February 28th, 2020, when the study is planned for completion, whichever occ urs first.
7.2 DRUG ADMINISTRATION
One treatment cycle is defined as 4 weeks (28 days) with BBI-608  administered continuously, and 
nab-paclitaxel with gemcitabine administered weekly for 3 conse cutive weeks with the fourth week 
off. BBI-608 administration will begin 2 days prior to the first nab-paclitaxel and gemcitabine infusion 
administered on Day 1 of Cycle 1. These two days are referred t o as Run-In Day 1 and Run-In Day 2 . 
The Run-in period may be extended by up to 3 additional calendar days. In case of gastrointestinal 
toxicity secondary to BBI-608, administration of nab-paclitaxel  with gemcitabine may be delayed for 
as long as necessary until resolution of symptoms.
Arm Agent(s) Dose and Route Duration
1 BBI-608  240 mg orally two times daily1,2 
Patients may continue to receive protocol 
therapy as long as they have not experienced 
any adverse events requiring permanent discontinuation of study medication and have not demonstrated disease progression based on 
RECIST 1.1 criteria. 
4,5Gemcitabine
+nab-PaclitaxelNab-Paclitaxel 125 mg/m2IV and
Gemcitabine 1000 mg/m2IV, on Days 
1, 8 and 153
2 Gemcitabine
+nab-Paclitaxel  Nab-Paclitaxel 125 mg/m2IV and
Gemcitabine 1000 mg/m2IV, on Days 
1, 8 and 153
1BBI-608 should be taken one hour before or two hours after a mea l, two times daily, with approximately 12 hours 
between doses. BBI-608 administration will begin 2 days prior to the nab-paclitaxel and gemcitabine infusions on 
day 1 of cycle 1. These two days are referred to as Run-in Day 1 andRun-in Day 2 (run-in period may be extended 
by up to 3 additional calendar days). Run-in Day 1 should occur  within 2 calendar days of patient randomization
for patients randomized to Arm 1. Patients randomized to Arm 2 must begin protocol treatment within 7 calendar 
days of randomization. In case of gastrointestinal toxicity seco ndary to BBI-608, administration of nab-paclitaxel 
and/or gemcitabine may be delayed  for as long as necessary until resolution of symptoms.
2Patients should be encouraged to maintain sufficient fluid inta ke while on protocol treatment, such as taking BBI-
608 with approximately 250 mL of fluid over the course of 30 min utes after the dose.
3Nab-paclitaxel 125 mg/m2will be administered intravenously over approximately 30 minutes  starting on Day 1 of 
Cycle 1, at least 2 hours after the first daily dose of BBI-608 . Gemcitabine 1000 mg/m2will be administered 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 25 CONFIDENTIALintravenously over approximately 30-60 minutes immediately follow ing nab-paclitaxel infusion. The infusions will 
repeat on Days 1, 8 and 15 of every 28-day cycle. 
4If either nab-paclitaxel and/or gemcitabine is discontinued due  to toxicity, BBI-608 may be continued as 
monotherapy until another criterion for stopping treatment is m et with the Sponsorâ€™s approval, if it is believed to 
be in the patientâ€™s best interest by the investigator and patien t, and with the patientâ€™s informed consent. If BBI-608
is discontinued due to toxicity, nab-paclitaxel and/or gemcitabi ne may be continued until another criterion for 
stopping treatment is met.
5If at the time of disease progression based on RECIST 1.1 crite ria on nab-paclitaxel and gemcitabine with BBI-
608, the patient has not experienced any adverse events requirin g permanent discontinuation of BBI-608,the patient 
is not a candidate for second-line chemotherapy, it is believed t o be in the patientâ€™s best interest by the investigator 
and patient, and with the patientâ€™s informed consent, BBI-608 ma y be continued in monotherapy following 
discontinuation of nab-paclitaxel and gemcitabine with the Spons orâ€™s approval. 
Patients will receive BBI-608 two times daily, approximately one hour prior to or two hours after 
meals, with the first dose given in the morning and the second dose given approximately 12 hours 
later.
Detailed instructions for the preparation, premedication, and a dministration of nab-paclitaxel with 
gemcitabine are provided in the Product Labels approved by US FD A and/or Summary of Product 
Characteristics. Nab-paclitaxel 125 mg/m2will be administered intravenously over approximately 30 
minutes starting on Day 1 of Cycle 1, following the first dose of BBI-608. Gemcitabine 1000 mg/m2
will be administered intravenously over approximately 30-60 min utes immediately following nab-
paclitaxel infusion. The infusions will repeat on Day 1, 8 and 15 of every 28-day cycle. In case of 
toxicity, dose adjustment is permitted.  
If either gemcitabine and/or nab-paclitaxel is/are permanently dis continued due to toxicity, BBI-608 
may be continued as monotherapy until another criterion for sto pping treatment is met with the 
Sponsorâ€™s approval, it is believed to be in the patientâ€™s best inte rest by the investigator and patient, and 
with the patientâ€™s informed consent. If BBI-608 is permanently discontinued due to toxicity, nab-
paclitaxel with gemcitabine may be continued until another crite rion for stopping treatment is met. 
Handling instructions for BBI-608 will be provided to all sites . Investigators may refer to the 
Investigator Brochure for detailed instructions.
Drug Dosing Schedule
Week112345678
nab-Paclitaxel/Gemcitabine Cycle 1 Cycle 2 and 
Beyond
XXX XXX
BBI-6082Cycle 1 Cycle 2 and 
Beyond
XXXXXXXX
1Nab-Paclitaxel/Gemcitabine weekly dosing is scheduled once weekl y for 3 consecutive weeks 
with forth week off. 
2BBI-608 dosing is scheduled twice daily continuously throughout  the study. 
7.3 ADVERSE EVENT PROPHYLAXIS
7.3.1 BBI-608 
Gastrointestinal Prophylaxis
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 26 CONFIDENTIALThe major adverse events associated with the use of BBI-608 are gastrointestinal events (nausea, 
diarrhea, and abdominal cramping) and fatigue. Fatigue is often  secondary to gastrointestinal events. 
There is no hematologic toxicity associated with BBI-608. We st rongly recommend that pre-existing 
laxative bowel regimens, such as stool softeners, be held start ing the day prior to first dose of study 
treatment and may be resumed in cases of no bowel movement duri ng the first 2 days of protocol 
treatment. Fiber supplementation may be continued. Additionally , prophylactic anti-diarrheal 
medications, such as Loperamide and/or Diphenoxylate/Atropine, starting 1 day prior to start of BBI-
608 are strongly recommended for all patients without history of c onstipation (just prior to 
randomization) for the first 4 weeks of study treatment with BBI -608. Antidiarrheal prophylaxis should 
be held if constipation develops. Details regarding the use of p rophylactic medication for the 
management of common BBI-608 related gastrointestinal adverse e vents are specified in the 
supplementary Adverse Event Management handout as well as in th e Pharmacy Manual.
No hematologic toxicity related  to BBI-608 treatment has been o bserved.
BBI-608 Pre-Medication Recommendations:
Category Specific Measures Start End
Anti-DiarrhealLoperamide 4 mg BID
or
Diphenoxylate/Atropine 
5 mg BID24 hours prior to the 
first dose of BBI608 on Run-In Day 1S t o p  a n t i - d i a r r h e a l  i f  t h e r e  a r e  n o  
bowel movements during the first 2 
days of administration of BBI-608. 
Should be continued for the first 4 
weeks of treatment with BBI-608.
Can be continued and/or modified 
a t  t h e  d i s c r e t i o n  o f  t h e  t r e a t i n g  investigator
Anti-EmeticOndansetron 8 mg once
orOther anti-emetic  (5HT3-
antagonist preferred)Approx. 1 hour prior 
t o  t h e  f i r s t  d o s e  o f  BBI608 on Run-In 
Day 1Should be continued for the first 4 
weeks of treatment with BBI-608.
May be continued and/or modified 
at discretion of treating investigator
7.3.2 Nab-Paclitaxel and Gemcitabine
Anti-Emetic Prophylaxis
Initial antiemetic prophylaxis is strongly recommended with a 5 HT3 agent (PO or IV) in combination 
with dexamethasone 8 or 10 mg (PO or IV) prior to administratio n of Gemcitabine. Dexamethasone 
may be continued at the dose of 4 mg twice daily or three times  daily for 3-4 days at the Investigatorâ€™s 
discretion. If a patient experiences nausea and/or vomiting fol lowing the first dose, Institutional 
guidelines and Investigatorâ€™s recommendations should be followe d for breakthrough antiemetic 
management.  
Hematopoietic Support Administration
G-CSF support may be given according to Institutional standards  for the treatment of neutropenia 
and/or thrombocytopenia, neutropenic fever or infections associ ated with neutropenia and for the 
prevention of febrile neutropenia in patients with an ANC < 500  cells/ml. Patients not experiencing 
resolution of neutropenia within 21 days, despite uninterrupted  granulocyte stimulating factor 
treatment, will discontinue study treatment. Erythropoietin may be administered at the discretion of 
the Investigator, consistent with Institutional guidelines.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 27 CONFIDENTIALSepsis Prophylaxis 
At the first occurrence of fever > 38.5 0C, patients should be instructed to immediately contact their 
physician. Prophylactic institution of broad-spectrum antibioti cs (such as amoxicillin/clavulanate 500 
mg PO 2-3 times daily) should be considered for febrile patient s at the Investigator discretion and/or 
as per Institutional standards. On day of randomization, patien ts should be provided with enough 
antibiotic for use at home, and they should be instructed to be gin taking it when they first record a 
temperature of > 38.5 0C (or if they feel they are developing a fever and a thermomete r is not available). 
They should also immediately contact their physician for guidan ce on where to go for blood counts to 
be evaluated for sepsis as soon as possible. Hospitalization or  evaluation in the emergency room may 
be required depending on their clinical presentation. Administra tion of prophylactic antibiotics to 
otherwise uncomplicated patients with biliary stents will be at  the discretion of the Investigator. Biliary 
stents should be monitored closel y to determine need for replac ement. 
Due to increased risk of sepsis in patients >80 years old, cand idate patients in this age group should 
be carefully followed clinically throughout study treatment. Th is patient population will also be 
carefully monitored by the independent DSMB. 
7.4 BBI-608 DOSE MODIFICATION
The major adverse events associated with the use of BBI-608 are gastrointestinal events (nausea, 
diarrhea, and abdominal cramping) and fatigue. Fatigue is often  secondary to gastrointestinal events. 
There is no hematologic toxicity associated with BBI-608. We re commend that pre-exiting laxative 
bowel regimens, such as stool softeners, be held starting the d ay prior to first dose of BBI-608 
treatment and may be resumed in cases of no bowel movement duri ng the first 2 days of BBI-608 
treatment. Fiber supplementation may be continued. Additionally , prophylactic anti-diarrheal 
medications, such as Loperamide and/or Diphenoxylate/Atropine, starting 1 day prior to start of BBI-
608 are strongly recommended for all patients treated with BBI-60 8. 
The guidelines that follow outline dosing modifications and rec ommended interventions should the 
above adverse events occur. 
Adverse events will be graded using the NCI Common Terminology C riteria for Adverse Events 
(CTCAE) Version 4.0 (see Appendix IV). If a patient experiences se veral adverse events and there are 
conflicting recommendations, please use the recommended dose ad justment that reduces the dose to 
the lowest level.
BBI-608 Dose Modification Recommen dations For Gastrointestinal Adverse Events:
Suspected BBI-608 -Related 
Adverse Event Investi gator Action
Grade 1 or tolerable Grade 2 SymptomsPatient should remain at current dose. Attempt pharmacologic me asures to 
minimize symptoms (see symptom specific treatment table below).
Intolerable Grade 2 SymptomsIf intolerable symptoms persist despite optimized medical manag ement, 
dose reduction and sufficient oral hydration are recommended. A  dose 
interruption of Â½ to 3 days prior to reduction can also be cons idered. 
Dosing should be reduced to the next Modification Level on the dose 
modification table . Pharmacologic symptom support and/or prophylaxis 
should be maintained. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 28 CONFIDENTIALAfter a dose reduction, AM and PM doses may be increased in 80 mg 
increments every 3-7 days as tolerated.*,**
Grade 3 or 4 SymptomsA dose interruption of Â½ to 3 days is recommended until symptom s are 
UHGXFHGWRÂ”WROHUDEOHJUDGH
Dosing should be reduced to the next Modification Level on the dose 
modification table . Pharmacologic symptom support and/or prophylaxis 
should be maintained. 
After a dose reduction, AM and PM doses may be increased in 80 mg 
increments every 3-7 days as tolerated.*,**
* If, during the course of re-escalation, a dosing regimen is n ot tolerated despite optimized medical management, 
dosing should return to the highest previously tolerated dosing  regimen.
** As ymmetr y between AM and PM dose is allowed durin g re-escalation (e.g. 160 m g AM/240 m g PM).
BBI-608 Dose Modification Table: 
Dose Level Dose
Full dose 240 mg twice daily (q12h)
Modification Level-1 80 mg twice daily (q12h), up-titrate as to lerated**
Modification Level-2 80 mg once daily*, up-titrate as tolerated **
* If 80 mg once daily is not tolerated, a dose interruption of 1 -3 days followed by re-challenge at 80 mg once daily is 
recommended.
** Morning and evening doses can be increased in 80 mg increment s every 3-7 days or slower as tolerated, up to 240
mg two times dail y. 
Recommended symptom-specific supportive treatment for common BB I-608-related adverse events is 
as follows (unless contraindicated). Prophylactic anti-diarrhea l medications, such as Imodium and/or 
lomotil, starting 1 day prior to start of BBI-608 are strongly recommended for all patients: 
BBI-608 GI Toxicity/Adverse Event Supportive Treatment:
Diarrhea & Abdominal Cramping Nausea, Vomiting, or Anorexia
Dicyclomine (e.g., Bentyl) : Recommended when the 
predominant issue is cramping or abdominal pain1stline: 5HT3-inhibitors (Ondansetron, 
Palonosetron, Granisetron)
Diphenoxylate/atropine (Lomotil)
Loperamide (Imodium)These agents 
may be also 
be useful in 
combination2ndline: Dexamethasone (Decadron) , ideally in 
combination with a 5HT3-inhibitor. Short term use 
can be very effective
Systemic opioids (e.g. Dilaudid, Codeine ): have been 
found effective in reducing abdominal pain and watery 
diarrheaOth er  a gen ts : anti-histamines, benzodiazepines, 
proton pump inhibitors/H2 antagonists, dopamine 
antagonists, and cannabinoids
Hyoscine (Buscopan, Scopolamine, Levsin) :A n t i -
spasmodic agents helpful for abdominal cramping
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 29 CONFIDENTIALBudesonide ( Entocort EC ):Corticosteroid with limited 
systemic absorption;  9 mg once daily for 8 to 12 weeks
Details regarding the use of supportive medication for the mana gement of common BBI-608-related 
adverse events are specified in the supplementary Adverse Event  Management handout as well as in 
the Pharmacy Manual.
7.4.1 Hematologic Adverse EventsNo hematologic toxicity related to BBI-608 treatment has been o bserved. Should a study subject 
experience a Grade 1 or 2 hematologic adverse event, dosing may  continue while an alternate 
explanation is sought and/or a therapeutic intervention is unde rtaken.  
In the unlikely event of a Grade 3 or 4 hematologic adverse eve nt, continued dosing will be at the 
discretion of the study Investigator. Since a Grade 3 or 4 hema tologic event attributed to BBI-608 has 
not been reported, a prompt evaluation for an alternate explana tion is strongly recommended.  
7.4.2 Non-Hematologic (Gastrointestinal) Adverse Events
The dose modifications above should be followed in the occurrenc e of gastrointestinal adverse events 
or in the event of their sequelae. BBI-608 dose modification sh ould not be followed for non-
gastrointestinal events as they are not expected with use of BB I-608. Toxic effects will be graded using 
the NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (Appendix IV).  
7.4.3 Other Situations Change in Urine Color and Odor: Occasionally, subjects have reported an orange-brown color chan ge 
to their urine. Rarely, subjects also report a new odor to thei r urine. All subjects should be made aware 
of the possibility of these effects. Dosing can be continued in  the presence of these events. 
7.5 NAB-PACLITAXEL AND GEMCITABINE DOSE MODIFICATION
Dose modifications for hematologic and non-hematologic toxiciti es (using NCI CTCAE Version 4.0) 
expected from nab-paclitaxel with gemcitabine should be performe d according to the 
recommendations outlined below. Dose modifications for non-gast rointestinal toxicities expected 
from nab-paclitaxel with gemcitabine may also follow institutio nal guidelines. There will no dose 
reductions or adjustments for lymphopenia or alopecia. Dose lev el modifications of nab-paclitaxel and 
gemcitabine will occur at two dose levels. Any toxicity requirin g dose level modification beyond the 
second dose modification warrants treatment discontinuation. An y further dose modification may be 
allowed in line with clinical practice per Sponsor and Investig ator agreement..  
When a dose reduction is required, no dose reescalation will be  permitted for the duration of study 
treatment (with exception for hematologic toxicity on Day 15 wh en re-escalation with G-CSF support 
is permitted following a dose reduction on Day 8 of the same cy cle). 
Nab-Paclitaxel and Gemcitabine Dose Modification Table: 
Dose Level Nab-Paclitaxel (mg/m2)1Gemcitabine (mg/m2)1
Starting Dose 125 1000
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 30 CONFIDENTIALModification Dose Level 1 100 800
Modification Dose Level 2275 600
1Dose reductions may or may not be concomitant. Please refer to specific hematologic and other toxicity 
modification recommendations outlined below.
2A maximum of 2 dose level reductions is allowed. 
7.5.1 Hematologic Toxicity
Prior to each dose of nab-paclitaxel with gemcitabine, the ANC and platelet count should be evaluated. 
Dose modifications for hematologic toxicities expected from nab -paclitaxel with gemcitabine should 
be performed depending to their occurrence within a given cycle  and according to the following 
Product label recommendations:  
Cycle 
DayANC
(cells/mm3)Platelet Count 
(cells/mm3)Gemcitabine Dosing1,2nab-Paclitaxel Dosing1,2
1 < 1500 Or < 100,000 Delay dosing by 1 week intervals 
until recover yDelay dosing by 1 week intervals until recover
y
8 500 to 1000 Or 50,000 to < 75,000 Reduce dosing by 1 Dose Level 
and treat on timeReduce dosing by 1 Dose 
Level and treat on time
< 500 Or < 50,000 Hold dosin g Hold dosin g
Day 15: IF Da y 8 doses were unmodified:
500 to 1000 Or 50,000 to < 75,000 Treat on time with Full Dose 
Level and give G-CSF3Treat on time with Full Dose Level and 
give G-CSF3
< 500 Or < 50,000 Hold dosing and give G-CSF3Hold dosing and give G-CSF
3
Day 15: IF Da y 8 doses were reduced:
> 1000 Or > 75,000 Return to Previous Dose Level, 
treat on time and give G-CSF3Return to Previous Dose Level, treat on time and give 
G-CSF
3
500 to 1000 Or 50,000 to < 75,000 Treat on time with same Dose 
Level as Day 8 and give G-CSF3Treat on time with same Dose Level as Day 8 and give 
G-CSF
3
< 500 Or < 50,000 Hold dosing and give G-CSF3Hold dosing and give G-
CSF3
Day 15: IF Da y 8 doses were held:
> 1000 Or > 75,000 Decrease Day 1 Dose by 1 Level, treat on time and give G-CSF
3Decrease Day 1 Dose by 1 Level, treat on time and give 
G-CSF
3
500 to 1000 Or 50,000 to < 75,000 Decrease Day 1 Dose by 2
Levels, treat on time and give G-CSF
3Decrease Day 1 Dose by 2Levels, treat on time and give G-CSF
3
< 500 Or < 50,000 Hold dosing and give G-CSF3Hold dosing and give G-CSF
3
Grade 3-4 Febrile Neutropenia at any point in the cycle(defined as temperature > 101
oF with a neutrophil count of
< 1000 cells/ml)4Hold dosing until fever resolution and ANC > 1500 and 
r e s u m e  a t  n e x t  l o w e r  d o s e  l e v e l  and do not re-escalate throughout 
the rest of treatment.Hold dosing until fever 
resolution and ANC > 1500 a n d  r e s u m e  a t  n e x t  l o w e r  d o s e  l e v e l  a n d  d o  n o t  r e -
escalate throughout the rest 
of treatment.
Recurrent Grade 3-4 Febrile Neutropenia at any point in the cycle
5Decrease dosing 2 Dose Levels (to 600 mg/m
2) and do not re-
escalate throughout the rest of 
treatment.Decrease dosing to next 
lower Dose Level and do not 
re-escalate throughout the 
rest of treatment.
1Once a dose of any drug is decreased for toxicity, re-escalatio n is not permitted (with exception of hematologic toxicity 
on Day 15 when re-escalation with G-CSF support is permitted fo llowing a dose reduction on Day 8 of the same cycle).
2Dose level reductions should be performed as shown in the dose m odification table above. 
3G-CSF administration is optional if only platelet count meets G -CSF administration criterion and ANC count is above 
threshold. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 31 CONFIDENTIAL4Febrile patients (regardless of neutrophil count) should have a  full sepsis diagnostic work-up while continuing broad 
spectrum antibiotics. Patients w ith persisting fever after 3 we eks, despite uninterrupted antibiotic treatment, will 
discontinue study treatment. Febrile neutropenic patients may a lso receive G-CSF to hasten the resolution of their febrile 
neutropenia (following Institutional guidelines and Investigato r judgment). In all cases blood counts must return to 
baseline before resuming chemotherapy treatment. 
5If patients do not experience resolution of neutropenia within 21 days, despite uninterrupted G-CSF treatment, study 
treatment will be discontinued.
7.5.2 Other Non-Hematologic Toxicities
Dose modification for other toxicities specified below expected  from nab-paclitaxel with gemcitabine
regimen occurring ON DAY 1 of any cycle or WITHIN a cycle shoul d be performed according to the 
following recommendations: 
Other Adverse Event Occurrence ON DAY 1 of Each 
CycleOccurrence WITHIN a Cycle
Grade 0, 1 or 2 toxicity including Grade 3 
alopecia and Grade 3 nausea/vomiting1S a m e  a s  D a y  1  o f  p r e v i o u s  c y c l e  except for Grade 2 cutaneous 
toxicit
y.2Same as Day 1 of the ongoing cycle 
except for Grade 2 cutaneous 
toxicit y.2
Grade 3 Toxicity (except for Grade 3 
nausea/vomiting/diarrhea/mucositis, alopecia, 
cutaneous toxicity and neuropathy)1,2,3,5Decrease dose of both nab-
paclitaxel and gemcitabine to the 
next lower Dose Level. Hold either nab-paclitaxel and/or 
gemcitabine until resolution of toxicity to < Grade 1. Then resume 
treatment with both drugs at the next lower Dose Level. 
Grade 4 Toxicity1,2,3,4,5(except for Grade 4 
diarrhea/mucositis, pulmonary embolism, 
cutaneous toxicit y and neuro pathy)Hold either nab-paclitaxel and/or gemcitabine depending on the type of non-
hematologic toxicity and the judgment of the Physician/Investig ator.
Treatment discontinuation de pendin g on the judgment of the Investi gator.
Dose Held in 2 Previous Consecutive Cycles Decrease gemcitabine dose to next lower Dose Level and continue 
throu ghout the rest of treatment
Grade 3-4 Diarrhea/Mucositis5Hold dosing with both nab-paclitaxel and gemcitabine until impro vement to 
< Grade 1 and resume both nab-paclitaxel and gemcitabine at next  low e r 
Dose Level.
Interstitial Pneumonitis (any Grade ) Discontinue stud y treatment.
1For treatment of Grade 3-4 nausea/vomiting, Initial antiemetic prophylaxis is recommended with a 5HT3 agent (PO or 
IV) in combination with dexamethasone 8 or 10 mg (PO or IV) pri or to administration of gemcitabine to be continued 
at 4 mg BID or TID for 3-4 days at the Investigatorâ€™s discretio n. Institutional guidelines and Investigatorâ€™s 
recommendations should be followed for breakthrough antiemetic management. BBI-608 dosing modification as 
outlined in Section 7.4 may be appropriate depending on the jud gment of the Investigator.
2Grade 2 or 3 cutaneous toxicity on Day 1 of any cycle requires reduction of both nab-paclitaxel and gemcitabine to the 
next lower Dose Level. If Grade 2-3 cutaneous toxicity recurs d espite dose reduction, treatment should be discontinued. 
3For Grade > 3 neuropathy, nab-paclitaxel treatment should be he ld and gemcitabine may be continued. Nab-paclitaxel 
treatment may be resumed at next lower level if neuropathy impr oves to < Grade 1. Discontinuation of treatment with 
nab-paclitaxel is recommended in cases of peripheral neuropathy resulting in > 21 day delay in nab-paclitaxel 
administration unless not deemed appropriate in the judgment of  the Investigator.
4Except for mild or asymptomatic pulmonary embolism treated with  low-molecular-weight heparin without interruption 
of therapy. Moderate to severe pulmonary embolism will require permanent discontinuation of treatment.
5For initial treatment of Grade 3-4 diarrhea/mucositis BBI-608 do sing modification may be initiated as per Section 7.4 
prior to modification of backbone chemotherapy dosing.
When laboratory parameters or adverse events indicate that either  or both nab-paclitaxel and/or 
gemcitabine infusions should be delayed, the infusions schedule d  f o r  t h a t  d a y  a r e  n o t  g i v e n . T h e  
infusions will be considered skipped and not made up. The next infusion will be administered on the 
following scheduled infusion day if the toxicity is resolved to an acceptable level. Laboratory 
parameters should be evaluated prior to the next scheduled infu sion and actions taken according to the 
protocol parameters.
If toxicity is thought by the Investigator to be related to bot h BBI-608 and nab-paclitaxel and 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 32 CONFIDENTIALgemcitabine, then the dose modification rules for both treatmen t regimens should be followed.
If either gemcitabine and/or nab-paclitaxel is/are held or discon tinued for toxicities solely related to 
gemcitabine and/or nab-paclitaxel, BBI-608 therapy may be continu ed until another discontinuation 
criterion for stopping therapy is met with the Sponsorâ€™s approva l, if it is believed to be in the patientâ€™s 
best interest by the investigator and patient, and with the pat ientâ€™s informed consent. 
If BBI-608 is permanently discontinued due to toxicity, nab-pacl itaxel and gemcitabine therapy may
be continued until another discontinuation criterion for stoppi ng therapy is met. 
7.6 BLINDING/UNBLINDING
This is an open label study. The primary endpoint of this study  is overall survival, the assessment of 
which is unlikely to be impacted by the open-label nature of th e study. 
However, to comply with ICH E6 (R2) Guideline for Good Clinical  Practice (2016) recommending 
the blinded review of planned analyses [http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guid elines/Efficacy/E6/E6_R2__Ste
p_4_2016_1109.pdf ], and to minimize the risk of any potential bias in the interim and final analyses, 
a blinding plan was implemented by the Sponsor and by the CRO t o maximize the integrity of the 
study. The Sponsor  blinding plan outlines the internal communic ation processes, data access levels, 
and firewalls that will be utilized to achieve study blinding i nternally. 
7.7 PATIENT MONITORING
For the duration that patients are on study therapy, adverse ev ent monitoring will be done continuously. 
Patients will be evaluated for adverse events at each visit, an d are to be instructed to call their physician 
to report any adverse events between visits.
7.8 CONCOMITANT MEDICATIONS/PROCEDURES
7.8.1 Permitted TreatmentsAll information regarding concomitant treatments (medications o r procedures) must be recorded on 
the patientâ€™s CRF (including the name of the medication or proc edure and duration of treatment).  
Palliative and supportive care is permitted for disease-related  symptoms for all patients. 
All palliative and supportive care measures may be administered  to patients in any study arm at the 
Investigatorâ€™s discretion. Incident palliative radiotherapy is permitted in any study arm while on study, 
but requirement of radiation to the target lesion(s) will quali fy the patient as having disease 
progression. 
Overall, CYP isoenzymes have an insignificant role in the biotr ansformation of BBI-608. The CYP 
P450 isoform 1A2 is the predominant isoform involved in the dru gâ€™s metabolism. Although the 
following drugs are permitted while on study treatment, all rea sonable measures should be done to 
avoid use of drugs that are strong inhibitors of CYP1A2 unless there is medical necessity for their use. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 33 CONFIDENTIALStrong CYP1A2 inhibitors include:  
oCiprofloxacin and other fluoroquinolones 
oFluvoxamine 
oEnoxacin 
oZafirlukast
Investigators may refer to the Investigator Brochure for additi onal information. 
Patients who require use of concomitant medications metabolized  by the CYP1A2, 2D6, 2C19, 3A4 
and 2C9 enzymes should be monitored, as per drug product label,  as use of BBI-608 can inhibit the 
abovementioned CYP enzymes leading to increased drug concentrat ions of the enzyme metabolites.
In addition, nab-paclitaxel is metabolized by CYP2C8 and CYP3A4 ; caution should be exercised when 
administering with drugs which a re CYP2C8 or CYP3A4 inducers or  inhibitors, e.g. amiodarone, 
cyclosporine, grapefruit juice, simvastatin etc.
7.8.2 Non-Permitted TreatmentsConcurrent chemotherapy, hormonal therapy (except corticosteroi ds), immunotherapy, biologic 
therapy OR other experimental agents should not be given to stu dy patients while on protocol 
treatment.
7.9 DURATION OF THERAPY
Patients may continue to receive protocol therapy as long as the y have not experienced any adverse 
events requiring permanent discontinuation of protocol treatmen t , h a v e  n o t  d e m o n s t r a t e d  d i s e a s e  
progression based on RECIST 1.1 criteria, it is believed to be i n the patientâ€™s best interest by the 
investigator and patient, or until February 28
th, 2020, whichever occurs first. For details concerning 
toxicity, please consult sections 7.3, 7.4 and 7.5. For a compl ete list of general criteria for stopping 
study treatment, please see section 11.0.  
Following disease progression based on RECIST 1.1 criteria, pat ients will permanently discontinue 
treatment with nab-paclitaxel and gemcitabine, but may continue BBI-608 treatment with the 
Sponsorâ€™s approval for as long as in the opinion of the investi gator and patient that it is believed to be 
in the patientâ€™s best interest and with the patientâ€™s informed consent, until February 28th, 2020 or the 
following requirements are met: 
1. Patient does not demonstrate a clinically apparent decline in  performance status.
2. Patient does not demonstrate clinically significant worsening  of disease related symptoms.
3. Patient does not have any new radiographic findings to warran t emergent intervention to
prevent morbidity (for example, impending cord compression). 
4. Patient demonstrates a tolerable toxicity profile with BBI-60 8 administration. 
7.10 PATIENT COMPLIANCE
Treatment compliance for BBI-608 is defined as the ratio, expre ssed as a percentage, of the number of 
BBI-608 capsules taken by a patient over the course of a time i nterval to the number of capsules 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 34 CONFIDENTIALintended to be taken over that same time interval. 
Treatment compliance for nab-paclitaxel with gemcitabine is defi ned as the ratio, expressed as a 
percentage, of the amount of each of the component drugs adminis tered to a patient (milligrams/m2)
over the course of a time interval to amount of the component I V drug intended to be administered
over that same time interval. 
Treatment compliance in all study arms will be monitored by dru g accountability, as well as the 
monitoring of patient-reported compliance. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 35 CONFIDENTIAL8.0 EVALUATION DURING AND AFTER PROTOCOL TREATMENT
Evaluations will be performed at different intervals throughout  the study. If dose delays occur for any 
reason on the study, other study assessments, including assessm ent by physician and QoL 
questionnaires, will not be delayed, but should continue at the  time indicated from randomization.
8.1 EVALUATION DURING PROTOCOL TREATMENT
Investi gations Timin g
Patient history and 
EvaluationyPhysical examination
yVital signs (temperature, heart rate, 
respiratory rate, blood pressure, O 2
saturation on room air)
yECOG Performance status
yConcurrent medication list
yWeightDay 1 of every 28 day study cycle, starting with Cycle 
2 (+/-3 days) or within 72 hours prior to each nab-
paclitaxel with gemcitabine infusion
Hematology yCBC + differential, Platelet countDays 1, 8 and 15 of every 28 day study cycle starting 
with Cycle 1 (+/-3 days)
(Hematology investigations should be performed 
within 72 hours prior to Day 1 of each study cycle, or within 72 hours prior to each nab-paclitaxel with gemcitabine infusion)
BiochemistryyCreatinine, Total Bilirubin, AST, ALT, 
Alkaline Phosphatase, LDH, Albumin, 
Sodium, Potassium, Magnesium, Phosphate,
BUN (blood urea nitro gen)Day 1 of every 28 day study cycle, starting with Cycle 1 (+/-3 days)
(Biochemistry and Urinalysis  investigations should be 
performed within 72 hours prior to Day 1 of each study cycle, or within 72 hours pr ior to first nab-paclitaxel 
with gemcitabine infusion of each cycle)
UrinalysisyDipstick (including protein, specific gravity, 
glucose and blood)
Other Investigations ySerum or urine pregnancy test 1 Day 1 of every 28 day study cycle, starting with Cycle 
2 (+/-3 da ys)
Adverse Events 2yAdverse Event evaluation must be done at 
each stud y visitDays 1, 8 and 15 of every 28 day study cycle
yAdverse Event evaluation b y phone On Run-in Da y 2 
Serious Adverse 
Events 3Serious Adverse Event evaluation will be done from the time of informed consent signature and for 30 
days followin g the last dose of protocol thera py.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 36 CONFIDENTIALCardiology 
AssessmentyECG Within 2 hours of completion of nab-paclitaxel with 
gemcitabine infusion on fi rst day of nab-paclitaxel 
with gemcitabine treatment and as clinically indicated 
thereafter
Radiology & ImagingyCT/MRI scan as per baseline assessment 
with tumor measurement and evaluation by RECIST 1.1 criteria 
4, 5Every 8 weeks (every 56 days) after randomization4, 5
(+/-5 days)
Correlative Studies ySubmission of blood sam ples 6At 4 weeks after C ycle 1 Da y 1 (+/-3 da ys)
Sparse PK Collection ySubmission of blood samples to central lab 6At Days 8 and 15 of Cycle 1, and at Day 1 of Cycle 2 
(corresponding to the 2nd, 3rdand 4thnab-paclitaxel 
with gemcitabine infusion da ys)
Quality of Life yEORTC QLQ-C307 At 4, 8, 12, 16 and 24 weeks after Cycle 1 Day 1 (+/- 3
days)
Nab-paclitaxel with 
gemcitabine 
AdministrationyIV nab-paclitaxel with gemcitabine infusion Days 1, 8 and 15 of every 4 week (28 day) study cycle, 
starting with Cyc le 1 (+/-3 days)
1In women of childbearing potential only a negative pregnancy te st must be demonstrated every 4 weeks until 4 weeks 
after the administration of the final dose of protocol therapy.  The minimum sensitivity of the pregnancy test must be 
25 IU/L or equivalent units of HCG.
2Adverse events will be recorded and graded according to the NCI  Common Terminology Criteria for Adverse Events 
version 4.0 (see Appendix IV). Adverse event assessment by phon e on Run-in day 2 is only applicable to patients receiving 
BBI-608.
3Serious adverse events will be recorded and graded according to the NCI Common Terminology Criteria for Adverse 
Events version 4.0 (see Appendix IV).
4The same method of assessment and the same technique should be used to identify and report each lesion at baseline and 
at reassessment during treatment. Tumor evaluations will contin ue until progressive disease is documented (as described 
in section 9.0). For patients who remain on protocol therapy af ter objective disease progression has been documented, no 
further imaging assessments are mandated, but where these occur as a component of care, tumor measurements an d 
assessment must be reported. 
5Copies of imaging assessments may be requested.
6Details for collection, processing, storing and shipping these samples will be provided in a separate procedure manual. 
7To be completed in clinic. Questionnaires should be completed p rior to any interactions with clinical team to avoid any 
influence.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 37 CONFIDENTIAL8.2 EVALUATION AFTER PERMANENT PROTOCOL TREATMENT DISCONTINUATIO N  
Investi gations Timin g
Patient History and 
Evaluation  yPhysical Examination
yVital signs (temperature, heart rate, 
respiratory rate, blood pressure, O 2
saturation on room air)
yWeight + ECOG Performance status
ySubsequent cancer therapy1
yConcurrent medication listAt the first regularly scheduled 4 week assessment at 
which the patient has been off study therapy for a minimum of 28 days. (+/- 3 days)
Adverse Events 2yAdverse Event evaluation2
Serious Adverse 
Events 3Serious Adverse Event evaluation will be done from the time of i nformed consent signature and for 30
days followin g the last dose of protocol thera py.
Overall Survival yAssess for survival of patient 4Starting at the first regularly scheduled 4 week 
assessment at which the patient has been off study 
therapy for a minimum of 28 days, every 4 weeks 
thereafter for 6 months, then every 3 months thereafter.
(+/- 7 da ys)
Other 
Investi gationsySerum or urine pregnancy test 5
At the first regularly scheduled 4 week assessment at 
which the patient has been off study therapy for a minimum of 28 days (+/- 3 days)Hematolo gy yCBC + differential, Platelet count
BiochemistryyCreatinine, Total Bilirubin, AST, ALT, 
Alkaline Phosphatase, LDH, Albumin, 
Sodium, Potassium, Magnesium, Phosphate,
BUN (blood urea nitro gen)
UrinalysisyDipstick (including protein, specific gravity, 
glucose and blood )
Cardiology 
AssessmentyECG At the first regularly scheduled 4 week assessment at 
which the patient has been off study therapy for a 
minimum of 28 da ys(+/- 3 da ys)
Radiology & ImagingyCT/MRI scan as per baseline assessment 
with tumor measurement and evaluation by 
RECIST 1.1 criteria 
6Every 8 weeks (56 days) after randomization until 
objective disease progression is documented.6  
(+/- 5 da ys)
Correlative studies ySubmission of blood samples7At first regularly scheduled 4 week assessment at which 
the patient has been off study therapy for a minimum of 
28 da ys (+/- 3 da ys)
Quality of Life yEORTC QLQ-C308At first regularly scheduled 4 week assessment at which 
the patient has been off study therapy for a minimum of 
28 da ys (+/- 3 da ys) 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 38 CONFIDENTIAL1After permanent protocol treatment discontinuation of nab-paclit axel and gemcitabine and BBI-608, Physical 
examination, vital signs, ECOG status and subsequent cancer tre atment will be recorded at the first regularly scheduled 4 
week assessment at which the patient has been off study therapy  for a minimum of 28 days (+/- 3 days). Subsequent cancer 
treatment will be captured until end of study. 
2Adverse events related to protocol treatment will be recorded a nd graded according to the NCI Common Terminology 
Criteria for Adverse Events version 4.0 (see Appendix IV). Advers e events relevant to cancer or to subsequent cancer 
treatments will not be captured. Attribution of adverse events will continue to be recorded following treatment 
discontinuation.
3Serious adverse events will be recorded and graded according to  the NCI Common Terminology Criteria for Adverse 
Events version 4.0 (see Appendix IV). 
4Post permanent study treatment discontinuation, overall surviva l status will be monitored on a monthly basis for 6 months 
and then every 3 months thereafter until death, the study close s or 3 years have elapsed since subject discontinuation from 
treatment. In the event that patient is unable to attend clinic , post-progression follow-up may be by means of telephone 
contact.
5In women of childbearing potential only. The minimum sensitivit y of the pregnancy test must be 25 IU/L or equivalent 
units of HCG.
6The same method of assessment and the same technique should be used to identify and report each lesion at baseline and 
at reassessment during treatment. Tumor evaluations will continu e until progressive disease is documented (as described 
in section 9.0). If a patient discontinues protocol treatment for a reason other  than objective progression, every effort 
should be made to obtain this assessment on the same schedule u ntil progression is observed. It is recommended that 
subsequent therapy not  be instituted until disease progression is documented. If a patient sta rts a new anti-cancer therapy 
prior to disease progression, then repeat imaging and tumor res ponse assessments should be discontinued.
7Details for collection, processing, storing and shipping these s amples will be provided in a separate procedure manual. 
The samples will be collected only if the patient discontinues protocol treatment prior to 4 weeks of therapy with nab-
paclitaxel with gemcitabine with or without BBI-608.  
8To be completed in clinic. Questionnaires should be completed p rior to any interactions with clinical team to avoid any 
influence. Questionnaire will be collected in the post-treatment  discontinuation period only if the patient discontinues 
nab-paclitaxel and gemcitabine with or without BBI-608 protocol treatment prior to 24 weeks of therapy and has an ECOG 
PS of less than 4 and has not been hospitalized for end of life  care.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 39 CONFIDENTIAL9.0 CRITERIA FOR MEASUREMENT OF STUDY ENDPOINTS
9.1 DEFINITIONS
9.1.1 Evaluable for Adverse EventsAll patients who have received at least one dose of study drug ( BBI-608 or Nab-Paclitaxel or 
Gemcitabine) will be evaluable for adverse events from the time  of their first dose.
9.1.2 Evaluable for OSAll randomized patients will be included in the analysis of OS,  which is defined as the time interval 
between the date of randomization and the date of death from an y cause. Patients who are still alive at 
the time of the final analysis , or who have become lost to foll ow-up will be censored at their last date 
known to be alive.  
9.1.3 Evaluable for PFSAll randomized patients will be included in the analysis of PFS , which is defined as the time interval 
between the date of randomization and the date of objective dis ease progression or death, whichever 
comes first. If neither event has been observed, then the patie nt will be censored at the date of the last 
tumor assessment.
Disease progression is defined as objective progression per REC IST 1.1 (Eisenhauer, 2009) .I t  i s  
required to perform, whenever possible, a radiological confirma tion of the clinical suspicion of tumor 
progression. In the situation where there is clinical suspicion  of progression but objective progression 
cannot be determined per RECIST 1.1, disease is defined as clin ical deterioration without objective 
evidence of progression. 
The date of disease progression is defined as the date when the  criteria for objective progression are 
first met. 
9.1.4 Evaluable for DCR
Patients who have measurable disease by RECIST 1.1 at randomiza tion will be included in the analysis 
of DCR which is defined as a composite of Stable Disease, Parti al Response and Complete Response 
as classified according to the definitions set out below (Eisenhauer, 2009) . For patients who 
discontinue protocol therapy prior to their first objective ass essment of response, it is imperative that 
an objective response assessment be undertaken as close to the protocol specified schedule as possible.
9.1.5 Evaluable for ORR
Patients with measurable disease by RECIST 1.1 at randomization  will be included in the analysis of 
ORR which is defined as a composite of Partial Response and Com plete Response as classified 
according to the definitions set out below (Eisenhauer, 2009) . For patients who discontinue protocol 
therapy prior to their first objective assessment of response, it is imperative that an objective response 
assessment be undertaken as close to the protocol specified sch edule as possible.
9.1.6 Evaluable for QoL Assessment
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 40 CONFIDENTIALAll patients who have completed the baseline quality of life qu estionnaire and at least one other QoL 
questionnaire are evaluable.
9.2 RESPONSE AND EVALUATION ENDPOINTS
Response and progression will be evaluated in this study using the revised international criteria (1.1) 
proposed by the RECIST committee. 
9.2.1 Measurable Disease
Measurable tumor lesions are defined as those that can be accurately measured in at leas t one 
dimension (longest diameter to be recorded) as > 20 mm with che st x-ray and as > 10 mm with CT 
scan, or clinical examination. Bone lesions are considered meas urable only if assessed by CT scan and 
have an identifiable soft tissue component that meets these req uirements (soft tissue component > 10 
m m  b y  C T  s c a n ) .  Malignant lymph nodes must be > 15mm in the short axis to be considered 
measurable; only the short axis will be measured and followed. All tumor measurements must be 
recorded in millimeters (or decimal fractions of centimeters). Previously irradiated lesions are not 
considered measurable unless progression has been documented in  the lesion. 
9.2.2 Non-Measurable Disease
All other lesions (or sites of disease), including small lesion s are considered non-measurable disease. 
Bone lesions without a measurable soft tissue component, leptom eningeal disease, ascites, 
pleural/pericardial effusions, lymphangitis cutis/pulmonis, inf lammatory breast disease, lymphangitic 
involvement of lung or skin and abdominal masses followed by cl inical examination are all non-
measurable. Lesions in previously irradiated areas are non-meas urable, unless progression has been 
demonstrated. 
9.2.3 Target Lesions
When more than one measurable tumor lesion is present at baseli ne all lesions up to a maximum of 5 
lesions total (and a maximum of 2 lesions per organ ) representative of all involved organs should be 
identified as target lesions and will be recorded and measured at baseline. Target lesions should be 
selected on the basis of their size (lesions with the longest d iameter), be representative of all involved 
organs, but in addition should be those that lend themselves to  reproducible repeated measurements .
Note that pathological nodes must meet the criterion of a short  axis of > 15 mm by CT scan and only 
the short axis of these nodes will contribute to the baseline sum. All ot her pathological nodes (those 
with short axis > 10 mm but < 15 mm) should be considered non-t arget lesions. Nodes that have a 
short axis < 10 mm are considered non-pathological and should n ot be recorded or followed (see 
10.2.4). At baseline, the sum of the target lesions (longest dia meter of tumor lesions plus short axis of 
lymph nodes: overall maximum of 5) is to be recorded. 
After baseline, a value should be provided on the CRF for all i dentified target lesions for each 
assessment, even if very small. If extremely small and faint le sions cannot be accurately measured but 
are deemed to be present, a default value of 5 mm may be used. If lesions are too small to measure and 
indeed are believed to be absent , a default value of 0 mm may b e used.
9.2.4 Non-Target Lesions
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 41 CONFIDENTIALAll non-measurable lesions (or sites of disease) plus any measu rable lesions over and above those 
listed as target lesions are considered  non-target lesions . Measurements are not required but these 
lesions should be noted at baseline and should be followed as â€œ presentâ€ or â€œabsentâ€.
9.2.5 Response A l l  p a t i e n t s  w i l l  h a v e  t h e i r  B E S T  R E S P O N S E  f r o m  t h e  s t a r t  o f  s t udy treatment until the end of 
treatment classified as outlined below: 
Complete Response (CR): disappearance of target and non-target . Pathological lymph nodes must 
have short axis measures < 10 mm (Note: continue to record the measurement even if < 10 mm and 
considered CR). Residual lesions (other than nodes < 10 mm) tho ught to be non-malignant should be 
further investigated (by cytology specialized imaging or other techniques as appropriate for individual 
cases (Eisenhauer, 2009) ) before CR can be accepted. 
Partial Response (PR): at least a 30% decrease in the sum of me asures (longest diameter for tumor 
lesions and short axis measure for nodes) of target lesions, ta king as reference the baseline sum of 
diameters. Non-target lesions must be non-PD. 
Stable Disease (SD): neither sufficient shrinkage to qualify fo r PR, nor sufficient increase to qualify 
for PD taking as reference the smallest sum of diameters on stu dy.
Progressive Disease (PD): at lea st a 20% increase in the sum of  diameters of measured lesions taking 
as references the smallest sum of diameters recorded on study (i ncluding baseline) AND an absolute 
increase of > 5mm. Appearance of new lesions will also constitu te progressive disease (including 
lesions in previously unassessed areas). For patients with on-s tudy tumor assessments with 
questionable findings of new lesions, such as cases where it is  possible that the lesions were present at 
baseline imaging albeit less visible, the patient may continue treatment (if patient is clinically doing 
well) for an additional 4-8 weeks, until the next scan which wi ll either confirm presence of a new 
lesion finding or exclude it. In exceptional circumstances, une quivocal progression of non-target 
disease may be accepted as evidence of disease progression, whe re the overall tumor burden has 
increased sufficiently to merit discontinuation of treatment or  where the tumor burden appears to have 
increased by at least 73% in volume. Modest increases in the si ze of one or more non-target lesions 
are NOT considered unequivocal progression. If the evidence of PD is equivocal (target or non-target), 
treatment may continue until the next assessment, but if confir med, the earlier date must be used. 
Table 2: Integration of Target, non-Target and New Lesions into  Response Assessment
Target Lesions Non-Target LesionsNew 
LesionsOverall ResponseBest Response for this 
Cate gory also Re quires
Target Lesions Â± Non Tar get Lesions
CR CR No CR Tumor nodes < 10mm
CR Non-CR/Non-PD No PR
CR Not all evaluated No PR
PRNon-PD/ not all 
evaluatedNo PR
SDNon-PD/ not all 
evaluatedNo SDDocumentation at least once > 6
wks. from baseline
Not all evaluated Non-PD No NE
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 42 CONFIDENTIALPD Any Any PD
Any PD An y PD
Any Any Yes PD
Non-Tar get Lesions ONLY
N/A CR No CR Tumor nodes < 10mm
N/A Non-CR/non-PD No Non-CR/non-PD
N/A Not all evaluated No NE
N/A Unequivocal PD Any PD
N/A An y Yes PD
Note: Patients with a global deterioration of health status requ iring discontinuation of treatment without radiological 
progression having been observed at that time should be reporte d as â€œsymptomatic deteriorationâ€. This is NOT 
objective PD. Every effort should be made to document the objec tive progression even after discontinuation of 
treatment.
9.3 RESPONSE DURATION
Response duration will be measured from the time measurement cr iteria for CR/PR (whichever is first 
recorded) are first met until the first date that recurrent or progressive disease is objectively 
documented, taking as reference the smallest measurements recor ded on study (including baseline).
9.4 STABLE DISEASE DURATION
Stable disease duration will be measured from the time of rando mization until the criteria for 
progression are met, taking as reference the smallest sum on st udy (including baseline).
9.5 METHODS OF MEASUREMENT
The same method of assessment and the same technique should be used to characterize each identified 
and reported lesion at baseline and during follow-up. Assessmen ts should be identified on a calendar 
schedule and should not be affected by delays in therapy. While  on study, all lesions recorded at 
baseline should have their actual measurements recorded at each  subsequent evaluation, even when 
very small (e.g. 2 mm). If it is the opinion of the radiologist  that the lesion has likely disappeared, the 
measurement should be recorded as 0 mm. If the lesion is believ ed to be present and is faintly seen but 
too small to measure, a default value of 5 mm should be assigne d. For lesions which fragment/split 
add together the longest diameters of the fragmented portions; for lesions which coalesce, measure the 
maximal longest diameter for the â€œmerged lesionâ€.
Additionally, for optimal tumor assessment scanning options are  listed below in the decreasing order 
of preference:
Order of 
PreferenceScanning Option
1 Chest-Abdomen-Pelvis CT with oral and I.V. contrast
2 Chest CT without I.V. contrast P LUS MRI Abdomen-Pelvis with or al and 
I.V. contrast1
3 Chest-Abdomen-Pelvis CT with oral contrast2
1If Iodine contrast media is medically contraindicated.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 43 CONFIDENTIAL2If Iodine contrast media is medically contraindicated and MRI c annot be performed. 
9.5.1 Clinical Lesions 
Clinical lesions will only be considered measurable when they a re superficial and > 10 mm as assessed 
using callipers (e.g. skin nodules). For the case of skin lesio ns, documentation by colour photography 
including a ruler to estimate the size of the lesion is recomme nded. If feasible, imaging is preferred.
9.5.2 Chest X-ray
Chest CT is preferred over chest X-ray, particularly when progr ession is an important endpoint, since 
CT is more sensitive than X-ray, particularly in identifying ne w lesions. However, lesions > 20 mm 
on chest X-ray may be considered measurable if they are clearly defined and surrounded by aerated 
lung.  
9.5.3 CT/MRI
CT is the best currently available and reproducible method to m easure lesions selected for response 
assessment. This guideline has defined measurability of lesions  on CT scan based on the assumption
that CT slice thickness is 5 mm or less. When CT scans have sli ce thickness greater than 5 mm, the 
minimum size for a measurable lesion should be twice the slice thickness. MRI is also acceptable in 
certain situations (e.g. for body scans). Other specialized ima ging or other techniques may also be 
appropriate for individual case (Eisenhauer, 2009) . For example, while PET scans are not considered 
adequate to measure lesions, PET-CT scans may be used providing  that the measures are obtained 
from the CT scan and the CT scan is of identical diagnostic qual ity to a diagnostic CT (with IV and 
oral contrast). 
9.5.4 Ultrasound Ultrasound is not useful in assessment of lesion size and shoul d not be used as a method of 
measurement. If new lesions are identified by ultrasound in the  course of the study, confirmation by 
CT is advised.
9.5.5 Endoscopy/Laparoscopy 
The utilization of these techniques for objective tumor evaluat ion is not advised. However, they can 
be useful to confirm complete pathological response when biopsi es are obtained or to determine 
relapse in trials where recurrence following complete response or surgical resection is an endpoint. 
9.5.6 HistologyThese techniques can be used to differentiate between PR and CR  in rare cases (for example, residual 
lesions in tumor types such as germ cell tumors, where known re sidual benign tumors can remain).
The cytological confirmation of the neoplastic origin of any ef fusion that appears or worsens during 
treatment when the measurable tumor has met criteria for respon se or stable disease is mandatory to 
differentiate between response or stable disease (an effusion m ay be a side effect of the treatment) and 
progressive disease.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 44 CONFIDENTIAL10.0 SERIOUS ADVERSE EVENT REPORTING
The descriptions and grading scales found in the NCI Common Ter minology Criteria for Adverse 
Events (CTCAE) will be utilized for Adverse Event (AE) and Serio us Adverse Event (SAE) reporting 
(version can be found in Appendix IV).  
All appropriate treatment areas should have access to a copy of  the CTCAE. A copy of the CTCAE 
can be downloaded from the CTEP web site: (http://ctep.cancer.gov/protocolDevelopment/electronic_applicati ons/ctc.htm ).
All serious adverse events (SAE) defined as per ICH guidelines (see below) and other adverse events 
must be recorded on case report forms. All SAEs must be reporte d to the Sponsor within 24 hours 
(Section 10.2).    
10.1 DEFINITION OF A PROTOCOL REP ORTABLE SERIOUS ADVERSE EVENT
All serious adverse events must be reported in an expedited manner (see Sec tion 10.2 for reporting 
instructions). These include events occurring from the time the  patient signs informed consent until 30 
days after last protocol treatment administration. Determinatio n of relationship between the event and 
study drug should be made by a qualified physician Investigator .  
A serious adverse event (SAE) is any adverse event that at any dose:
results in death;
is life-threatening;
requires inpatient hospitalization or prolongation of existing hospitalization (excluding 
hospital admissions for study drug administration); 
results in persistent or significant disability or incapacity;
is a congenital anomaly/birth defect.
is an important medical event. 
  
Note: clinically significant test results should be recorded on  the AE CRF using the appropriate 
CTCAE description and grading scale. 
10.2 SERIOUS ADVERSE EVENT REPORTING INSTRUCTIONS
SAE reporting will commence following the signature of the info rmed consent and continue for 30
days following the last dose of BBI-608 and/or Nab-Paclitaxel an d/or Gemcitabine. Any SAE 
occurring following patient signature of informed consent and p rior to patient randomization must be 
submitted to the Sponsor/Sponsor Designee for review and confir mation of randomization eligibility
prior to patient randomization and/or study drug administration , even if the patient completely 
recovered from the SAE. Additionally, any SAE occurring at any time following administration of the 
final dose of protocol treatment  that is suspected to be relate d to study treatment must be reported.
All SAEs must be reported using the SAE Report Form for this tr ial. 
Within 24 hours: Submit Initial Serious Adverse Event Report 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 45 CONFIDENTIALWithin 7 days: Submit Follow-up Serious Adverse Event Report upd ated with as much 
detail as possible. 
   Detailed instructions for the  submission of SAE Reports will b e provided separately.  
10.3 PROCEDURES IN CASE OF AN OVERDOSE
Use of BBI-608 in doses in excess of that specified in the prot ocol should be reported in the following 
manner: 
If an adverse event(s) is associated with (â€œresults fromâ€) the overdose of BBI-608, the overdose and 
adverse event are reported on the SAE Report Form, even if no o ther criteria for serious are met. The 
SAE Report Form should be submitted within 24 hours. The overdo se should also be recorded on the 
relevant AE form in the eCRF using the term â€œaccidental or inte ntional overdose with adverse effect.â€
If the overdose of BBI -608 is not associated with an adverse ev ent, the overdose is reported as a non-
serious AE, on the relevant AE form in the eCRF within 24 hours , using the event term â€œaccidental or 
intentional overdose without adverse effect.â€ The Clinical Rese arch Associate responsible for the 
investigational center should also be notified of the event wit hin 24 hours. 
Investigators/site personnel are to consult the local, approved  product labels for nab-paclitaxel with 
gemcitabine treatment regimen for guidance on the definition of a n overdose of these agents as well 
as for guidance on reporting of any AE or SAE associated with o verdose of either nab-paclitaxel or 
gemcitabine. Overdose of either nab-paclitaxel  or gemcitabine should also be  reported to the Sponsor 
in accordance with overdose reporting guidelines above. 
10.4 OTHER PROTOCOL REPORTABLE EVENTS â€“ PREGNANCY/EXPOSURE REPORT ING
WOCBP may be enrolled in this c linical trial. WOCBP are defined  as women who have had a 
menstrual period during the last year and have not had a hyster ectomy. Precautions are required to be 
taken to prevent pregnancy during the clinical trial when the r esearch population includes WOCBP. 
This includes pregnancy testing, use of effective methods of bi rth control, and pregnancy as an 
exclusion factor. The trial sample informed consent form includ es the potential for unidentified risks 
to the embryo/fetus. It also includes general information on pregnancy prevention an d the required 
minimum period during which birth control must be utilized.  
10.4.1 Pregnancy Prevention
WOCBP and males who are enrolled in the trial must be informed of the requirement to use 
contraception as outlined in the eligibility criteria (Sections  4.1 and 4.2). Investigators are advised to 
inform the female partners of male participants when appropriat e and compliant with local policy.  
A highly effective method of birth control is defined as those which result in a failure rate of <1% per 
year when used consistently and correctly. 
10.4.2 Pregnancy Occurring in WOCBP Exposed to Study Agent Any female participant who becomes pregnant during the course o f the trial should be instructed to 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 46 CONFIDENTIALstop taking study medication immediately.
The Investigator should provide counselling and discuss the ris ks and possible side effects to the 
embryo/fetus from BBI-608 and nab-paclitaxel with gemcitabine. Monitoring should continue until 
conclusion of the pregnancy. The same should occur for female p artners of a male participant, or any 
female exposed to BBI-608 when appropriate and compliant with l ocal policy. 
10.4.3 Pregnancy/Exposure Reporting The Investigator is required to report to the sponsor any pregn ancy where the embryo/fetus could have 
been exposed to BBI-608. This means pregnancies occurring in fe male participants, female partners 
of male participants, or females exposed through direct contact  with the agent during their pregnancy 
(for example, environmental exposure involving direct contact w ith the agent). Pregnancies occurring 
until 30 days in female patients and until 90 days in partners o f male patients, after the completion of 
BBI-608 must also be reported. Pregnancies occurring until 180 da ys in female patients and until 180 
days in partners of male patients, after the completion of nab- paclitaxel and/or gemcitabine must also 
be reported. 
The Investigator is required to inform the Sponsor within 24 ho urs of learning of the pregnancy using 
the SAE reporting form appropriate for the trial as indicated a bove. In the Adverse Event column 
please enter the following: â€œpregnancy, puerperium and perinata l conditions â€“ other, specifyâ€ (fetal 
exposure). Please note that the patient identification number m ust correspond to the participant in the 
main trial. Specifically, in the case of pregnancy in the femal e partner of a male participant, the male 
participantâ€™s patient identification number should be used for reporting purposes.  
The SAE form must be updated to reflect the outcome of the preg nancy. For example: 
yâ€œpregnancy, puerperium and perinatal conditions â€“ other, specif yâ€ (normal live birth),
yâ€œpregnancy, puerperium and perinatal conditions â€“ other, specif yâ€ (therapeutic abortion), or 
yanother term under "pregnancy, puerperium and perinatal conditi ons" as applicable. 
I n f o r m a t i o n  o n  t h e  m e d i c a l  h i s t o r y  o f  t h e  p a r e n t s  t h a t  m a y  r e l a te to assessing any potential fetal 
outcomes is requested, as is information on the health of the newborn . The narrative section of the 
SAE form should be used to communicate all relevant information  pertaining to the pregnancy. 
10.5 RESPONSIBILITY FOR REPORTING SERIOUS ADVERSE EVENTS TO REGU LATORY 
AGENCIES
Boston Biomedical, or the delegated CRO, will provide expedited reports of SAEs to FDA and other 
applicable regulatory authorities, for those events which meet regulatory requirements for expedited 
reporting, i.e. events which are BOTH serious AND unexpected, AND which are related to treatment
BBI-608 (suspected unexpected serious adverse reaction [SUSAR]) :
yUnexpected adverse events are those which are not consistent in either nat ure or severity with the 
reference safety information contained in the Investigatorâ€™s Br ochure  
yAdverse events considered related to protocol treatment are those events which have a 
reasonable possibility of being related to BBI-608. 
Boston Biomedical will determine w hich SAEs meet the criteria f or regulatory reporting.  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 47 CONFIDENTIAL10.6 REPORTING SAFETY REPORTS TO INVESTIGATORS 
Boston Biomedical, or the delegated CRO, will notify Investigato rs of all Safety Reports (Serious 
Adverse Events (SAEs) from this trial and Safety Updates (SUs) from other clinical trials) that are 
reportable to regulatory authorities. This includes all serious  events that are unexpected and related 
(i.e. possibly, probably, or definitely) to protocol treatment.   
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 48 CONFIDENTIAL11.0 PROTOCOL TREATMENT DISCONTINUATION AND THERAPY AFTER STOPPI NG 
ALL STUDY TREATMENT
11.1 CRITERIA FOR DISCONTINUING PROTOCOL TREATMENT
Patients should stop protocol treatment in the following instan ces:
yProgressive Disease (see section 9.2.5) 
yPregnancy
yIntercurrent illness which would, in the judgement of the Inves tigator, affect assessments of 
clinical status to a significant degree, and require discontinu ation of protocol therapy 
yUnacceptable toxicity
yRequest by the patient
If a patient discontinues protocol treatment for objective prog ression on nab-paclitaxel and 
gemcitabine with BBI-608 (Arm 1), the patient together with thei r investigator, may elect to continue 
treatment with BBI-608 in monotherapy with the Sponsorâ€™s approv al, provided no discontinuation 
criterion involving BBI-608-related adverse events is met, it i s believed to be in the patientâ€™s best 
interest by the investigator and patient, and with the patientâ€™ s informed consent.
If a patient permanently discontinues protocol treatment for a reason other than objective progression, 
every effort should be made to obtain tumor evaluations on the same schedule until progression is 
observed. 
Efforts should be made to maintain the investigations schedule and continue follow-up, even if patients 
discontinue protocol treatment prematurely and/or no longer att end the participating institution.  
11.2 DURATION OF PROTOCOL TREATMENT 
Patients may continue to receive  protocol treatment as long as they have not experienced any adverse 
events requiring permanent discontinuation of study medication and have not demonstrated disease 
progression based on RECIST criteria, if it is believed to be in  t h e  p a t i e n t â€™ s  b e s t  i n t e r e s t  o r u n t i l  
February 28th, 2020, when the study is planned for  completion, whichever occ urs first.  
There will be no cross-over to BBI-608-containing study arm in combination with nab-paclitaxel and 
gemcitabine (Arm 1) from the nab-paclitaxel and gemcitabine only study arm (Arm 2) and vice versa. 
11.3 THERAPY AFTER PROTO COL TREATMENT IS PER MANENTLY DISCONTINUE D
Treatment after all protocol therapy has been permanently disco ntinued is at the discretion of the 
Investigator. Information on post-study anti-cancer treatment w ill be collected in this study.
11.4 FOLLOW-UP OFF PROTOCOL TREATMENT
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 49 CONFIDENTIALFollow-up will continue after treatment completion according to  the plan described in the protocol (see 
Section 8.2). Efforts should be made to maintain the investigat ions schedule and continue follow-up, 
even if patients permanently discontinue protocol treatment prema turely and/or no longer attend the 
participating institution. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 50 CONFIDENTIAL12.0 CENTRAL REVIEW PROCEDURES, TISSUE COLLECTION, AND CORRELATI VE 
STUDIES 
12.1 CENTRAL RADIOLOGY REVIEW
There will be no central radiology review for this study. 
12.2 CENTRAL PATHOLOGY REVIEW
There will be no central pathology review for this study. 
12.3 TISSUE COLLECTION
Protocol-Mandated Correlative Studies: 
The submission of a representative diagnostic tumor tissue and of a blood sample for correlative studies 
defined in Section 13.6 (Correlative Studies) is mandatory for p articipation in this trial (although 
submission of the tissue does not have to occur prior to random ization). Where local center regulations 
prohibit submission of blocks of tumor tissue, two 2 mm cores of  tumor from the block and 5-20
unstained slides of representative tumor tissue are requested. W here 2 mm cores of tumor from the 
block are unavailable, 5-20 unstained slides of representative tumor tissue are requested. Where no 
previously resected or biopsied tumor tissue exists, on the app roval of the Sponsor/designated CRO, 
the patient may still be considered eligible for the study.
After patient consent, blood sample and paraffin tumor blocks wil l be the preferred tissue material to 
collect. If tumor blocks are unavailable, then two 2 mm cores o f tumor from the block and 5-20 
specimen slides are preferred. If two 2 mm cores of tumor from the block are unavailable, 5-20 
specimen slides will be acceptable. If, at any time, the submit ting hospital requires the block to be 
returned for medical or legal concerns, it will be returned by courier on request. 
Samples will be used for research purposes only and will not be  sold. Patients will not be identified by 
name. The only identification of tissue will be by a patient st udy number assigned at the time of 
randomization to the trial. Material issued to researchers will  be anonymous and only identified by a 
coded number. 
Testing for hereditary genetic defects predisposing to malignan t disease will not be carried out without 
the expressed consent of the patient.  
All patients on whom a blood sample and/or diagnostic tumor blo ck is collected will be aware of this 
retrieval and will have given their consent.
12.4 SPARSE PHARMACOKINETIC PLASMA SAMPLE COLLECTION â€“ NAB-PACLI TAXEL 
WITH GEMCITABINE AND BB I-608 (ARM 1 ONLY)  
Plasma samples for sparse pharmacokinetics (PK) analysis will b e obtained from all patients 
randomized to nab-paclitaxel with gemcitabine and BBI-608 study  arm (Arm 1) at the study visits 
occurring on Days 8 and 15 of Cycle 1, and Day 1 of Cycle 2 (corre sponding to nab-paclitaxel with 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 51 CONFIDENTIALgemcitabine infusion days). Patients randomized to nab-paclitaxel  and gemcitabine arm alone (Arm 2) 
will not undergo collection of blood for sparse PK analysis.  
Day 8 (Cycle 1) Study Visit: 
The Day 8 (Cycle 1) visit should be scheduled prior to 10 AM. On the day of this visit, patients should 
be instructed to wait to take their first daily dose of BBI-608  until they arrive in clinic. After arrival in 
the clinic, but approximately 5 minutes prior to administration  of the first daily dose of BBI-608, a 
plasma sample will be obtained. Nab-paclitaxel infusion will be started approximately 2 hours after 
BBI-608 administration. A second plasma sample will be obtained  within 60-180 minutes after the 
start of nab-paclitaxel infusion. A third plasma sample will be  obtained within 240-480 minutes after 
the start of nab-paclitaxel infusion.  
Day 15 (Cycle 1) Study Visit: 
The Day 15 (Cycle 1) visit should be scheduled prior to 10 AM. On the day of this visit, patients should 
be instructed to take their first daily dose of BBI-608 until t hey arrive in clinic. After arrival in the 
clinic, but approximately 5 minutes prior to administration of the first daily dose of BBI-608, a plasma 
sample will be obtained. Nab-paclitaxel infusion will be starte d approximately 2 hours after BBI-608 
administration. A second plasma sample will be obtained within 60-180 minutes after the start of nab-
paclitaxel infusion. A third plasma sample will be obtained wit hin 240-480 minutes after the start of 
nab-paclitaxel infusion.  
Day 1 (Cycle 2) Study Visit: 
The Day 1 (Cycle 2) visit should be scheduled prior to 10 AM. On the day of this visit, patients should 
be instructed to wait to take their first daily dose of BBI-608  until they arrive in clinic. After arrival in 
the clinic, but approximately 5 minutes prior to administration  of the first daily dose of BBI-608, a 
plasma sample will be obtained. Nab-paclitaxel infusion will be  started approximately 2 hours after 
BBI-608 administration. A second plasma sample will be obtained  within 60-180 minutes after the 
start of nab-paclitaxel infusion. A third plasma sample will be  obtained within 240-480 minutes after 
the start of nab-paclitaxel infusion.  
For all days during which a plasma sample is obtained for PK an alysis, the precise time of all doses of 
BBI-608 (on the day of sampling and the day prior), the precise  time of the initiation of nab-paclitaxel 
and gemcitabine administration, and the precise time of all PK sampling must be captured. 
Samples will be processed, stored and shipped according to the instructions provided in the separate
Sparse PK sampling laboratory manual for this study.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 52 CONFIDENTIAL13.0 STATISTICAL CONSIDERATIONS
Detailed methodology for summary and statistical analyses of th e data collected in this study will be 
documented in a statistical analysis plan (SAP), which will be maintained by the sponsor.  The SAP 
may modify the plans outlined in the protocol; however, any maj or modifications of the primary 
endpoint definition and/or its analysis will also be reflected in a protocol amendment. 
13.1 OBJECTIVES AND DESIGN 
The primary objective of this study is to assess the effect of orally administered BBI-608 plus weekly 
nab-paclitaxel with gemcitabine (Arm 1), in comparison to weekly  nab-paclitaxel with gemcitabine
(Arm 2) on the Overall Survival (OS) in patients with metastati c PDAC. 
Key secondary objectives for this study include comparisons of PFS in the general population, DCR
in the general population and ORR in the general population. Ot her secondary objectives include
Adverse Events and Quality of Life Assessment in the general po pulation between the two treatment 
arms.
This is a multi-center, prospective, open-label, randomized Pha se III trial. Patients will be randomized 
to receive either BBI-608 plus weekly nab-paclitaxel with gemci tabine, or weekly nab-paclitaxel with 
gemcitabine in a 1:1 ratio and will be stratified by geographica l region (North America/Western 
Europe/Australia vs. Japan/Korea vs. Rest of the World), ECOG pe rformance status (ECOG 0 versus 
ECOG 1), and presence of liver metastases (yes versus no).
13.2 STUDY ENDPOINTS AND ANALYSIS
13.2.1 Primary Endpoint 
OS in the General Study Population 
Unless otherwise specified, all efficacy analyses will be based  on the Primary Analysis Set, which 
includes all randomized patients. Patients will be analyzed as randomized. As a sensitivity analysis, 
the Per Protocol population will also be analyzed for key effic acy endpoints. 
Overall Survival in the general study population, the primary en dpoint of this study, is defined as the 
time from randomization to death from any cause. Patients who a re alive at the time of the final analysis 
or who have become lost to follow-up will be censored at their last date known to be alive. Patients 
will be analyzed in the arm to which they are randomized regard less of the treatment they received 
(intent-to-treat analysis). The survival experience of patients  in both treatment groups will be 
summarized by the Kaplan-Meier method and compared primarily by a stratified log-rank test 
adjusting for stratification variables at randomization.  
Sensitivity analyses based on stratified Cox proportional hazar ds model will also be performed. These 
sensitivity analyses are not included in the multiplicity adjus tment for secondary outcomes detailed 
below and, as such, do not control for type I error. Geographica l region (North America/Western 
Europe/Australia vs. Japan/Korea vs. Rest of the World), ECOG p erformance status (ECOG 0 versus
ECOG 1), and presence of liver metastases (yes versus  no) will be the stratification factors to define 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 53 CONFIDENTIALthe stratified Cox proportional hazards model.  
Subgroup analysis and the corresponding forest plot analysis may be performed using the stratification 
factors mentioned above as well as the following factors: 
xPrimary tumor location (head versus other)
xLevel of CA19-9 (normal versus  <59 x ULN versus  >59 x ULN)
xAge (< 65 versus  > 65)
xSex (male versus female)
xNumber of metastatic sites at baseline (1 versus  > 2) 
xRace (white, black, Asian, other)
xCountry (Canada, USA, Europe, others) 
13.2.2 Key Secondary Endpoints 
The following secondary outcomes will be assessed. 
PFS in the General Study Population 
PFS in the general study population is defined as the time from randomization to the first objective 
documentation of disease progression or death due to any cause. If a patient has not progressed or died 
at the time of final analysis, PFS will be censored on the date of the last tumor assessment. This 
includes patients who are lost to follow-up or have withdrawn c onsent.  
DCR in the General Study Population
DCR is defined as the proportion of patients with a documented complete response, partial response, 
and stable disease (CR + PR + SD) based on RECIST 1.1. The prim ary estimate of DCR will be based 
on patients with measurable disease by RECIST 1.1 at randomizat ion.  
ORR in the General Study Population
ORR is defined as the proportion of patients with a documented complete response and partial response 
(CR + PR) based on RECIST 1.1. The primary estimate for ORR wil l be based on patients with 
measurable disease by RECIST 1.1 at randomization. 
13.2.3 Other Secondary Endpoints 
Safety Analysis
All patients who have received at least one dose of study drug w ill be included in the safety analysis. 
The incidence of adverse events will be summarized by type of a dverse event and severity using the 
NCI Common Terminology Criteria for Adverse Events Version 4.0.  A Fisherâ€™s exact test may be used 
to compare adverse events between the two arms.
QoL Analysis 
The QoL of patients will be assessed using EORTC QLQ-30 while t he patient remains on BBI-608 as 
per Section 8.1. The EORTC QLQ- 30 is a self-administered cancer  specific questionnaire with multi-
dimensional scales. It consists of both multi-item scales and s ingle item measures, including five 
functional domains, a global quality of life domain, three symp tom domains, and six single items. 
Scoring of the EORTC QLQ-30 data will be completed following th e procedures recommended by the 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 54 CONFIDENTIALEORTC Study Group on Quality of Life. For each domain or single  item measure a linear 
transformation will be applied to standardize the raw score to r ange between 0 and 100. The quality of 
life data will be analyzed to look for statistically and clinic ally significant differences between the 
BBI-608 plus nab-paclitaxel with gemcitabine versus  nab-paclitaxel with gemcitabine groups. 
Questionnaire compliance rates will be ascertained for each gro up at each measurement time point. 
Mean baseline scores for each subscale and summary scores will be calculated.
The endpoints in QoL analysis are the mean EORTC QLQ-C30 QoL ch ange scores from baseline at 
time 2 (~8 weeks from Cycle 1 Day 1) and time 4 (~16 weeks from C ycle 1 Day 1) for the physical 
function and global health status/quality of life subscale scor es. Wilcoxon tests will be used to compare 
the difference at each of these two time points between two tre atment arms for each of these two 
subscales. The proportion of patients in either arm with at lea st a minimum of 10 unit(s) deterioration 
in change scores at both 8 and 16 weeks from Cycle 1 Day 1 will  be compared by means of Fisherâ€™s 
exact test.
13.2.4 Exploratory Endpoints OS in the Predefined Biomarker-positive Population
OS in the general predefined biomarker-positive population is d efined as the time from randomization 
to death due to any cause. If a patient has not died at the tim e of final analysis, OS will be censored on 
the date of the last follow up assessment. This includes patien ts who are lost to follow-up or have 
withdrawn consent.  
PFS in the Predefined Biomarker-positive Population
PFS in the predefined biomarker-positive population is defined as the time from randomization to the 
first objective documentation of disease progression or death d ue to any cause. If a patient has not 
progressed or died at the time of final analysis, PFS will be c ensored on the date of the last tumor 
assessment. This includes patients who are lost to follow-up or  have withdrawn consent.  
ORR and DCR in the Predefined Biomarker-positive Population
ORR in the predefined biomarker-positive population is defined as the proportion of patients with a 
documented complete response and partial response (CR + PR) bas ed on RECIST 1.1. The primary 
estimate for ORR will be based on patients with measurable dise ase by RECIST 1.1 at randomization. 
DCR in the predefined biomarker-positive population is defined as the proportion of patients with a 
documented complete response, partial response, and stable dise ase (CR + PR + SD) based on RECIST 
1.1. The primary estimate of DCR will be based on patients with  measurable disease by RECIST 1.1 
at randomization.  
13.3 SAMPLE SIZE AND DURATION OF STUDY
The primary study endpoint for all patients on the study is OS.   
The study is designed to have a power of 90% and a one-sided al pha of 2.5% to detect a 20% reduction 
in the continuous risk of death (HR 0.80, which corresponds to an increase of median survival from 
8.5 to 10.63 months) in the Intention to Treat (ITT) general st udy population. The 864thevent will 
trigger the final analysis. It is estimated that 864 events wil l be required to detect a 20% reduction in 
the risk of death which woul d be observed by randomizing 1132 p atients over 24 months with patient 
follow up for an additional 12 months, for total study duration of 36 months. It is anticipated that up 
to 5% dropout rate will occur for the entire study.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 55 CONFIDENTIALThe overall power of the study will be approximately 90% after the multiplicity control procedure is 
considered.
When the required number of events for the primary endpoint has  been reached, all randomized 
patients still alive will continue study follow up through to t heir deaths.  
13.4 SAFETY MONITORING
Adverse events will be monitored on an on-going basis by centra l review. 
13.5 INTERIM ANALYSIS
Prior to this amendment, there was one interim analysis presente d to the independent DSMB. 
Additionally, DSMB reviewed safety data during conduct of the st udy. The role and responsibility of 
the DSMB are defined in a separate Charter.
The interim analysis involved a stratified log-rank test. Nomina l p-values were based on the Lan-
DeMets error spending function using an Oâ€™Brien-Fleming stoppin g boundary in order to preserve the 
overall one-sided alpha level of 0.025. 
The interim analysis was performed when approximately 432 deaths  (50% of the required events) were
observed.  The interim analysis was for futility only, with the f utility boundary set at HR > 1. Safety 
data and primary analysis based on approximately 432 events were  presented to the DSMB on June 
24th, 2019. The DSMB reviewed the results on July 1st, 2019. Based on the recommendation of the 
DSMB, the Sponsor informed investigators on July 2nd, 2019 that the study would be discontinued due 
to futility. For patients enrolled to Arm 1, the Sponsor advise d that patients stop treatment with BBI-
608 but given that no safety concerns were identified by the DS MB, in cases in which a patient appears 
to be deriving benefit from BBI-608 in the opinion of the inves tigator and with the patientâ€™s informed 
consent, continuation of protocol therapy was permitted. Patient s enrolled to Arm 2 were given the 
option to continue receiving standard of care therapy within th e study.  
Patients may continue to receive protocol therapy until a disconti nuation criterion is met, if believed 
to be i n th e pat ien tâ€™ s bes t int ere st by  the inv est ig ator  and pat ient, and with the patientâ€™s informed 
consent, or until February 28th, 2020, whichever occurs first. 
At study completion, analysis will be conducted for primary end point of OS as outlined in Section 13. 
Additionally, all secondary and exploratory analyses will be pe rformed as outlined in the protocol.  
13.6 CORRELATIVE STUDIES
The correlative science component of the CanStem111P trial will  include tumor and blood based 
assays to identify biomarkers of benefit from BBI-608 therapy, as well as biomarkers of BBI-608 
resistance. The purpose of these studies is to explore the poss ible relationship between biomarkers and 
disease response. The research aims to validate molecular marker s such as genes (DNA) and gene 
products (mRNA or proteins), with m easurements of their sequenc e, post translation modifications or 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 56 CONFIDENTIALdegree of expression, that can guide the use of appropriate thera peutic treatment regimens. The 
ultimate goal of identifying molecular markers is to improve su bject responses and other measures of 
clinical benefit by matching an individual subjectâ€™s tumor diag nostic profile with an anticancer agent 
that has demonstrated a therapeutic advantage in subjects with a similar diagnostic profile. If such a 
marker can be identified, the samples and results may also aid i n  t h e  d e v e l o p m e n t  o f  d i a g n o s t i c  
devices.
Using data from this and other trials, the relationship between  a number of molecular markers 
DVVRFLDWHGZLWKWKH67$7È• -catenin and other related pathways, and the clinical outcomes with BBI-
608 therapy may be explored. Multiple molecular markers in a para ffin-embedded tumor tissue sample 
can be determined by analyzing R NA and protein in the tissue sa mple. 
In addition to analysis of potential biomarkers of benefit from  BBI-608 therapy, an analysis of markers 
of resistance to BBI-608 will be conducted using blood samples drawn at baseline as well at 4 weeks 
post initiation of therapy. This analysis may involve SNPs, CYP S, and metabolomics.
Paraffin-embedded tumor specimens, or cores (two 2 mm cores of tumor from the block) and 5-20 
unstained slides obtained from paraffin embedded specimens will  be required. Where it is not possible 
to obtain two 2 mm cores of tumor from the block, 5-20 unstaine d slides of representative tumor tissue 
are also acceptable. Patients who do not have available archiva l tissue may enroll on the study with 
permission of the Sponsor/CRO.
Blood samples will be collected prior to dosing with BBI-608 an d then at week 4 while on BBI-608 in 
combination with nab-paclitaxel and gemcitabine. 
The following analysis will be performed to investigate the rel ationship between endpoints and 
biomarker levels (e.g. phospho-STAT3, etc): 
For each biomarker, Cox Proportional Hazards model will be used  to model the relationship between 
Overall Survival, Progression-Free Survival and duration of res ponse with baseline value of the 
biomarker. The model will also include assigned treatment, inte raction between treatment and 
biomarker, and will be stratifie d by baseline ECOG performance status. 
For biomarkers with post-baseline measurements, similar analysi s will be done with change from 
baseline of a biomarker as a covariate, for both time points. An  additional model that includes 
prognostic factors may be investigated. 
The relationship between the endpoint and binary biomarkers (e. g. baseline phospho-STAT3 status, ÃŸ-
catenin, etc) will be also examined using the log-rank test, st ratified by treatment and baseline ECOG 
performance status. Subgroup analysis by the status of the bina ry biomarker may also be performed. 
The Kaplan-Meier method will be used to describe overall surviv al, progression-free survival and 
duration of response by the status of the biomarker (e.g. phosp ho-STAT3-high vs. phospho-STAT3-
low) and by treatment group. 
The relationships between the binary response variable (e.g. ob jective response, DCR) with baseline 
values of biomarkers as well as with their change from baseline  and at week 4 time point during 
treatment with nab-paclitaxel and gemcitabine with or without BB I-608 will be investigated using 
logistic regression that includes assigned treatment and biomar ker value and treatment-by-biomarker 
interaction, stratified by baseline ECOG performance status. An  additional model that includes 
prognostic factors may be investigated. The relationship betwee n response and binary biomarkers (e.g. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 57 CONFIDENTIALbaseline phospho-STAT3 status or STAT3 status) will also be exa mined using the CMH test, stratified 
by treatment and baseline ECOG performance status. Subgroup ana lysis by the status of the binary 
biomarker may also be performed. 
Exploratory analyses, in addition to those described in this se ction, such as alternative modeling 
approaches and analyses of other biomarkers are expected and ma y be performed. All analyses 
described in this section are based on availability of data.
13.7 SPARSE PHARMACOKINETIC ANALYSIS
Exploratory analyses will be performed on the bioanalytic data obtained from sparse plasma sampling 
in order to characterize the population pharmacokinetics of BBI -608. Demographic and 
pathophysiologic factors that affect plasma concentration of BB I-608 and nab-paclitaxel with 
gemcitabine in this population of patients with metastatic PDAC will be examined. The exposure-
response relationship between clinical and safety endpoints and  BBI-608/nab-paclitaxel with 
gemcitabine exposure will also be examined.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 58 CONFIDENTIAL14.0 PUBLICATION
Boston Biomedical, Inc. acknowledges that the Investigator(s) ha ve certain professional 
responsibilities to report to the scientific community on findi ngs in clinical investigations they conduct. 
A Principal Investigator shall have the right to publish the re sults of research performed under this 
protocol; provided, such publication does not disclose any Confi dential Information or trade secrets of 
Boston Biomedical (other than the Clinical Results).  
If the Study is conducted as part of a multi-center protocol, P rincipal Investigator at each institution 
agrees not to independently publish their findings except as pa rt of an overall multi-center publication. 
No other publication is allowed before the primary peer-reviewe d scientific publication
The primary author agrees to, prior to submitting a manuscript,  abstract, or any other written or oral 
presentation describing the Results for publication or presentat ion, forward to Boston Biomedical a 
copy of the item to be submitted for publication or presentatio n no less than forty-five (45) days prior 
to their submission. Upon reasonable request by Boston Biomedic al, the primary author agrees to 
withhold such publication an additional 30 days to permit the p reparation and filing of related patent 
applications. In addition, Boston Biomedical shall have the rig ht to require the primary author to delete 
from any publication or presentation any Confidential Informati on (other than the Clinical Results) of 
Boston Biomedicalâ€™s and to require that any publication or pres entation concerning the Study 
acknowledge the Sponsorâ€™s support.  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 59 CONFIDENTIAL15.0 RESEARCH OUTSIDE THE TERMS OF THIS PROTOCOL
Boston Biomedical has a legal res ponsibility to report fully to  the regulatory authorities all the results 
of administration of its investigational drugs.
No investigative procedures other than those described in this protocol shall be undertaken on subjects 
enrolled in this study (unless required for the care of the sub ject), without the agreement of the 
IRB/Ethics Committee and Boston Biomedical. The nature and resul ts of any such procedures must be 
recorded and reported by a method agreed between Boston Biomedi cal and the Investigator. The 
consent of the subjects must be obtained before any such proced ures are undertaken.
The investigative drug provided to the Investigator for use und er this protocol may not be used for any 
other purpose, including another  study, compassionate use, or p ersonal use. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 60 CONFIDENTIAL16.0 ETHICAL, REGULATORY AND ADMINISTRATIVE ISSUES
16.1 REGULATORY CONSIDERATIONS
All institutions must conduct this trial in accordance with Int ernational Conference on Harmonization-
Good Clinical Practice (ICH-GCP) Guidelines. 
The conduct of this trial must comply with local laws and natio nal regulations [e.g. in the United States 
of America with applicable US FDA Regulations; in Canada with D ivision 5 of the Canadian 
Regulations Respecting Food and Drugs (Food and Drugs Act)] rel evant to the use of new therapeutic 
agents in the country of conduct. 
16.2 INCLUSIVITY IN RESEARCH
Individuals must not be excluded from participation in clinical  trials on the basis of attributes such as 
culture, religion, race, national or ethnic origin, colour, men tal or physical disability (except 
incapacity), sexual orientation, sex/gender, occupation, ethnic ity, income, or criminal record, unless 
there is a valid reason (i.e. safety) for the exclusion.  
In accordance with the Declaration of Helsinki and the Tri-Coun cil Policy Statement (TCPS), 
vulnerable persons or groups will not be automatically excluded  from a clinical trial (except for 
incompetent persons) if participation in the trial may benefit the patient or a group to which the person 
belongs.  
However, extra protections may be necessary for vulnerable pers ons or groups. It is the responsibility 
of the local Investigator and Institutional Review Board (IRB) to ensure that appropriate mechanisms 
are in place to protect vulnerable persons/groups. In accordanc e  w i t h  T C P S ,  r e s e a r c h e r s  a n d  I R B  
should provide special protections for those who are vulnerable  to abuse, exploitation or 
discrimination. As vulnerable populations may be susceptible to  coercion or undue influence, it is 
especially important that informed consent be obtained appropri ately.  
Centers are expected to ensure compliance with local IRB or ins titutional policy regarding 
participation of vulnerable persons/groups. It is the centerâ€™s responsibility to ensure compliance with 
all local SOPs. 
Persons who cannot give informed consent (i.e. mentally incompe tent persons, or those physically 
incapacitated such as comatose persons) are not to be recruited  to this study. It is the responsibility of 
the local Investigator to determine the subjectâ€™s competency, i n accordance with applicable local 
policies and in conjunction with the local IRB (if applicable).  
Subjects who were competent at the time of enrollment in the cl inical trial but become incompetent 
during their participation do not automatically have to be remo ved from the study. When re-consent 
of the patient is required, Investigators must follow applicabl e local policies when determining if it is 
acceptable for a substitute decision maker to be used. The Spons or will accept re-consent from a 
substitute decision maker. If this patient subsequently regains  capacity, the patient should be re-
consented as a condition of continuing participation. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 61 CONFIDENTIAL16.3 OBTAINING INFORMED CONSENT
Informed consent will be obtained for each participant/potentia l participant in this trial, in accordance 
with ICH-GCP section 4.8. The center is responsible for ensuring  that all local policies are followed.
Additionally, in accordance with GCP 4.8.2, the Sponsor may requ ire that participants/potential 
participants be informed of any new information may impact a pa rticipantâ€™s/potential participantâ€™s 
willingness to participate in the study. 
Based upon applicable guidelines and regulations (Declaration o f Helsinki, ICH-GCP), a participating 
Investigator (as defined on the participants list) is ultimatel y responsible, in terms of liability and 
compliance, for ensuring informed consent has been appropriatel y obtained. The Sponsor recognizes 
that in many centers other personnel (as designated on the part icipants list) also play an important role 
in this process. In accordance with GCP 4.8.5, it is acceptable  for the Principal Investigator to delegate 
the responsibility for conducting the consent discussion. 
The Sponsor requires that each participant sign a consent form prior to their enrolment in the study to 
document his/her willingness to take part. The Sponsor may also require, as indicated above, that 
participants/potential participants be informed of new informat ion if it becomes available during the 
course of the study. In conjunction with GCP 4.8.2, the communi cation of this information should be 
documented. 
The Sponsor allows the use of translators in obtaining informed consent. Provision of translators is the 
responsibility of the local center. Centers should follow applic able local policies when procuring or 
using a translator for the purpose of obtaining informed consen t to participate in a clinical trial. 
In accordance with ICH-GCP 4.8.9, if a subject is unable to rea d, then informed consent may be 
obtained by having the consent form read and explained to the s ubject. This process must be thoroughly 
documented. 
16.3.1 Obtaining Consent for Pregnancy/Exposure Reporting Information from and/or about the subject (i.e. the pregnant fe male, the newborn infant, male partner) 
should not be collected about or from them unless or until they  are a willing participant in the research. 
The rights and protections offered to participants in research apply and consent must be obtained prior 
to collecting any information about or from them. If the pregna nt female is not a participant in the 
main trial, consent shoul d be obtained via use of the exposure/ pregnancy follow-up consent form. 
In the case of information collected about a ne wborn, consent should be provided by the legal 
guardian. In cases where the legal guardian is the participant in the main trial, consent is obtained 
via the main consent. If the legal guardian is not the trial participant, consent should be obtained via 
the exposure/pregnancy follow-up consent.  
Participants will not be withdrawn from the main trial as a res ult of refusing or withdrawing permission 
to provide information related to the pregnancy /exposure . Similarly, male participants will not be 
withdrawn from the main study s hould their partner refuse/withd raw permission. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 62 CONFIDENTIAL16.4 DISCONTINUATION OF THE TRIAL
The study is planned for completion on February 28th, 2020, at which time the Sponsor will cease 
provision of protocol treatment.
If this trial is discontinued for any reason by the Sponsor pri or to February 28th, 2020, all centers will 
be notified in writing of the discontinuance and the reason(s) why. If the reason(s) for discontinuance 
involve any potential risks to the health of patients participa ting on the trial or other persons, the 
Sponsor will provide this information to centers as well.
If this trial is discontinued at any time by the center (prior t o closure of the trial by the Sponsor), it is 
the responsibility of the Principal Investigator to notify the Sponsor of the discontinuation and the 
reason(s) why.  
Whether the trial is discontinued by the Sponsor or locally by the center, it is the responsibility of the 
Principal Investigator to notify the local Institutional Review Board and all clinical trials subjects of 
the discontinuance and any potential risks to the subjects or o ther persons.
Following trial closure after demonstrating overall survival be nefit, and until the time that BBI-608 is 
commercially available, all patients randomized on the trial ma y have an opportunity to receive 
treatment with BBI-608; provided, that the Principal Investigat or has determined that such continued 
treatment would be in the best interest of the patient, and sub ject to approval by the applicable 
regulatory authorities. This will be done via a new, open label  extension study, or in another manner 
as determined by the Sponsor, requiring additional regulatory a pproval. 
16.5 RETENTION OF PATIENT RECORDS AND STUDY FILES
All essential documents must be m aintained in accordance with I CH-GCP. 
The Principal Investigator must ensure compliance with GCP Guid eline from every person involved 
in the conduct of the clinical trial at the site. 
Essential documents must be retained for 25 years following the  completion of the trial at the center
(25 years post final analysis, last data collected, or closure n otification to IRB, whichever is later), or 
until notified by the Sponsor that  documents no longer need to be retained. 
In accordance with GCP 4.9.7, upon request by the monitor, audi tor, IRB or regulatory authority, the 
Investigator/institution must make all required trial-related r ecords available for direct access. 
The Sponsor will inform the Investigator/Institution as to when  the essential documents no longer need 
to be retained. 
16.6 ON-SITE MONITORING/AUDITING
In addition to the routine review of case report forms and supp orting documents sent to the central 
office, site monitoring will be conducted at participating cent ers in the course of the study as part of 
the overall quality assurance programme. The monitors/auditors will require access to patient medical 
records to verify the data, as well as pharmacy, essential docu ment binders, standard operating 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 63 CONFIDENTIALprocedures (including electronic information) and ethics docume ntation. 
At any time, your site may be subject to an inspection by a reg ulatory agency such as the Health 
Canada Inspectorate or the FDA. Your site may also be subject t o an audit by the Sponsor.  
16.7 CASE REPORT FORMS
This trial will use a web-based Electronic Data Capture (EDC) s ystem for all data collection. Details 
for accessing the EDC system and completing the on-line Case Re port Forms will be provided 
separately. 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 64 CONFIDENTIALREFERENCES
Cancer Stem Cell, special issue: June 10 special issue of Journ al of Clinical Oncology [J Clin Oncol. 2008 
26(17)].  
Akira, S. (1999). Functional Roles of STAT Family Proteins: Les sons from Knockout Mice. Stem Cells ,17(3), 
138-146.  
Al-Hajj, M., & Clarke, M. (2004). S elf-renewal and solid tumor stem cells. Oncogene ,23(43), 7274-7282.  
Blazer, M., Wu, C., Goldberg, R., Phillips, G., Schmidt, C., & M uscarella, P. et al. (2014). Neoadjuvant 
Modified (m) FOLFIRINOX for Locally Advanced Unresectable (LAPC ) and Borderline Resectable (BRPC) 
Adenocarcinoma of the Pancreas. Annals of Surgical Oncology .  
Arpin, C. C., Mac, S., Jiang, Y., Cheng, H., Grimard, M., Page,  B. D., ... & Rosa, D. A. (2016). Applying 
Small Molecule Signal Transducer and Activator of Trancription- 3 (STAT3) Protein Inhibitors as Pancreatic 
Cancer Therapeutics. Molecular Cancer Therapeutics , molcanther-0003. 
Boman, B., & Wicha, M. (2008). Cancer Stem Cells: A Step Toward  the Cure. Journal of Clinical Oncology ,
26(17), 2795-2799.  
Chen LT, Von Hoff DD, Li CP, et al. (2015). Expanded analyses o f NAPOLI-1: Phase 3 study of MM-398 
(nal-IRI), with or without 5-fluorouracil and leucovorin, versu s 5-fluorouracil and leucovorin, in metastatic 
pancreatic cancer (mPAC) previously treated with gemcitabine-ba sed therapy. Journal of Clinical Oncology,
33, suppl 3, abstr 234.
Cho, R., & Clarke, M. (2008). Recent advances in cancer stem ce lls. Current Opinion in Genetics & 
Development ,18(1), 48-53.  
Clevers, H. (2011). The cancer stem cell: premises, promises an d challenges. Nature Medicine , 313-319.  
Conroy, T., Desseigne, F., Ychou, M., Bouche, O., Guimbaud, R.,  & Becouarn, Y. et al. (2011). FOLFIRINOX 
versus Gemcitabine for Metastatic Pancreatic Cancer. New England Journal of Medicine ,364(19), 1817-1825.  
Corbo, V., Tortora, G., & Scarpa, A. (2012). Molecular patholog y of pancreatic cancer: from bench-to-bedside 
translation. Current Drug Targets ,13(6), 744-752. 
Corcoran, R. B., Contino, G., De shpande, V., Tzatsos, A., Conra d, C., Benes, C. H., ... & Bardeesy, N. (2011). 
STAT3 plays a critical role in KRAS-induced pancreatic tumorige nesis. Cancer Research ,71(14), 5020-5029. 
Davis, J., Pandalai, P., Ripley, R., Langan, R., & Avital, I. ( 2012). Expanding Surgical Treatment of Pancreatic 
Cancer. Pancreas ,41(5), 678-684.  
Denley, S., Jamieson, N., McCall, P., Oien, K., Morton, J., & C arter, C. et al. (2013). Activation of the IL-
6R/Jak/Stat Pathway is Associated with a Poor Outcome in Resect ed Pancreatic Ductal Adenocarcinoma. 
Journal of Gastrointestinal Surgery ,17(5), 887-898.  
Eisenhauer, E., Therasse, P., Bogaerts, J., Schwartz, L., Sarge nt, D., & Ford, R. et al. (2009). New response 
evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). European Journal of Cancer ,
45(2), 228-247.  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 65 CONFIDENTIALFofaria, N. M., & Srivastava, S. K. (2014). STAT3 induces anoik is resistance, promotes cell invasion and 
metastatic potential in pancreatic cancer cells. Carcinogenesis , bgu233. 
Fukuda, A., Wang, S., Morris, J., Folias, A., Liou, A., & Kim, G. et al. (2011). Stat3 and MMP7 Contribute to 
Pancreatic Ductal Adenocarcinoma Initiation and Progression. Cancer Cell ,19(4), 441-455.  
Goldstein D, El Maraghi RH et al. (2014). Updated survival from  a randomized phase III trial (MPACT) of 
nab-Paclitaxel plus gemcitabine versus gemcitabine alone for pa tients (pts) with metastatic adenocarcinoma of 
the pancreas. Journal of Clinical Oncology, 32, suppl 3, abstr 178.
Gupta, P., Chaffer, C., & Weinber g, R. (2009). Cancer stem cell s: mirage or reality?. Nature Medicine ,15(9), 
1010-1012.  
Gupta, P., Fillmore, C., Jiang, G., Shapira, S., Tao, K., Kuper wasser, C., & Lander, E. (2011). Stochastic State 
Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells. Cell,147(5), 1197.  
Hanahan, D., & Weinberg, R. (2011). Hallmarks of Cancer: The Ne xt Generation. Cell,144(5), 646-674.  
Hermann, P., Huber, S., Herrler, T., Aicher, A., Ellwart, J., &  Guba, M. et al. (2007). Distinct Populations of 
Cancer Stem Cells Determine Tum or Growth and Metastatic Activit y in Human Pancreatic Cancer. Cell Stem 
Cell,1(3), 313-323.  
Hidalgo, M. (2010). Pancreatic Cancer. New England Journal of Medicine ,362(17), 1605-1617.  
Hochberg, Y. (1988). A Sharper Bonferroni Procedure for Multipl e Tests of Significance. Biometrika ,75(4), 
800.  
Holland, S., DeLeo, F., Elloumi, H., Hsu, A., Uzel, G., & Brods ky, N. et al. (2007). STAT3 Mutations in the 
Hyper-IgE Syndrome. New England Journal of Medicine ,357(16), 1608-1619.  
Hong, S., Wen, J., Bang, S., Park, S., & Song, S. (2009). CD44- positive cells are responsible for gemcitabine 
resistance in pancreatic cancer cells. International Journal of Cancer ,125(10), 2323-2331.  
Ibrahem, S., Al -Ghamdi, S., Baloch, K., Muhammad, B., Fadhil, W., Jackson, D., ... & Ilyas, M. (2014). 
STAT3 paradoxically st LPXODWHVÈ• -FDWHQLQH[SUHVVLRQEXWLQKLELWVÈ• -catenin function. International Journal of 
Experimental Pathology , 95(6), 392-400. 
Kawada, M., Seno, H., Uenoyama, Y., Sawabu, T., Kanda, N., & Fu kui, H. et al. (2006). Signal Transducers 
and Activators of Transcription 3 Activation Is Involved in Nuc lear Accumulation of Ã‚ -Catenin in Colorectal 
Cancer. Cancer Research ,66(6), 2913-2917.  
Klimstra, D. (2007). Nonductal neoplasms of the pancreas. Mod Pathol ,20(1s), S94-S112.  
Lee, C., Dosch, J., & Simeone, D. (2008). Pancreatic Cancer Ste m Cells. Journal of Clinical Oncology ,26(17), 
2806-2812.  
Lesina, M., Kurkowski, M., Ludes, K., Rose-John, S., Treiber, M ., & Kloppel, G. et al. (2011). Stat3/Socs3 
Activation by IL-6 Transsignaling Promotes Progression of Pancr eatic Intraepithelial Neoplasia and 
Development of Pancreatic Cancer. Cancer Cell ,19(4), 456-469.  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 66 CONFIDENTIALLi, C., Heidt, D., Dalerba, P., Burant, C., Zhang, L., & Adsay,  V. et al. (2007). Identification of Pancreatic 
Cancer Stem Cells. Cancer Research ,67(3), 1030-1037.  
Maeda, S., Shinchi, H., Kurahara, H., Mataki, Y., Maemura, K., & Sato, M. et al. (2008). CD133 expression 
is correlated with lymph node metastasis and vascular endotheli al growth factor-C expression in pancreatic 
cancer. Br J Cancer ,98(8), 1389-1397.  
Li, Y.Z., Rogoff, H.A., Keates, S., Gao, Y., Murikipudi, S., Mi kule, K., Leggett, D., Li, W., Pardee, A.B., Li, 
C.J. (2015) PNAS , 112(6), 1839-1844. 
Mahaseth, H., Brutcher, E., Ka uh, J., Hawk, N., Kim, S., & Chen , Z. et al. (2013). Modified FOLFIRINOX 
Regimen With Improved Safety and Maintained Efficacy in Pancrea tic Adenocarcinoma. Pancreas ,42(8), 
1311-1315.  
Maurer, W., Bretz, F. (2013). Multiple testing in group sequent ial trials using graphical approaches. Statistics 
in Biopharmaceutical Research , 5, 311-320. 
Niwa, H., Burdon, T., Chambers, I., & Smith, A. (1998). Self-re newal of pluripotent embryonic stem cells is 
mediated via activation of STAT3. Genes & Development ,12(13), 2048-2060.  
Ohara, Y., Oda, T., Sugano, M., Hashimoto, S., Enomoto, T., & Ya mada, K. et al. (2013). Histological and 
prognostic importance of CD44+/CD 24+/EpCAM+ expression in clini cal pancreatic cancer. Cancer Science ,
104(8), 1127-1134.  
Ponti, D. (2005). Isolation a nd In vitro Propagation of Tumorig enic Breast Cancer Cells with Stem/Progenitor 
Cell Properties. Cancer Research ,65(13), 5506-5511.  
Pramanik, K. C., Fofaria, N. M., Gupta, P., Ranjan, A., Kim, S.  H., & Srivastava, S. K. (2015). Inhibition of 
È•-catenin signaling suppr HVVHVSDQFUHDWLFWXPRUJURZWKE\GLVUXSWLQJQXFOHDUÈ• -catenin/TCF-1 complex: 
critical role of STAT-3. Oncotarget ,6(13), 11561. 
Rasheed, Z., & Matsui, W. (2012). Biological and clinical relev ance of stem cells in pancreatic 
adenocarcinoma. Journal of Gastroenterology And Hepatology ,27, 15-18.  
Scholz, A., Heinze, S., Detjen, K., Peters, M., Welzel, M., & H auff, P. et al. (2003). Activated signal transducer 
and activator of transcription 3 (STAT3) supports the malignant  phenotype of human pancreatic cancer. 
Gastroenterology ,125(3), 891-905.  
Shah, A., Summy, J., Zhang, J., P ark, S., Parikh, N., & Gallick , G. (2007). Development and Characterization 
of Gemcitabine-Resistant Pancreatic Tumor Cells. Annals of Surgical Oncology ,14(12), 3629-3637.  
Shahda, S., El-Rayes, B., O'Ne il, B., Starodub, A., Hanna, W., & Borodyansky, L. et al. (2016). A Phase Ib 
study of Cancer Stem Cell (CSC) Pathway inhibitor BBI-608 in co mbination with Nab-paclitaxel and 
gemcitabine (nab-PTX) in patients (pts) with metastatic pancrea tic ductal adenocarcinoma (mPDAC). Journal 
of Clinical Oncology . 
Siegel, R., Naishadham, D., & Jema l, A. (2013). Cancer statisti cs, 2013. CA: A Cancer Journal for Clinicians ,
63(1), 11-30.  
Singh, S., Srivastava, S., Bhardwaj, A., Owen, L., & Singh, A. (2010). CXCL12-CXCR4 signalling axis 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 67 CONFIDENTIALconfers gemcitabine resistance to pancreatic cancer cells: a no vel target for therapy. Br J Cancer ,103(11), 
1671-1679.  
Venkatasubbarao, K., Peterson, L., Zhao, S., Hill, P., Cao, L.,  & Zhou, Q. et al. (2013). Inhibiting signal 
transducer and activator of transcription-3 increases response to gemcitabine and delays progression of 
pancreatic cancer. Molecular Cancer ,12(1), 104. 
Von Hoff, D., Ervin, T., Arena, F., Chiorean, E., Infante, J., & Moore, M. et al. (2013). Increased Survival in 
Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. New England Journal of Medicine ,369(18), 1691-
1703.  
Von Hoff, D., Ramanathan, R.K., Borad, M.J., Laheru, D.A., Smit h, L.S., Wood, T.E., et al. (2011). 
Gemcitabine plus nab-Paclitaxel is an active regimen in patient s with advanced pancreatic cancer: a Phase I/II 
trial. Journal of Clinical Oncology, 29(34), 4548-4554. 
:KLWH%&KLHQ$	'DZVRQ' '\VUHJXODWLRQRI:QW È•-Catenin Signaling in Gastrointestinal
Cancers. Gastroenterology ,142(2), 219-232.  
Winter, J., Cameron, J., Campbell, K., Arnold, M., Chang, D., &  Coleman, J. et al. (2006). 1423 
Pancreaticoduodenectomies for Pancreatic Cancer: A Single-Insti tution Experience. Journal of 
Gastrointestinal Surgery ,10(9), 1199-1211.  
Zhang, Y., Morris, J., Yan, W., Schofield, H., Gurney, A., & Si meone, D. et al. (2013). Canonical Wnt 
Signaling Is Required for Pancreatic Carcinogenesis. Cancer Research ,73(15), 4909-4922.  
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 68 CONFIDENTIALAPPENDIX I - PATIENT EVALUATION FLOW SHEET: ARM 1 (TREATMENT WI TH NAB-
PACLITAXEL AND GEMCITABINE WITH BBI-608) 
1 Patient will be excluded from participation if any of the foll owing occurs at < 72 hours prior to randomization: increase in 
ECOG PS (two observers will be required to assess performance s tatus on each occasion and if discrepant, the one with the 
highest deterioration of performance will be considered true), w eight loss of >10% from baseline testing, > 20% decrease in 
serum albumin from baseline testing, or clinically significant change in vital signs. 
2 Medical history must include date of diagnosis including histo logical or cytological documentation of malignancy.
3 Any anesthesia procedures, such as spinal block or other injec tions administered for pain control following Baseline 
Evaluation will be reported at < 72 hours prior to randomization .
4 Adverse events will be graded according to the NCI Common Term inology Criteria for Adverse Events version 4.0 (see 
Appendix IV). Following permanent protocol treatment discontinua tion, patients will be assessed for any protocol treatment 
related adverse events every 8 weeks, starting with the 4 week post-protocol treatment  discontinuation visit.
5 Adverse event assessment by phone should be performed on Run-In Day 2 . 
6 Baseline creatinine or creatinine clearance may be used to dem onstrate eligibility.
7 If required laboratory tests cannot be performed prior to rand omization within indicated timelines due to technical reasons, 
lab retest and prolongation of the screening period for 3 worki ng days is allowed. Laboratory testing performed as part of 1218 1 5 18 1 5<14 days prior to 
randomization
<3 days prior to 
randomization1
4 weeks post 
protocol treatment 
(+/- 7 days)
Every 4 weeks for the first 
6 months, then every 3 
months thereafter (+/- 7 
days)
X
X
X7 XX
X7 XX X
X7
X7 XX X
X7 XX X
X X3 XX
X X5 XXXXXX X X
X7 XXXXXX X
X7 XX X
X7 XXX X
X7 XXX X
X7 XX X
X7
X7
XX X
X7 XX
X
X X12X12
XX X12
XX X14
X
XXXXXXXX
XXXXSubmission of representative block of diagnostic tumor 
tissue Upon request after randomization
Assessment for survival of patient
19Blood collection for correlative studies
Blood collection for sparse PK analysis
Quality of Life Assessment (EORTC QLQ-C30)13
Begin BBI-608 Administration15
Gemcitabine with Nab-Paclitaxel Infusion17
Subsequent Cancer Therapy18Dispense BBI-60816Radiology & Imaging11 Every 8 weeks (56 days) +/- 5 days from randomization until pro gressive disease is 
documentedTumor marker (CA 19-9)Coagulation (PT + PTT)Hematology9, 10
Albumin10Biochemistry6, 10
Urinalysis 10Total Bilirubin10Tests & Procedures
Day
Adverse Event Assessment4
Pregnancy test, serum or urine (if applicable)7,8
ECG (12-lead)Timing & Window
Height
WeightECOG Performance StatusConcurrent Medication ListAfte r Pe rmane nt 
Treatment 
DiscontinuationRun-In Cycle 1 Cycle 2 & Beyond Pre-
Randomization 
(Baseline)During Protocol Tre atme nt
+/- 3 days
Informed Consent
Prior Medical and Therapeutic History
2
Physical Examination
Vital Signs (temperature, heart rate, blood pressure, 
respiratory rate, O 2 saturation on room air)To begin <2 
days after 
randomization15
Can be 
extended up to 
3 days
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 69 CONFIDENTIALstandard of care prior to patient signature of the informed con sent for the study will be acceptable as baseline labwork as lo ng 
as testing is performed < 14 days prior to randomization.
8 In women of childbearing potential only. The minimum sensitivi ty of the pregnancy test must be 25 IU/L or equivalent units 
of HCG.
9 Hematology should be done within 72 hours prior to nab-paclita xel + gemcitabine administr ation. Laboratory testing 
performed as part of standard of care prior to patient signature  of the informed consent for the study will be acceptable as 
baseline labwork as long as testing is performed < 14 days prio r to randomization.
10 Laboratory investigations should be performed within 72 hours prior to Day 1 of each Cycle of protocol treatment. Laboratory 
testing performed as part of standard of care prior to patient signature of the informed consent for the study will be accepta ble 
as baseline labwork as long as testing is performed < 14 days p rior to randomization. Total bilirubin will need to be repeated 
at <72 hours prior to randomization only for patients with Base line total bilirubin >1 and <1.5 x ULN.
11 Standard tumor measurement procedures will be followed to ass ess response to therapy. The same method of assessment and 
the same technique should be used to identify and report each l esion at baseline and at reassessment during treatment. Tumor 
evaluations will continue until progressive disease is document ed. For patients who remain on protocol therapy after objective  
disease progression has been documented, no further imaging ass e s s m e n t s  a r e  m a n d a t e d ,  b u t  w h e r e  t h e s e  o c c u r  a s  a  
component of care, tumor measurements and assessment must be re ported. Tumor assessments should be obtained within +/- 
5 days of protocol specified schedule. Qualifying scans performe d as part of standard of care prior to patient signature of the  
study informed consent will be acceptable as baseline scanning a s  l o n g  a s  s c a n n i n g  i s  p e r f o r m e d  <  1 4 d a y s  p r i o r  t o  
randomization.
12 Sample will be collected 4 weeks after Day 1 Cycle 1 and will  not be performed beyond Cycle 2. A sample will be collected 
following protocol treatment discontinuation if discontinuation  occurs prior to 4 weeks of therapy.
13 To be completed in clinic. Questionnaires should be completed  at baseline and at 4, 8, 12, 16 and 24 weeks from Cycle 1 Day 
1 for as long as patient remains on protocol therapy or until d eterioration to ECOG PS 4 or hospitalization for end of life ca re.
14 EORTC QLQ-C30 ques tionnaire will be collected in the post-pro tocol discontinuation period only if the patient discontinues 
protocol treatment prior to 24 weeks of therapy and has an ECOG  PS of less than 4 and has not been hospitalized for end of 
life care.
15 BBI-608 administration will begin 2 days prior to the nab-pacli taxel+gemcitabine infusion on Day 1 of Cycle 1. These two 
d a y s  a r e  r e f e r r e d  t o  a s  Run-in Day and Run-in Day 2 .Run-in Day 1 should occur within 2 calendar days of patient 
randomization. The run-in period may be extended by up to 3 additional calendar days.
16 Patients continuing  on BBI-608 m onotherapy post disease progre ssion on nab-paclitaxel and gemcitabine will maintain the 
s am e  s c he dule  of  e v e nts , e x c e pt no  lo ng e r ha v e  v is its  or  b loo dw ork or  A E a s s e s sm e nt o n D a y  8 or  D a y  15 of  t he  c y c le 
following treatment discontinuation of nab-paclitaxel and gemcit abine. 
17 Nab-paclitaxel with gemcitabi ne administration should proceed  according to institutional standard practice (with respect to 
pre-treatment laboratory evaluation, clinical assessment, pre-m edication, and monitoring during and after infusion).
18 Subsequent cancer treatment w ill be captured until end of stu dy.
19 After the first visit at which the patient has been off proto col treatment (BBI-608 and nab-paclitaxel with gemcitabine) for 4  
weeks, monitored on a monthly basis for 6 months and then every  3 months thereafter until death, the study closes or 3 years 
have elapsed since subject discontinuation from treatment. In th e event that patient is unable to attend clinic, post-progressi on 
follow-up may be by means of telephone contact.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 70 CONFIDENTIALAPPENDIX II - PATIENT EVALUATION FLOW SHEET: ARM 2 (TREATMENT W ITH NAB 
PACLITAXEL AND GEMCITABINE)  
18 1 5 18 1 5<14 days prior to 
randomization
<3 days prior to 
randomization1
4 weeks post 
protocol treatment 
(+/- 7 days)
Every 4 weeks for the first 
6 months, then every 3 
months thereafter (+/- 7 
days)
X
X
X6XX
X6XX X
X6
X6XX X
X6XX X
X X3XX
X XXXXXX X X
X6XXXXXX X
X6XX X
X7XX X X
X6XX X X
X6XX X
X6
X6
XX X
X6XX
X
X X11X11
XX X13
XXXXXX
XX
XXSubmission of representative block of diagnostic tumor 
tissue Upon request after randomization
Assessment for survival of patient16Blood collection for correlative studies
Quality of Life Assessment (EORTC QLQ-C30)12
Gemcitabine with Nab-Paclitaxel Infusion14
Subsequent Cancer Therapy15Radiology & Imaging10 Every 8 weeks (56 days) +/- 5 days from randomization until pro gressive 
disease is documentedTumor marker (CA 19-9)Coagulation (PT + PTT)Hematology8, 9
Albumin9Biochemistry5,9
Urinalysis9Tests & Procedures
Day
Adverse Event Assessment4
Pregnancy test, serum or urine (if applicable)6,7
ECG (12-lead)Timing & Window
Height
Weight
ECOG Performance Status
Concurrent Medication List
Total Bilirubin9Afte r Pe rmane nt 
Treatment 
DiscontinuationCycle 1 Cycle 2 & Beyond Pre-
Randomization 
(Baseline)During Protocol Tre atme nt
C1D1 to begin < 4 days after randomization
+/- 3 days
Informed Consent
Prior Medical and Therapeutic History2
Physical Examination
Vital Signs (temperature, heart rate, blood pressure, 
respiratory rate, O 2 saturation on room air)
1 Patient will be excluded from participation if any of the foll owing occurs at < 72 hours prior to randomization: increase in
ECOG PS (two observers will be required to assess performance s tatus on each occasion and if discrepant, the one with the 
highest deterioration of performance will be considered true), weight loss of >10% from baseline testing, > 20% decrease in 
serum albumin from baseline testing, or clinically significant change in vital signs.
2 Medical history must include date of diagnosis including histol ogical or cytological documentation of malignancy.
3 Any anesthesia procedures, such as spinal block or other injec tions administered for pain control following Baseline 
Evaluation will be reported at < 72 hours prior to randomizatio n.
4 Adverse events will be graded according to the NCI Common Term inology Criteria for Adverse Events version 4.0 (see 
Appendix IV). Following permanent protocol treatment discontinua tion, patients will be assessed for any protocol treatment 
related adverse events every 8 weeks, starting with the 4 week post-protocol treatment  discontinuation visit.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 71 CONFIDENTIAL5 Baseline creatinine or creatinine clearance may be used to dem onstrate eligibility.
6 If required laboratory tests cannot be performed prior to rand omization within indicated timelines due to technical reasons, 
lab retest and prolongation of the screening period for 3 worki ng days is allowed. Laboratory testing performed as part of 
standard of care prior to patient signature of the informed con sent for the study will be acceptable as baseline labwork as lo ng 
as testing is performed < 14 days prior to randomization.
7 In women of childbearing potential only. The minimum sensitivi ty of the pregnancy test must be 25 IU/L or equivalent units 
of HCG.
8 Hematology should be done within 72 hours prior to nab-paclita xel + gemcitabine administration. Laboratory testing 
performed as part of standard of care prior to patient signatur e of the informed consent for the study will be acceptable as 
baseline labwork as long as testing is performed < 14 days prio r to randomization.
9 Laboratory investigations should be performed within 72 hours p rior to Day 1 of each Cycle of protocol treatment. Laboratory 
testing performed as part of standard of care prior to patient signature of the informed consent for the study will be accepta ble 
as baseline labwork as long as testing is performed < 14 days p rior to randomization. Total bilirubin will need to be repeated 
at <72 hours prior to randomization only for patients with Base line total bilirubin >1 and <1.5 x ULN.
10 Standard tumor measurement procedures will be followed to ass ess response to therapy. The same method of assessment and 
the same technique should be used to identify and report each l esion at baseline and at reassessment during treatment. Tumor 
evaluations will continue until progressive disease is document ed. For patients who remain on protocol therapy after objective  
disease progression has been documented, no further imaging ass e s s m e n t s  a r e  m a n d a t e d ,  b u t  w h e r e  t h e s e  o c c u r  a s  a  
component of care, tumor measurements and assessment must be re ported. Tumor assessments should be obtained within +/- 
5 days of protocol specified schedule. Qualifying scans perform ed as part of standard of care prior to patient signature of th e 
study informed consent will be acceptable as baseline scanning a s  l o n g  a s  s c a n n i n g i s  p e r f o r m e d  <  1 4  d a y s  p r i o r  t o  
randomization.
11 Sample will be collected 4 weeks after Day 1 Cycle 1 and will  not be performed beyond Cycle 2. A sample will be collected 
following protocol treatment discontinuation if discontinuation  occurs prior to 4 weeks of therapy.
12 To be completed in clinic. Questionnaires should be completed  at baseline and at 4, 8, 12, 16 and 24 weeks from Cycle 1 Day 
1 for as long as patient remains on protocol therapy or until d eterioration to ECOG PS 4 or hospitalization for end of life ca re.
13 EORTC QLQ-C30 ques tionnaire will be collected in the post-pro tocol discontinuation period only if the patient discontinues 
protocol treatment prior to 24 weeks of therapy and has an ECOG  PS of less than 4 and has not been hospitalized for end of 
life care.
14 Nab-paclitaxel with gemcitabine administration should begin w ithin 7 calendar days of randomization and pro ceed according 
to institutional standard practice (with respect to pre-treatme nt laboratory evaluation, clinical assessment, pre-medication, and 
monitoring during and after infusion).
15 Subsequent cancer treatment w ill be captured until end of stu dy.
16 After the first visit at which the patient has been off proto col treatment (nab-paclitaxel with gemcitabine) for 4 weeks, 
monitored on a monthly basis for 6 months and then every 3 mont hs thereafter until death, the study closes or 3 years have 
elapsed since subject discontinuation from treatment. In the eve nt that patient is unable to attend clinic, post-progression 
follow-up may be by means of telephone contact.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 72 CONFIDENTIALAPPENDIX III - PERFORMANCE STATUS SCALES/SCORES
PERFORMANCE STATUS CRITERIA
Karnofsky and Lansky performance scores are intended to be multiples of 10.
ECOG (Zubrod) Karnofsky Lansky*
Score Description Score Desc ription Score Description
0 Fully active, able to carry on all 
pre-disease performance 
without restriction.100Normal, no complaints, no 
evidence of disease.100 Fully active, normal.
90Able to carry on normal activity; 
minor signs or symptoms of disease.90Minor restrictions in physically 
strenuous activity.
1 Restricted in physically 
strenuous activity but ambulatory and able to carry 
out work of a light or sedentary 
nature, e.g. light housework, office work.80Normal activity with effort; some 
signs or symptoms of disease.80 Active, but tires more quickly.
70Cares for self, unable to carry on 
normal activity or do active work.70Both greater restriction of and 
less time spent in play activity.
2 Ambulatory and capable of all 
selfcare but unable to carry out 
any work activities. Up and 
about more than 50% of waking hours.60Requires occasional assistance, but 
is able to care for most of his/her needs.60Up and around, but minimal 
active play; keeps busy with quieter activities.
50Requires considerable assistance 
and frequent medical care.50Gets dressed, but lies around 
much of the day; no active play; able to participate in all quiet 
play and activities.
3 Capable of only limited 
selfcare; confined to bed or 
chair more than 50% of waking hours.40Disabled, requires special care and 
assistance.40Mostly in bed; participates in 
quiet activities.
30Severely disabled, hospitalization 
indicated. Death not imminent.30In bed; needs assistance even for 
quiet play.
4 Completely disabled. Cannot 
carry on any selfcare. Totally 
confined to bed or chair.20Very sick, hospitalization 
indicated. Death not imminent.20Often sleeping; play entirely 
limited to very passive activities.
10Moribund, fatal processes 
progressing rapidly.10 No play; does not get out of bed.
* The conversion of the Lansky to ECOG scales is intended for N CI reporting purposes only.
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 73 CONFIDENTIALAPPENDIX IV - NCI COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENT S 
The descriptions and grading scales found in the NCI Common Ter minology Criteria for Adverse Events 
(CTCAE) version 4.0 will be utilized for Adverse Event (AE) rep orting. All appropriate treatment areas should 
have access to a copy of the CTCAE version 4.0. A copy of the C TCAE version 4.0 can be downloaded from 
the CTEP web site:
(http://ctep.cancer.gov/protocolDevelopment/electronic_applicati ons/ctc.htm ).
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 74 CONFIDENTIALAPPENDIX V - QUALITY OF LIFE ASSESSMENT
Introduction 
The assumption that control of symptoms will automatically impr ove quality of life is probably true but hasn't 
yet been tested, especially in determining how certain symptoms  may or may not affect quality of life. Current 
literature reveals interesting things; two in particular are:
xadditional and useful information may be obtained from quality of life measurements
xa growing consensus that the goal of medical care today for mos t patients is the preservation of function 
and well-being in everyday life
We have reached the stage where the collection of information a bout psychological distress, social disruption, 
emotional trauma and painful side-effects is not only necessary  but a routine component in many protocols. 
Quality of life data can be used in a variety of ways:
xto try to achieve the best possible outcome for patients
xto evaluate the extent of change in the quality of life of an i ndividual or group across time
xto evaluate new treatments and technologies
xto support approval of new drug applications 
xto try to provide the best value for health care dollars 
xto compare costs and benefits of various financial and organiza tional aspects of health care services
In the future, approval of not only drugs but also new therapie s or methods of delivery will most likely be 
based on a combination of quality of life, survival, response, and adverse event data.
Instructions for Administrati on of a Quality of Life Questionna ire.  
The instructions below are intended as a guide for the administ ration of the Quality of Life questionnaire. 
1. Preamble
Quality of life data are collected for research purposes, and w ill usually not be used for the patientâ€™s individual 
medical care. The assessment is in the form of a self-report qu estionnaire. Therefore, it must be completed by 
the patient only, without translation, coaching or suggestions as to the "correct" answer by relatives or health 
care personnel.
The usual scheduled times to obtain the questionnaires are as f ollows: 
xpre-randomization or pre-registration (baseline)
xduring treatment 
xduring follow-up 
The information provided by the patient in the completed questi onnaire is confidential and should not be 
discussed with or shown to anyone  who is NOT mentioned in the c onsent form signed by the patient. 
If a particular question has not been answered, please document  the reason(s) in the appropriate space on the 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 75 CONFIDENTIALquestionnaire. If the whole questionnaire has not been complete d, please document the reason(s) on the 
appropriate case report forms.
2. Pre-Treatment Assessment
It should be explained to the patient that the purpose of the q uestionnaire is to assess the impact of treatment 
on different areas of the patient's life, e.g.: psychological d istress, social disruption, side-effects, et cetera.
Study staff should collect the questionnaire as soon as it has b een completed, check to see that each question 
has been answered and gently remind the patient to answer any i nadvertently omitted questions. If a patient 
states that s/he prefers not to answer some questions and gives  a reason(s), the reason(s) should be noted on 
the questionnaire. If a specific reason is not given, this also  should be noted on the questionnaire. 
3. Assessments During Treatment
The quality of life questionnaire should be given to the patien t before being seen by the doctor, and prior to 
treatment on the day of treatment, as required by the schedule in the protocol. If the patient does not have a 
doctor visit scheduled, or if it was not possible for the patie nt to complete the questionnaire before being seen 
by the doctor, s/he should still complete the questionnaire pri or to treatment.
4. Assessments During Follow-up 
The quality of life questionnaire should be given to the patien t before being seen by the doctor, for as long as 
the patient continues on Protocol therapy, as required by the s chedule at approximately: 
4, 8, 12, 16 and 24 weeks or until deterioration to ECOG PS 4 o r hospitalization for end of life care  
the first regularly scheduled 4 week assessment at which the pa tient has been off study therapy for a minimum 
of 28 days (+/- 3 days) if study therapy discontinuation occurred  prior to 24 weeks and until deterioration to 
ECOG PS 4 or hospitalization for end of life care 
A patient may, on occasion, be reluctant to complete the questi onnaire because they feel unwell. In that case, 
you may express sympathy that things are below par, but state t hat this is exactly the information we require 
if we are to understand more about how quality of life is affec ted. You may also remind them that it takes only 
a few minutes to complete.
It defeats the whole purpose of the assessment if it is delayed until the patient feels better!
5. What If . . .
The patient should complete the questionnaires at the clinic. T he exception is that the design of some trials 
may require the patient to take the questionnaire home with the m after leaving the clinic, and complete it on 
the specific day, because a return visit to the clinic is not s cheduled.
There may be circumstances when the patient does not complete t he questionnaire as required in the clinic. 
Three situations are described below. In these cases, it is ben eficial if quality of life data can still be collected.
A. The patient leaves the clinic before the questionnaire could be administered, or someone forgets to give the 
questionnaire to the patient.  
Contact the patient by phone informing him or her that the ques tionnaire was not completed. Ask the patient 
if s/he is willing to complete one: 
CanStem111P
Protocol Date: 2019-JUL-31
Amendment #5 
  
CONFIDENTIAL 76 CONFIDENTIALIf yes, mail a blank questionnaire to the patient, and make arra ngements for return of the questionnaire in a 
timely fashion. Record the date it was mailed and the date rece ived on the questionnaire.
If this is not feasible, then ask the patient if s/he is willing  to complete a questionnaire over the phone. If the 
patient agrees, read out the questions and range of possibiliti es, and record the answers. Make a note on the 
questionnaire that the questionnaire was completed over the pho ne. 
If no, note the reason why the questionnaire was not completed on the appropriate case report form.
B. The patient goes on an extended vacation for several months and won't attend the clinic for regular visit(s).Ensure that the patient has a supply of questionnaires, with in structions about when to complete them, and how 
to return them. If it is known beforehand, give the patient bla nk questionnaires at the last clinic visit; if the 
extended absence is not known in advance, mail the blank questi onnaires to the patient. Written instructions 
may help ensure that the patient stays on schedule as much as p ossible.  
C. The patient does not want to complete the questionnaire in clinic. Should the patient not wish to answer the questionnaire in the clinic but insists on taking it home, and failing 
to comply with the patient's wishes is likely to result in the questionnaire not being completed at all, then the 
patient may take the questionnaire home with instructions that i t is to be completed the same day. When the 
questionnaire is returned, the date on which the questionnaire was completed should be noted and a comment 
made on the questionnaire as to why  the patient took it away fr om the clinic before completion.  
This box to be completed by the clinical research coordinator: Study ID #: ___________  Pt. Initials: ____ ____ ____ 
Page 1 of 3 Please go on to the next page
EORTC QLQ-C30 (Core 30 Questionnaire Version 3.0 Â© copyright 19 95 EORTC Quality of Life Study Group. All rights reserved.)European Organization for Resear ch and Treatment of Cancer (EORT C)
Quality of Life Questionnaire
We are interested in some things about you and your health. Ple ase answer all of the questions yourself by 
circling the number that best applies to you. There are no "rig ht" or "wrong" answers. The information that 
you provide will remain strictly confidential.
Not
At AllA
LittleQuite
a BitVery
Much
1. Do you have any trouble doing strenuous activities, like 
carrying a heavy shopping bag or a suitcase?1 2 3 4
2. Do you have any trouble taking a long walk? 1 2 3 4
3. Do you have any trouble taking a short walk outside of the 
house?1 2 3 4
4. Do you need to stay in a bed or a chair during the day? 1 2 3 4
5. Do you need help with eating , dressing, washing yourself 
or using the toilet?1 2 3 4
During the past week:Not
At AllA
LittleQuite
a BitVery
Much
6. Were you limited in doing either your work or other daily 
activities?1 2 3 4
7. Were you limited in pursuing your hobbies or other 
leisure time activities?1 2 3 4
8. Were you short of breath? 1 2 3 4
This box to be completed by the clinical research coordinator: Study ID #: ___________  Pt. Initials: ____ ____ ____ 
Page 2 of 3 Please go on to the next page
EORTC QLQ-C30 (Core 30 Questionnaire Version 3.0 Â© copyright 19 95 EORTC Quality of Life Study Group. All rights reserved.)During the past week:Not
At AllA
LittleQuite
a BitVery
Much
9. Have you had pain? 1 2 3 4
10. Did you need to rest? 1 2 3 4
11. Have you had trouble sleeping? 1 2 3 4
12. Have you felt weak? 1 2 3 4
13. Have you lacked appetite? 1 2 3 4
14. Have you felt nauseated? 1 2 3 4
15. Have you vomited? 1 2 3 4
16. Have you been constipated? 1 2 3 4
17. Have you had diarrhea? 1 2 3 4
18. Were you tired? 1 2 3 4
19. Did pain interfere with your daily activities? 1 2 3 4
20. Have you had difficulty in concentrating on things, like 
reading a newspaper or watching television?1 2 3 4
21. Did you feel tense? 1 2 3 4
22. Did you worry? 1 2 3 4
This box to be completed by the clinical research coordinator: Study ID #: ___________  Pt. Initials: ____ ____ ____ 
Page 3 of 3
EORTC QLQ-C30 (Core 30 Questionnaire Version 3.0 Â© copyright 19 95 EORTC Quality of Life Study Group. All rights reserved.)During the past week:Not
At AllA
LittleQuite
a BitVery
Much
23. Did you feel irritable? 1 2 3 4
24. Did you feel depressed? 1 2 3 4
25. Have you had difficulty remembering things? 1 2 3 4
26. Has your physical condition or  medical treatment interfered 
with your family life?1 2 3 4
27. Has your physical condition or  medical treatment interfered 
with your social activities?1 2 3 4
28. Has your physical condition or medical treatment caused 
you financial difficulties?1 2 3 4
For the following questions please circle the number between 1 and 7 that best applies to you.
29. How would you rate your overall health during the past week?
1
Very Poor2 3 4 5 6 7
Excellent
30. How would you rate your overall quality of life during the past  week?
1
Very Poor2 3 4 5 6 7
Excellent
Please check to make sure you have answered all the questions.
Please fill in your initials to indicate that you have complete d this questionnaire: ______________
Today's date (Year, Month, Day): ______________________________ __ 
Thank you. 